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Abstract  
Sleeping sickness, caused by Trypanosoma brucei, is a deadly disease that affects some 
of the poorest countries in sub-Saharan Africa. Although the disease prevalence is 
declining, strengthening of the current control efforts, including introduction of more 
adequate chemotherapeutic options, is needed to prevent the re-emergence of yet 
another epidemic. Nitroaromatic compounds, such as nifurtimox (in combination with 
eflornithine) and fexinidazole (in clinical trials), have been recently introduced for the 
treatment of the second stage of sleeping sickness. These compounds are believed to act 
as pro-drugs that require intracellular enzymatic activation for antimicrobial activity. 
Here, the role of the bacterial-like nitroreductase TbNTR as a nitrodrug activating 
enzyme is examined through overexpression and knock-out studies in T. brucei. 
Multiple attempts to purify soluble recombinant TbNTR from E. coli were unsuccessful, 
because the recombinant protein was found to be membrane associated. In keeping with 
the role of TbNTR in nitrodrug activation, loss of an NTR gene copy in T. brucei was 
found to be one, but not the only, mechanism that may lead to nitrodrug resistance. 
Furthermore, in the bloodstream form of T. brucei, resistance was relatively easy to 
select for nifurtimox, with no concurrent loss of virulence and at clinically relevant 
levels. More worryingly, nifurtimox resistance led to a decreased sensitivity of these 
parasites to other nitroaromatic compounds, including a high level of cross-resistance to 
fexinidazole. Conversely, generation of fexinidazole resistance resulted in cross-
resistance to nifurtimox. Should these findings translate to the field, emerging nitrodrug 
resistance could reverse all recent advances in the treatment of sleeping sickness, made 
since the introduction of eflornithine 20 years ago. Therefore, all efforts should be made 
to ensure nitroaromatic drugs are used only in drug combination therapies against 
sleeping sickness, in order to protect them from emerging resistance.  
 
Chapter 1 -      
Introduction  
 - 2 -
1.1. Human African trypanosomiasis and the African trypanosome  
Human African trypanosomiasis (HAT, sleeping sickness) is one of the deadliest 
neglected tropical diseases, which is considered invariably fatal if untreated. This 
vector-borne parasitic disease is endemic in 36 sub-Saharan African countries, placing a 
population of ~60 million people at risk. Yet, fewer than 6 million people have been 
under active surveillance at any one time. As a result, during the peak (1997 – 1998) of 
the latest sleeping sickness outbreak, fewer than 40,000 cases were reported per year, 
whereas the annual total number of cases was estimated to be in the range of 300,000 to 
500,000 (Brun et al., 2010; Simarro et al., 2008; Stuart et al., 2008; WHO Expert 
Committee, 1998). The prevalence of HAT has subsequently been reduced (Figure 1.1) 
through the implementation of vector control and population surveillance programmes, 
as well as through improving awareness and access to diagnostic and treatment tools in 
the disease-endemic countries. Currently, the number of reported HAT cases is at its 
lowest level for half a century (<10,000 cases in 2009), and the estimated number of 
total cases is only 30,000 per year (Human African trypanosomiasis (sleeping sickness): 
epidemiological update, 2006; Simarro et al., 2011). However, this temporary success 
might affect negatively the maintenance of control and surveillance activities (Simarro 
et al., 2008). Cessation of such activities in the 1960s, combined with population 
displacement and exposure to hidden disease foci, was thought to be the main trigger for 
resurgence of the disease. Although in the past, this was primarily caused by civil unrest 
and lack of political stability, neglect of control activities due to any circumstances 
could easily lead to yet another sleeping sickness epidemic in the future (Simarro et al., 
2011; Stuart et al., 2008).  
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1.1.1. Trypanosoma brucei – the aetiological agent  
African trypanosomiasis is caused by the obligate parasite Trypanosoma brucei, of the 
order Kinetoplastida. Species of this order are unicellular, motile, flagellated protozoa, 
characterised by the presence of a single large mitochondrion, which contains a 
compacted DNA network termed the “kinetoplast” (Stuart et al., 2008). There are three 
subspecies of T. brucei, two of which – T. b. gambiense and T. b. rhodesiense, are the 
aetiological agents of the human form of the disease known as sleeping sickness. The 
third subspecies, T. b. brucei, is non-infective to humans but causes a similar wasting 
disease in cattle (nagana, or “depressed and low in spirits”; Fairlamb, 2003).  
The three subspecies of T. brucei are morphologically indistinguishable from 
each other but differ in their geographical distribution (Figure 1.1 and section 1.1.2), 
host specificity, and in the case of the human-infective forms, in disease progression.   
T. b. gambiense, which accounts for the majority (~95%) of HAT cases, is endemic in 
foci throughout West and Central Africa. Humans are thought to be the main reservoir 
for T. b. gambiense, and only few other animals have been found to carry this 
subspecies of T. brucei (Burri and Brun, 2009). In terms of disease progression, T. b. 
gambiense causes the more chronic form of sleeping sickness, which on average takes  
2 – 3 years from onset to death in untreated patients, but on rare occasions, it can last 
over 6 – 7 years (Checchi et al., 2008a; Checchi et al., 2008b). By contrast, T. b. 
rhodesiense is prevalent in the eastern parts of Africa and causes the more acute form of 
sleeping sickness, which progresses from infection to death within 3 – 12 months (Odiit 
et al., 1997, as cited by Fevre et al., 2004). However, sleeping sickness due to T. b. 
rhodesiense is rare (<5% of all HAT cases; Simarro et al., 2011) and is generally 
considered a zoonosis. In addition to humans, T. b. rhodesiense can infect many wild 
and domestic animals, of which cattle are an important reservoir (Burri and Brun, 
2009). The last subspecies, T. b. brucei is spread throughout sub-Saharan Africa and is 
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closely related to T. b. rhodesiense (Balmer et al., 2011). T. b. brucei also affects a wide 
range of vertebrates but is not pathogenic to humans, due to its susceptibility to lysis by 
human serum (Vanhamme and Pays, 2004).  
 
1.1.2. Transmission and life cycle of T. brucei  
African trypanosomiasis is a vector-borne disease, transmitted by species of the genus 
Glossina (order Diptera), commonly known as tsetse flies. There are over 20 Glossina 
spp., all of which are restricted by climatic and environmental factors to the tropical and 
sub-tropical parts of Africa, between the Sahara and Somali deserts to the north and the 
Kalahari and Namibian deserts to the south (Jordan, 1993). Within these broad 
geographical limits, specific habitat requirements provide the basis for separation of the 
Glossina genus into three groups. Species of the fusca group, which are forest dwellers, 
do not commonly feed on humans and have not been shown to act as vectors of human-
infective T. brucei. By contrast, species of the morsitans group, which are responsible 
for the transmission of T. b. rhodesiense, are found in foci throughout the savannah 
woodlands of East Africa (Figure 1.1). Finally, species of the palpalis group are found 
along river banks and lake shores, as well as in the lowland rainforests of West and 
Central Africa, where they transmit T. b. gambiense (Jordan, 1993). An important 
exception is the transmission of T. b. rhodesiense by species of the palpalis group in 
south-east Uganda. Uganda is the only country in which both forms of sleeping sickness 
exist: T. b. gambiense to the north-west and T. b. rhodesiense to the south-east (Human 
African trypanosomiasis (sleeping sickness): epidemiological update, 2006). Although 
these two disease foci are currently isolated (Batchelor et al., 2009; Picozzi et al., 
2005), a potential overlap between them will present huge difficulties in terms of the 
correct choice of diagnostic and treatment tools, which differ substantially between the 
two forms of the disease (see sections 1.1.3 and 1.2).  
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The restrictive habitat requirements of Glossina spp., combined with their 
dependence on the presence of woody vegetation for resting sites (tsetse flies rest for 
>23 h per day; Jordan, 1993), account for the fact that transmission of sleeping sickness 
occurs predominantly in rural settings. Thus, the communities affected by African 
trypanosomiasis often live in remote and very poor areas, which have little or no access 
to healthcare facilities and are difficult to reach by trypanosomiasis control and 
surveillance teams (Brun et al., 2010; Chappuis et al., 2010; Fevre et al., 2006). Such a 
lack of healthcare and infrastructure has implications not only on the patients, many of 
which remain undiagnosed and do not receive treatment, but also on the tools that can 
be used to fight sleeping sickness. In addition to being safe and effective, these tools 
also need to be cost efficient, easy to use/administer in the field, stable under tropical 
conditions and ideally not require the use of elaborate equipment (Deborggraeve and 
Buscher, 2010; Frearson et al., 2007; Simarro et al., 2008).  
Transmission of T. brucei is biological, which means that trypanosomes must 
undergo an essential part of their life cycle in the insect vector (Figure 1.2), before they 
can become infective to the mammalian host (Medical Insects and Arachnids, 1993; 
Fenn and Matthews, 2007). Mechanical transmission of T. brucei, whereby no 
development takes place in the vector, has been demonstrated only under laboratory 
conditions and is highly unlikely to play any role in the field (as discussed by Jordan, 
1993 and Moloo et al., 2000). In tsetse flies, the development of T. brucei takes 3 – 5 
weeks (Brun et al., 2010), during which trypanosomes go through a series of 
proliferative and non-proliferative (adaptive) life cycle stages, whilst migrating from the 
midgut of the fly to the salivary glands (Figure 1.2; Vickerman, 1985). Completion of 
this process is not always successful and depends on many vector- and parasite-specific 
factors (Matthews, 2011; Welburn and Maudlin, 1999). As a result, only ~0.1% of tsetse 
flies are found to carry matured human-infective trypanosomes in the field. However, 
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once an infection has been established, a fly can potentially transmit the disease to all 
suitable hosts it feeds on for the rest of its life* (Jordan, 1993; Stuart et al., 2008).  
In humans, the life cycle of T. brucei begins when an infected tsetse fly deposits 
mature metacyclic trypanosomes in the dermal connective tissue during a blood meal 
(Vickerman, 1985; Figure 1.2). At the bite site, a localised inflammatory skin response 
may lead to the formation of a painful trypanosomal chancre (a hard, defined swelling; 
Burri and Brun, 2009), where the infective, non-dividing metacyclics transform into 
proliferative slender bloodstream forms (BSF). The latter escape the chancre through 
the draining lymphatics, and migrate to the lymph nodes and eventually, to the 
bloodstream. During the first stage of sleeping sickness, slender forms multiply 
extracellularly in the haemolymphatic system, at 5- to 10-hourly intervals (Fries and 
Fairlamb, 2003; Vickerman, 1985). Throughout the infection, the levels of parasitaemia 
in the blood fluctuate in a wave-like pattern (first described by Ross and Thomson, 
1910). The main reason for these fluctuations is thought to be an arms-race between the 
parasite, which constantly changes the composition of its surface coat by antigenic 
variation, and the immune system of the host, which responds by generating antibodies 
against the main circulating variant of T. brucei (Pays and Nolan, 1998). In addition to 
the immune system, trypanosomes may further be responsible for the successive 
declines in parasitaemia, by differentiating into non-dividing, stumpy forms at high 
densities (Figure 1.2). These forms, unlike slender BSF trypanosomes, are believed to 
be pre-adapted for survival in the insect vector, where they continue to differentiate, in 
order to complete their life cycle (Fenn and Matthews, 2007). With the progression of 
the disease, trypanosomes cross the walls of the blood vessels and the choroid plexus to 
                                                 
* It is difficult to estimate the epidemiological impact of a single infected fly, due to conflicting reports on 
the longevity of Glossina, the role of a T. brucei infection thereon, and the number and frequency of 
blood meals. Further difficulties are presented by the specific host preferences, which vary hugely among 
Glossina spp., and the availability of hosts the fly can feed on, not all of which may be susceptible to the 
particular subspecies of T. brucei (Fevre et al., 2006; Jordan, 1993; Pepin and Meda, 2001; Welburn and 
Maudlin, 1999; WHO Expert Committee, 1998).  
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invade the central nervous system (CNS), which marks the beginning of the second, 
final stage of HAT (Fries and Fairlamb, 2003). To date, it has not been established with 
certainty whether trypanosomes differentiate into new forms during CNS invasion, or 
whether they remain morphologically and biochemically identical to those found in the 
bloodstream. Early studies with laboratory rodents report a variety of morphological T. 
brucei forms in the brain, including intracellular trypomastigotes (Abolarin et al., 1982) 
and even amastigotes (Beckers et al., 1981). More recently, it has been speculated that 
trypanosomes could enter the CNS by migrating through the cells of the blood-brain 
barrier (thus presenting as intracellular trypomastigotes) rather than through the tight 
junctions between these cells (Enanga et al., 2002; Stoppini et al., 2000). The 
morphology of T. brucei in the brain is perhaps less important than the biochemical 
composition of these parasites, which has yet to be characterised. If CNS trypanosomes 
are biochemically different from their bloodstream counterparts, it is possible that they 
might respond differently to chemotherapy (Enanga et al., 2002). Last but not least, the 
ability of trypanosomes to proliferate in the CNS has not been directly demonstrated 
(Enanga et al., 2002), although some authors seem convinced that T. brucei do multiply 
by binary fission not only in the blood and lymph but also in the CNS (Vickerman, 
1985). What has been demonstrated on multiple occasions, however, is that 
trypanosomes within the brain can re-establish an infection in the bloodstream. For 
example, following an apparent clearance of T. brucei from the blood of infected mice, 
brain homogenates (but not blood) from these mice could cause an infection in recipient 
animals (Gray et al., 1982). In a similar way, T. b. gambiense isolates from the 
cerebrospinal fluid of second-stage HAT patients were able to establish an infection in 
laboratory animals and to a lesser extent to proliferate in vitro (Giroud et al., 2009). If 
trypanosomes are not completely cleared by chemotherapy, not only can they infect 
other organisms/recipients, but also re-establish an infection in the same individual, as 
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has been demonstrated in a melarsoprol-refractory T. b. rhodesiense patient (Checkley 
et al., 2007). Collectively, these studies indicate that should drug resistance be selected 
in the course of chemotherapy, T. brucei have the ability to re-emerge in the 
bloodstream, where they would not only cause a relapse in the infected individual, but 
also be available for transmission by the blood-feeding vector.  
The successful transmission of T. brucei is partly dependent on their ability to 
survive the transition from host to vector and vice versa. To adapt to these very different 
environments, trypanosomes undergo complex morphological and biochemical changes 
during the various stages of their life cycle. Some of the most prominent of these 
changes occur in the mitochondrion, regarding utilisation of the available energy 
sources (Vickerman, 1985). In the midgut of the fly, where glucose is present only 
transiently after a blood meal, procyclics are thought to use proline – similar to their 
vector, and potentially several other amino acids, as their main source of energy. The 
mitochondrion of procyclic T. brucei is relatively enlarged, with its branched inner 
membrane forming discoid cristae and featuring a fully functional, cytochrome-
dependent electron transport chain, which generates a proton gradient to drive the 
synthesis of ATP (Besteiro et al., 2005; Vickerman, 1985). By contrast, in the 
mammalian bloodstream, where glucose is constantly available, slender BSF 
trypanosomes dispense with the components of the cytochrome chain and the 
tricarboxylic acid cycle, and generate ATP solely and wastefully by aerobic glycolysis. 
In addition, the smaller and smoother, cristae-lacking mitochondrion of BSF T. brucei 
functions at a reduced capacity, consuming rather than generating ATP in order to 
maintain the proton gradient across its membranes. Nonetheless, in slender forms, the 
mitochondrion remains an essential organelle, due to its role in maintaining the 
glycolytic redox balance (Besteiro et al., 2005; Vickerman, 1965; Vickerman, 1985). 
Another set of important changes that occur as trypanosomes transit from host to vector 
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and vice versa takes place on the cell surface, which is completely covered by a 
monolayer of densely packed, stage-specific glycoproteins (Pays and Nolan, 1998). In 
procyclic T. brucei, this surface coat is composed of procyclic acidic repetitive proteins 
(procyclins), which are thought to be highly resistant to the proteases of the tsetse 
midgut. Furthermore, the large carbohydrate chains covalently attached to procyclins 
are thought to form a glycocalyx to protect the remaining surface proteins (Mehlert et 
al., 1998; Pays and Nolan, 1998). Although in the mammalian bloodstream T. brucei 
are not threatened by such digestive enzymes, they are constantly exposed to the 
immune system of the host, from which they are protected by a coat of variant surface 
glycoproteins (VSG). The VSG monolayer is sufficiently dense to restrict access to the 
plasma membrane for components of the complement pathway of the innate immune 
system, but not for small molecules and nutrients (Mehlert et al., 1998). To evade the 
acquired immune system, BSF T. brucei periodically change the composition of their 
surface coat to a new antigenic variant of VSG, thereby avoiding recognition by 
antibodies against previous variants (Pays, 2006). Although in the T. brucei genome 
there are over 1000 VSG genes, only one of which is expressed at any given time, the 
true repertoire of antigenic variants is virtually limitless due to the ability of 
trypanosomes to modify the existing VSG sequences by homologous DNA 
recombination (Pays, 2006; Stuart et al., 2008). On the one hand, this constant variation 
of the antibody-accessible coat ensures the survival of at least a small proportion of the 
trypanosome population by preventing the host from effectively clearing the infection 
without treatment. On the other hand, the inexhaustible repertoire of antigenic variants 
precludes the development of a potential vaccine against HAT, which leaves 
chemotherapy and vector control as the only options for the millions under threat of 
contracting the disease (Fries and Fairlamb, 2003; Stuart et al., 2008).  
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1.1.3. Clinical manifestation and diagnosis of HAT  
Sleeping sickness caused by either T. b. gambiense or T. b. rhodesiense progresses in 
two stages and is ultimately fatal if untreated. However, the clinical features and 
duration, as well as the available diagnostic tools, differ between the two forms of the 
disease (Brun et al., 2010). During the first, haemolymphatic stage of the more chronic 
T. b. gambiense infection, symptoms vary between patients, and are highly unspecific 
and reminiscent of other microbial and viral infections, including malaria. These 
symptoms often include fever, headache, lymphadenopathy, joint and muscle pain, 
fatigue and general malaise, all of which occur in cycles as the immune system responds 
to the successive waves of parasitaemia. More specific symptoms of stage-one chronic 
sleeping sickness include pruritus and facial oedema, as well as the classic 
Winterbottom’s sign, which is manifested as a swelling of the posterior cervical lymph 
nodes in approximately 85% of clinical patients (Brun et al., 2010; Burri and Brun, 
2009; Stuart et al., 2008). With time, the febrile episodes appear with reduced frequency 
and intensity, and are usually followed by a long asymptomatic period (Burri and Brun, 
2009). By contrast, stage-one sleeping sickness due to T. b. rhodesiense progresses 
much more acutely, and fever develops within a few weeks of infection (Burri and 
Brun, 2009). A trypanosomal chancre, not normally observed in T. b. gambiense 
patients, may also appear in the first 1 – 2 weeks at the site of the infective tsetse bite. 
Conversely, the Winterbottom’s sign, which is characteristic of West African 
trypanosomiasis, is usually absent in T. b. rhodesiense patients, although other lymph 
nodes (submandibular, axillary and inguinal) may be affected during this stage (Brun et 
al., 2010; Burri and Brun, 2009).  
The leading symptoms of second-stage T. b. gambiense infections are 
predominantly neurological, due to the invasion of the CNS by trypanosomes and the 
resulting chronic inflammation of the brain. These symptoms can be classified as motor 
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(slurred speech, tremors), sensory, sleep and mental anomalies, the latter, ranging from 
highly aggressive, manic behaviour to confusion and complete apathy. Sleep anomalies, 
after which the disease was named, are also highly characteristic of the second stage of 
West African trypanosomiasis and include dysregulation of the sleep-wake cycle and 
fragmentation of the sleep pattern (Brun et al., 2010; Burri and Brun, 2009; Fries and 
Fairlamb, 2003). Other symptoms, which are of minor clinical relevance in T. b. 
gambiense infections, such as cardiac and endocrine dysfunctions, may become more 
pronounced in second-stage T. b. rhodesiense patients. Furthermore, many of the 
neurological symptoms are absent in the East African form of sleeping sickness, 
probably due to the much faster progression of the disease (Brun et al., 2010; Burri and 
Brun, 2009). Although most of the brain damage that occurs during chronic sleeping 
sickness may be reversed following treatment, in the absence of treatment, patients will 
continue to deteriorate (Burri and Brun, 2009; Fries and Fairlamb, 2003). Unlike stage-
one symptoms, the symptoms of second-stage chronic sleeping sickness increase in 
frequency and severity with time, eventually leading to considerable weight loss, coma 
and death, often caused by concurrent bacterial infections. Untreated T. b. rhodesiense 
sleeping sickness will also lead to death, but at a much faster rate (Brun et al., 2010).  
The clinical features of sleeping sickness are not sufficiently specific to exclude 
the presence of other brain or chronic inflammatory conditions. Therefore, before the 
patients are exposed to the highly toxic drugs that are currently available for the 
treatment of HAT (see section 1.2), confirmation of the disease by laboratory tests is 
required (Burri and Brun, 2009; Chappuis et al., 2005). In T. b. gambiense-endemic 
countries, diagnosis of HAT usually follows a three-step process of screening, 
diagnostic confirmation and staging. Initial screening of large number of patients in the 
field is performed with the relatively quick and easy-to-use card agglutination test for 
trypanosomiasis (CATT/T. b. gambiense; developed by Magnus et al., 1978), which 
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uses a single, frequently-encountered variable antigen type of T. b. gambiense to detect 
antibodies in the patient’s blood. However, this test is limited in both its sensitivity 
(may not detect patients with T. b. gambiense of other antigen types) and specificity 
(may detect patients with malaria or with transient non-infective trypanosomes; 
Chappuis et al., 2005). Although other more sensitive serological tests, such as 
immunofluorescent and enzyme-linked immunosorbent (ELISA) assays, are also 
available, these remain confined to laboratory settings by the need for elaborate 
equipment. Regardless of their sensitivity or specificity, serological tests are not able to 
distinguish recent from current infections, as antibodies remain in circulation for years 
after the infection has been cleared (Chappuis et al., 2005). Hence, to confirm the 
diagnosis of seropositive individuals, detection of the trypanosomes by parasitological 
or molecular methods is required. Under field conditions, the method of choice for 
parasitological confirmation is microscopy on lymph node aspirates or blood samples, 
despite the unsatisfactory detection limit (5,000 – 10,000 trypanosomes ml-1). Where 
appropriate facilities exist, this limit could be reduced to 100 – 500 trypanosomes ml-1 
by prior concentration of the sample using field-adapted centrifugation techniques. 
Nevertheless, during this process, as many as 30% of infected patients may remain 
undiagnosed, due to the highly variable levels of parasitaemia, which can fall below 100 
T. b. gambiense cells ml-1 (Chappuis et al., 2005). The alternative parasitological 
methods, whereby potentially infected blood is used to inoculated suitable culture media 
or susceptible laboratory animals, are unsuitable for diagnostic purposes because viable 
trypanosomes can only be detected after several days or even weeks post inoculation 
(Burri and Brun, 2009; Chappuis et al., 2005). In addition, there are several extremely 
sensitive, molecular-based techniques (summarised in Deborggraeve and Buscher, 
2010) for the detection of trypanosomes, such as DNA/RNA amplification or 
fluorescence in situ hybridisation. However, these complex, molecular-based techniques 
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remain currently inapplicable in the resource-poor setting of rural Africa, despite 
various strategies that have been undertaken to simplify them. Furthermore, the proper 
evaluation of these methods on a large scale, as well as the clinical significance of 
detecting very low levels of trypanosomal DNA/RNA in patients, have been questioned 
(Chappuis et al., 2005; Deborggraeve and Buscher, 2010). Finally, the last diagnostic 
step for patients with confirmed sleeping sickness is determination of the disease stage. 
At present, second-stage HAT can be detected solely by examination of the 
cerebrospinal fluid for an increased white blood cell count (variable lower limit of 5 – 
20 cells μl-1) and potentially, for the presence of trypanosomes. Both of these criteria 
require the use of a microscope and hence, suffer from the same lack of sensitivity as 
other microscopic methods described above. Another highly specific marker for second 
stage sleeping sickness is increased levels of IgM in the cerebrospinal fluid, which can 
be detected by a simple latex agglutination test. However, this method is still awaiting 
validation and similar to the other criteria, requires the highly invasive lumbar puncture 
to obtain cerebrospinal fluid (Brun et al., 2010; Stuart et al., 2008).  
The diagnosis of sleeping sickness due to T. b. rhodesiense is different from the 
screening, confirmation and staging pattern established for diagnosis of T. b. gambiense 
infections. To date, no equivalent of any serological tests is available for the screening 
of human East African trypanosomiasis, although some of the molecular screening 
methods, based on amplification of subspecies-specific DNA, have been applied to 
detect T. b. rhodesiense in animals (Stuart et al., 2008; Welburn et al., 2001). 
Consequently, the initial, speculative diagnosis of T. b. rhodesiense infections is based 
on clinical presentation, which is usually more acute, and on the history of patient 
exposure to the vector (Brun et al., 2010). However, the lack of specificity of this 
approach has lead to a substantial delay (60 days on average in Uganda) before an 
accurate diagnosis can be reached and treatment initiated (Odiit et al., 2004, as 
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referenced by Fevre et al., 2006). In contrast to T. b. gambiense cases, where initial 
screening is straightforward but subsequent confirmation can be problematic, it is 
relatively easy to confirm suspected T. b. rhodesiense cases by microscopy of blood 
samples or chancre aspirates, even without prior concentration of the sample, because of 
the relatively high levels of parasitaemia. Although inapplicable as a diagnostic tool, 
detection of T. b. rhodesiense may also be performed by inoculation into a wide range 
of laboratory animals, whereas very few, mostly immunocompromised, rodents are 
susceptible to T. b. gambiense. The final, staging part of the diagnostic process is the 
only one that is identical for T. b. gambiense and T. b. rhodesiense infections, and 
carries the same risks for the patient (Burri and Brun, 2009; Chappuis et al., 2005). 
Nonetheless, determination of the stage of sleeping sickness is vital for both T. b. 
gambiense and T. b. rhodesiense patients because the treatment options differ 
considerably between the first and second stage of the disease (Stuart et al., 2008). 
 
1.2. Chemotherapy of sleeping sickness  
There are five different drugs currently available for the chemotherapy of sleeping 
sickness (Table 1.1). However, not all of them are equally applicable against all forms 
of the disease. Choice of the correct treatment is highly dependent on the disease stage 
and the causative subspecies of T. brucei, as well as on the availability of the drugs, 
which can be a major issue in HAT-affected areas (Simarro et al., 2011; Stuart et al., 
2008). Two of the drugs – pentamidine and suramin are effective only against the first, 
haemolymphatic stage of sleeping sickness, because their physicochemical properties 
prevent them from penetrating through the blood-brain barrier and into the CNS (Fries 
and Fairlamb, 2003). The remaining treatment options are effective against both first- 
and second-stage HAT, although there are other reasons why their use is avoided in 
stage-one patients, as detailed below.  
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1.2.1. Drugs against first-stage HAT  
Pentamidine  
Pentamidine (Pentam 300; Nebupent; Pentacarinat; Lomidine) has been the drug of 
choice against early-stage T. b. gambiense infections since it was first introduced in 
1941, because it is relatively well tolerated compared to the remaining HAT treatment 
options. However, due to its much lower efficacy against T. b. rhodesiense, pentamidine 
is not used against East African trypanosomiasis (Burri and Brun, 2009; Fairlamb, 
2003). Pentamidine is an aromatic diamidine, which is highly soluble in water (as the 
di-isethionate or di-mesylate salt) and almost fully protonated at physiological pH. 
These properties account for the inability of the drug to cross the blood-brain barrier, as 
well as for its poor absorption in the gastrointestinal tract, which in turn necessitates 
parenteral administration (Fries and Fairlamb, 2003). Pentamidine is usually given via a 
deep intramuscular (i.m.) injection, although this can be painful and in some cases, may 
lead to sterile abscesses or necroses at the injection site. Nonetheless, this route is 
preferred over intravenous (i.v.) administration of the drug, because the latter may cause 
severe and life-threatening hypotension. Additional frequently-observed side effects of 
this drug include hypoglycaemia (and potentially, diabetes mellitus), gastrointestinal 
disturbances, blood dyscrasias, and damage to the kidneys, heart and liver (Burri and 
Brun, 2009; Fries and Fairlamb, 2003).  
 
Suramin  
Suramin (Bayer 205; Germanin) is active against first-stage sleeping sickness caused by 
T. b. gambiense and by T. b. rhodesiense, although its use against early-stage T. b. 
gambiense infections is not recommended, because of the severe allergic reactions that 
may develop in patients co-infected with onchocerciasis (common in western and 
central Africa; Brun et al., 2010). Suramin was developed in the early 1920s as part of 
 - 16 -
the very first two series of synthetic antitrypanosomal agents – synthetic dyes and 
organic arsenical (Williamson, 1970). Suramin is a dye-related, polyanionic sulfonated 
naphthylamine with a high molecular mass and polarity, which prevents it from entering 
the CNS. Similar to pentamidine, suramin is highly water-soluble and requires 
parenteral administration, although in this case the i.v. route is preferred (Fries and 
Fairlamb, 2003). During administration of suramin, adverse hypersensitivity reactions 
may develop, such as nausea and vomiting, pruritus, urticaria and even shock, hence the 
requirement for a test dose. Other, delayed side effects of suramin include kidney 
damage (usually reversible), exfoliative dermatitis, peripheral neuropathy, par- and 
hyperaesthesia of hands and feet, haemolytic anaemia and other blood dyscrasias 
resulting from bone marrow toxicity (Brun et al., 2010; Burri and Brun, 2009; Fries and 
Fairlamb, 2003).  
 
1.2.2. Drugs against second-stage HAT  
Melarsoprol  
Since its introduction in 1949, melarsoprol (Mel B; Arsobal) has been the only drug that 
is active against both T. b. gambiense and T. b. rhodesiense in the late stages of sleeping 
sickness (Table 1.1; Fries and Fairlamb, 2003). However, melarsoprol is not completely 
effective. Treatment failure rates, normally in the range of 5 – 8%, soared up to 16 – 
30% at the turn of the 21st century in T. b. gambiense foci in some of the most affected 
countries – Angola, Democratic Republic of Congo, Sudan and Uganda (Figure 1.1 A). 
This increase in relapse rates was probably due to emerging drug resistance, although 
this has not been verified for T. b. gambiense, and other vector- and parasite-related 
factors cannot be excluded (Brun et al., 2001; Robays et al., 2008). Nonetheless, 
melarsoprol remains a first-line treatment for late-stage T. b. gambiense HAT in many 
regions which have no access to or cannot afford the use of eflornithine. Melarsoprol is 
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also the only, hence first-line treatment for second-stage T. b. rhodesiense infections, 
with no effective alternatives available for relapse cases (Simarro et al., 2011; Stuart et 
al., 2008). In addition to the failing efficacy, another major disadvantage of melarsoprol 
is the unacceptable drug toxicity. Melarsoprol is an organoarsenic compound, which 
triggers severe reactive encephalopathy in 5 – 10% of all treated cases, approximately 
half of these resulting in fatality. The cause of this extreme adverse reaction is 
debatable, although it is most probably independent of the trypanosome, as the same 
reaction has been observed in melarsoprol-treated patients with advanced leukaemia 
(Fairlamb, 2003; Soignet et al., 1999). Unfortunately, an abridged 10-day treatment 
schedule, which is now recommended for melarsoprol against T. b. gambiense (see 
Table 1.1), has failed to reduce the incidence of reactive encephalopathy compared to a 
standard 26-day regimen. Nonetheless, the shorter regimen offers other important 
advantages over previous schedules, such as reduction in the hospitalisation time and 
treatment cost (Burri and Brun, 2009; Fairlamb, 2003; Schmid et al., 2004). In all cases, 
melarsoprol, which is insoluble in water, needs to be administered strictly via an i.v. 
injection, dissolved in propylene glycol. This solvent is highly irritating and may cause 
thrombophlebitis in the surrounding tissues if leaked during injection. Administration of 
melarsoprol is also associated with some common side effects, such as fever, headache, 
vomiting and abdominal pain, as well as with more severe adverse reactions, including 
skin irritations (pruritus and maculopapular eruptions), peripheral neuropathy (motor 
and sensory), myocardial damage, renal dysfunction and hepatotoxicity (Burri and 
Brun, 2009; Fairlamb, 2003; Fries and Fairlamb, 2003).  
 
Eflornithine  
Eflornithine (DL-α-difluoromethylornithine, DFMO; Ornidyl) was recognised as an 
antitrypanosomal agent in the 1980s; however, it was not until 1990 before it was 
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approved for the treatment of T. b. gambiense cases in both stages of the disease. The 
drug cannot be used against T. b. rhodesiense, which is naturally refractory to 
eflornithine by virtue of its higher turnover rate of ornithine decarboxylase (the essential 
enzyme that is inhibited by eflornithine), and some other contributing factors (Fries and 
Fairlamb, 2003). Even though eflornithine is a much safer alternative to melarsoprol, its 
high cost ($710 per treatment), logistically-challenging packaging (40 kg per kit 
containing equipment for 2 full treatments) and complex regimen (56 infusions at 6-h 
intervals, see Table 1.1) have severely limited its use in many remote regions in rural 
Africa (Simarro et al., 2011; Stuart et al., 2008). Furthermore, the development of 
eflornithine as an oral formulation, which was expected to alleviate some of the above 
issues, has been hampered by the poor and stereoselective absorption of the drug 
(favouring the less active isomer) following oral dosing (Brun et al., 2010; Jansson et 
al., 2008). At present, the main risks for patients receiving i.v. eflornithine is the 
development of a bacterial infection (potentially leading to sepsis) at the site of 
injection, although this can be avoided by preventive care. The main adverse reactions 
associated with administration of eflornithine are bone marrow toxicity with blood 
dyscrasias, gastrointestinal disturbances (nausea, vomiting and diarrhoea) and 
convulsions. These effects are caused by the cytostatic action of the drug and are 
reversible upon cessation of treatment (Burri and Brun, 2009).  
 
Nifurtimox-eflornithine combination therapy (NECT)  
The combination of eflornithine with the nitrofuran nifurtimox (Bayer 2502; Lampit) 
was first evaluated for the treatment of late-stage T. b. gambiense in 2001 as part of a 
clinical trial comparing three drug combinations: melarsoprol with eflornithine, 
melarsoprol with nifurtimox and eflornithine with nifurtimox. The study was aimed at 
addressing the multitude of disadvantages of the existing antitrypanosomal drugs, with 
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the rationale that using these drugs in combination would reduce the possibility of 
developing drug resistance and would allow lower drug doses to be used, thus 
potentially reducing toxicity and simplifying drug administration without compromising 
treatment efficacy. Contrary to these expectations, the clinical trial had to be interrupted 
on ethical grounds, due to the notably high drug-related mortality in the arms containing 
melarsoprol (Priotto et al., 2006). Nonetheless, the combination of eflornithine with 
nifurtimox appeared to be relatively effective and well tolerated, which was 
subsequently confirmed in a randomised phase III clinical trial – the cure rate for NECT 
was high (96.5%), with fewer patients suffering adverse effects than with eflornithine 
monotherapy (Priotto et al., 2009).  
Prior to these clinical trials, nifurtimox had been used mainly to treat acute 
South-American trypanosomiasis (Chagas’ disease; caused by Trypanosoma cruzi; 
Rassi et al., 2010), but was never approved as a monotherapy for the treatment of HAT 
due to its insufficient efficacy (30 – 80% cure rate with different regimens) and dose-
dependent toxicity. However, nifurtimox had been used on compassionate grounds in 
melarsoprol-refractory T. b. gambiense patients with no access to eflornithine (Bouteille 
et al., 2003; Pépin and Milord, 1994).  
A major advantage of nifurtimox over the existing antitrypanosomal agents is 
that it can be administered orally. Furthermore, NECT uses half the amount of 
eflornithine compared to the monotherapy (Table 1.1). In turn, the reduced drug 
quantity helps to alleviate the two main obstacles for the implementation of eflornithine 
against HAT – cost ($360 per NECT course) and logistics (the same 40-kg kit now 
contains materials for four NECT courses instead of two eflornithine treatments; 
Simarro et al., 2011; Yun et al., 2010). In terms of disadvantages, although the new 
NECT regimen is simpler than eflornithine alone, its remains complicated and resource-
intensive (Yun et al., 2010). Furthermore, nifurtimox is not free from side effects, such 
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as gastrointestinal (nausea, vomiting, abdominal pain, anorexia) and neurological 
disturbances (convulsions, tremor and agitation, and occasionally – peripheral 
neuropathy), as well as allergic skin reactions. However, the adverse effects of 
nifurtimox are rarely life-threatening, and only some gastrointestinal disturbances were 
found to be significantly increased in NECT compared to eflornithine monotherapy 
(Burri and Brun, 2009; Fries and Fairlamb, 2003; Priotto et al., 2009).  
 
1.2.3. Potential novel chemotherapeutics for the treatment of HAT  
The chemotherapeutic agents that are currently available against sleeping sickness are at 
best ineffective and at worst – highly toxic. Therefore, if elimination of HAT as a public 
health risk is to be achieved, as set by the World Health Organisation (Simarro et al., 
2011), new and improved drugs will be required, since the current strategy of re-
analysing and optimising existing regimens and combinations thereof seems to have 
reached its peak with the implementation of NECT. In an effort to discover and develop 
novel therapeutics, the Drugs for Neglected Diseases initiative (DNDi) has brought 
forward into clinical development another nitroaromatic compound, similar to 
nifurtimox – the 5-nitroimidazole fexinidazole (Hoechst 239). Fexinidazole entered 
phase I clinical trials in 2009 for use against second-stage sleeping sickness and is 
expected to progress to phase II clinical trials in the near future. Furthermore, 
compounds from two other chemical classes (oxaboroles and diamidines) are currently 
in pre-clinical development for potential use against sleeping sickness (Barrett, 2010). 
 
1.3. Nitroaromatic pro-drugs  
1.3.1. A historical overview  
In recent years, interest in the use of nitroheterocyclic compounds as chemotherapeutic 
agents appears to be on the increase, not only for use against African sleeping sickness 
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but also against other infectious diseases, and even in cancer chemotherapy. For 
example, the 4-nitroimidazo-oxazine PA-824 is currently under clinical investigation 
for the treatment of tuberculosis (Ginsberg et al., 2009), whereas the 5-nitrothiazole 
nitazoxanide (Alinia®) has completed phase II clinical trials for the treatment of 
hepatitis C (Keeffe and Rossignol, 2009). Another drug, the dinitrobenzene CB1954, 
has also recently completed phase I and II clinical trials as part of a virus-directed 
enzyme pro-drug therapy (VDEPT) for prostate cancer (Patel et al., 2009). However, 
nitroaromatic drugs are not new to the medical scene. Interest in the chemotherapeutic 
properties of nitroaromatics was sparked by the discovery of Stillman and colleagues 
(Dodd et al., 1944) that addition of a nitro group (-NO2) to the 5-position of simple 
furan derivatives significantly increases their antibacterial activity. The first 
nitroaromatic compound to be used for its antimicrobial properties was the 5-nitrofuran 
derivative nitrofurazone (5-nitro-2-furaldehyde semicarbazone; Furacin), which was 
successfully applied as a topical agent for the treatment of wounds during the second 
world war (Miura and Reckendorf, 1967). Shortly afterwards (1946 – 1951), 
nitrofurazone was found to have antitrypanosomal activity in experimental mouse 
models of infection (Grunberg and Titsworth, 1973; Williamson, 1962). These findings, 
combined with the knowledge that the drug was orally active and can enter the CNS, 
allowed nitrofurazone to proceed into clinical trials during the 1950s for the treatment 
of both T. b. gambiense and T. b. rhodesiense patients, most of whom were already 
refractory to pentamidine, suramin and organoarsenicals. Although nitrofurazone 
elicited cure in approximately half of these “hopeless” patients, who would otherwise 
have died for lack of alternative treatment, the high toxicity of nitrofurazone did not 
justify its further use in humans, other than in its original topical application (Miura and 
Reckendorf, 1967; Williamson, 1962; Williamson, 1970). During the 1960s, several 
other nitrofurans, including furaltadone (Altafur), were found to have antitrypanosomal 
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activity but were subsequently abandoned because of insufficient effectiveness and high 
neurotoxicity. Similar to nitrofurazone, these compounds were also found to cause 
haemolytic anaemia in patients with the glucose-6-phosphate dehydrogenase deficiency 
trait commonly found in Africa (Grunberg and Titsworth, 1973; Pépin and Milord, 
1994; Williamson, 1970). However, hope for the use of nitrofurans against HAT was 
renewed in the early 1970s, when nifurtimox was shown to be better tolerated and more 
effective than nitrofurazone against T. cruzi infections in animals (Haberkorn and 
Gonnert, 1972) and to be active against acute Chagas’ disease in humans (81% cure 
rate; Wegner and Rohwedde, 1972a). Following from these findings, the activity of 
nifurtimox against T. b. gambiense was demonstrated first in rats and then in a cautious 
clinical trial in four European T. b. gambiense patients (Janssens and Demuynck, 1977). 
Although subsequent clinical trials with various nifurtimox regimens during the 1980s 
(reviewed by Bouteille et al., 2003 and Pépin and Milord, 1994) did not report 
incidences of haemolytic anaemia, the efficacy of the drug against T. b. gambiense was 
variable (30 – 80% cure rate) and its toxicity increased with higher doses and prolonged 
treatment (Pépin et al., 1992). Consequently, nifurtimox never received approval as a 
monotherapy against HAT and was left only as a last resort drug for second-stage HAT 
patients refractory to all other available treatments. Finally, some two decades later, 
nifurtimox found its place in the chemotherapy of sleeping sickness as part of a 
combination therapy with eflornithine that was added to the Model List of Essential 
Medicines of the World Health Organisation in 2009 (Yun et al., 2010).  
In parallel with nitrofurans, a similar class of aromatic compounds – the 
nitroimidazoles, was also investigated in terms of antimicrobial activity. The first 
indications that nitroimidazoles are chemotherapeutically active were given in the early 
1950s, when Japanese scientists isolated the natural antibiotic azomycin and revealed its 
chemical structure as a 2-nitroimidazole. Although azomycin was too toxic for clinical 
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application, its efficacy against infections with the microaerophilic protozoan 
Trichomonas prompted further research. By the end of the 1950s, a whole series of 
nitroimidazoles had been synthesised, which included metronidazole (2-methyl-5-
nitroimidazole-1-ethanol; Flagyl) among others (Grunberg and Titsworth, 1973; Raether 
and Hänel, 2003). This drug was one of the first nitroimidazoles to be successfully 
introduced into clinical practice, and remains widely applied for the treatment of 
microaerophilic protozoal and anaerobic bacterial infections (Löfmark et al., 2010). The 
effect of metronidazole on T. b. rhodesiense appears to have been investigated almost 
immediately after the drug was synthesised – as early as 1961*. However, to our 
knowledge, since this first report, there have only been a few studies on the use of 
metronidazole against sleeping sickness (caused by T. b. rhodesiense), which appeared 
in the period 1985 – 1996 and which indicated that this drug alone was not able to clear 
CNS infections even at toxic doses (see references in Foulkes, 1996). Similar to 
metronidazole, most nitroimidazole compounds tend to be most active against various 
anaerobic bacteria and protozoa, but are relatively inactive against aerobic organisms 
(Grunberg and Titsworth, 1973). Nevertheless, there are some exceptions to this, 
notably the 2-nitro derivative benznidazole (Roche 7-1051; Rochagan; Radanil), which 
was introduced in the 1970s for the treatment of South American trypanosomiasis. 
Benznidazole is still the drug of choice against Chagas’ disease, as it is better tolerated 
than nifurtimox (Gutteridge, 1985; Rassi et al., 2010). However, it is ineffective against 
the African trypanosome, as demonstrated in a chronic mouse model of infection 
(Poltera et al., 1981). Another nitroimidazole that was synthesised in the 1970s, 
fexinidazole, was initially reported to have a very good activity against both T. cruzi 
and T. brucei infections in mice, in addition to its high efficacy against anaerobic 
                                                 
* The following article, which could not be accessed, was the oldest found in a PubMed search for 
“metronidazole” and one of the following terms “Trypanosoma”, “African” or “sleeping sickness”: 
Adriaenssens K. (1961) [Metronidazole in a case of sleeping sickness caused by Trypanosoma 
rhodesiense]. Ann. Soc. Belg. Med. Trop. 41, 393-395, in Dutch.  
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protozoa (Jennings and Urquhart, 1983; Raether and Seidenath, 1983). However, 
fexinidazole was abandoned in its pre-clinical development due to unspecified toxicity 
issues (Gutteridge, 1985). Similar “toxicity and commercial considerations” precluded 
the development of other 5-nitroimidazoles with antitrypanosomal activity that were 
investigated during the 1980s and 1990s, including MK(Merk) 436 and megazol (CL 
64855) (Barrett, 2010; Gutteridge, 1985; Jennings, 1993). Despite the suspected 
mutagenicity of fexinidazole, the need for improved chemotherapy of sleeping sickness 
has led to the recent re-evaluation of this compound. The study by DNDi revealed that 
fexinidazole is indeed safe in mammalian systems and confirmed the efficacy of the 
drug against all subspecies of T. brucei and against both stages of sleeping sickness. 
Consequently, after many years on the shelf, fexinidazole has finally moved from pre-
clinical development into clinical trials for use against HAT (Torreele et al., 2010).  
 
1.3.2. Mode of action and activation of nitroaromatic drugs  
The available scientific evidence indicates that the nitro group is essential for the mode 
of action of nitroaromatic compounds, which are believed to act as pro-drugs and to 
require enzyme-mediated reduction of the nitro group to become cytotoxic. This 
reduction can proceed via one- or two-electron transfer (Figure 1.3). In the case of one-
electron reactions, a nitro anion radical (-NO2·-) is formed that is highly unstable and, 
under anaerobic conditions, can react with and cause damage to various intracellular 
components (Marr and Docampo, 1986). However, in the presence of molecular 
oxygen, the nitro radical is oxidised to the parental nitro pro-drug, generating a 
superoxide anion (O2·-). This process is often referred to as futile redox cycling (Viode 
et al., 1999). Dismutation of the superoxide anion can lead to the formation of other 
reactive oxygen species, such as hydrogen peroxide (H2O2) and hydroxyl radicals 
(·OH), which can be highly damaging to the cellular components (Docampo et al., 
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1981). If the capacity of the cells antioxidant defence system is overwhelmed, the build-
up of reactive oxygen species can cause oxidative damage to proteins and lipids and 
eventually lead to cell death. For example, in T. cruzi the accumulation of high levels of 
hydrogen peroxide has been implicated in the mode of action of nifurtimox (Docampo 
and Moreno, 1986).  
Similar to the African trypanosome, T. cruzi are thought be highly susceptible to 
oxidative stress, as they lack catalase and glutathione. Instead, removal of hydrogen 
peroxide and maintenance of the intracellular thiol redox balance depend exclusively on 
a unique for the kinetoplastids co-factor, termed trypanothione (bis-glutathionyl-
spermidine) (Docampo, 1990; Fairlamb and Cerami, 1992). In some instances, futile 
redox cycling of nitroaromatic pro-drugs can be regarded as a form of detoxification, 
providing that the cell is able to cope with the resulting oxidative stress. For example, 
futile cycling of benznidazole in T. cruzi is a form of detoxification, as it prevents the 
built-up of the toxic nitro anion radicals and occurs sufficiently slowly to allow 
effective removal of the superoxide anion (Marr and Docampo, 1986). A similar 
mechanism of detoxification by redox cycling has also been proposed to operate in 
some strains of Trichomonas, which are resistant to metronidazole only under aerobic 
conditions (Townson et al., 1994).  
There is also a third possibility for the nitro radical – under anaerobic 
conditions, two such radicals may react to form one molecule of the original pro-drug 
and one molecule of the toxic nitroso (-NO) derivative (Marr and Docampo, 1986). 
Alternatively, a nitroso derivative can be formed either via a sequential one-electron 
transfer or via direct two-electron reduction of the parent pro-drug. Usually, the nitroso 
intermediate is reduced in further two-electron transfer steps to form hydroxylamino     
(-NHOH), and in some cases amino (-NH2) derivatives (Roldan et al., 2008). In theory, 
the nitroso and hydroxylamino compounds may also undergo one-electron reductions, 
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but there is no evidence for these reactions in biological systems (Docampo and 
Moreno, 1986). However, unstable hydroxylamino derivatives can disproportionate to 
form a toxic nitroso and an amino derivative (Tang et al., 2005). Finally, 
hydroxylamino derivatives may react non-enzymatically with thioesters, such as acetyl 
CoA, to form N-acetoxy species. The latter can act as alkylating agents and bind 
covalently to DNA or cause DNA interstrand crosslinking (Knox et al., 2003; Tang et 
al., 2005).  
The intracellular fate of nitroaromatic pro-drugs is largely dependent on the 
availability of reducing enzymes, which vary with the organism and have different 
redox potentials. One-electron transfer reactions are typically carried out by oxygen-
sensitive oxidoreductases, commonly referred to as type II nitroreductases. Typical type 
II nitroreductases include xanthine oxidase, glutathione reductase, cytochrome c 
reductase and cytochrome P450 reductase in aerobic organisms, as well as hydrogenase 
and ferredoxin:pyruvate oxidoreductase in anaerobic protozoa (Koder et al., 2002; 
Townson et al., 1994). Conversely, two-electron transfers are carried out by type I, 
oxygen-insensitive nitroreductases. With the exception of some few mammalian 
enzymes, such as DT-diaphorase and xanthine dehydrogenase, type I nitroreductases are 
usually bacterial flavoproteins, which use NADH or NADPH as a co-factor (Koder et 
al., 2002; Roldan et al., 2008).  
Due to the exclusive use of nifurtimox and benznidazole in the treatment of 
South American trypanosomiasis, trypanosomal enzymes involved in the activation of 
nitrodrugs have been studied primarily in T. cruzi. A number of enzymes involved in 
redox reactions have been proposed to metabolise nitro pro-drugs in T. cruzi, including 
old yellow enzyme (TcOYE, prostaglandin F2α synthase; Kubata et al., 2002), 
trypanothione reductase (TcTryR), lipoamide dehydrogenase and several 
NADPH:cytochrome P450 reductases (Blumenstiel et al., 1999; Henderson et al., 1988; 
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Portal et al., 2008; Viode et al., 1999). It has been proposed that TcOYE is the most 
important enzyme in activation of nitro pro-drugs, as evidenced by its loss in T. cruzi 
with in vitro-induced benznidazole resistance (Murta et al., 2006), and by the inhibition 
of all detectable nitroreductase activity in T. cruzi lysates treated with anti-TcOYE 
antibodies (Kubata et al., 2002). However, a homologue of TcOYE is lacking in T. 
brucei, which has been confirmed by the sequencing of the T. brucei genome (Berriman 
et al., 2005). Unexpectedly, the genome sequencing project of T. brucei also revealed 
the presence of a putative nitroreductase gene (Tb927.7.7230; TbNTR), similar to type I 
bacterial nitroreductases. The role of this nitroreductase in nitro pro-drug activation 
formed the basis of this current study. During the course of this study, Wilkinson and 
co-workers reported that laboratory-induced resistance to nifurtimox was associated 
with loss of the TbNTR homologue in T. cruzi, confirming a role of TcNTR in nitro pro-
drug activation (Wilkinson et al., 2008). This, and subsequent work by Wilkinson and 
colleagues will be discussed in more detail in other chapters.  
 
1.3.3. Resistance to nitroaromatic drugs in trypanosomes  
Natural variations in the susceptibility of T. cruzi to nitroaromatic compounds were 
already evident when nifurtimox was first introduced for the treatment of Chagas’ 
disease in the 1960s, although the occurrence of natural resistance to nitroaromatics in 
T. cruzi was disputed at the time (Haberkorn and Gonnert, 1972; Wegner and 
Rohwedde, 1972b). However, subsequent characterisation of domestic and sylvatic 
isolates of T. cruzi revealed that some strains, which have not been exposed to drug 
pressure, were naturally resistant to both nifurtimox and benznidazole (Filardi and 
Brener, 1987).  
There is evidence that natural variation in susceptibility to nitroaromatics may 
also occur in T. brucei. For example, when nitrofurazone was initially tested in animal 
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models of HAT (in guinea pigs and mice), it was noticed that after a single dose, its 
efficacy was strain- and subspecies-dependent, and that T. b. rhodesiense were generally 
less susceptible than T. b. gambiense. Furthermore, mice infected with a certain isolate 
of T. b. rhodesiense could not be cured by nitrofurazone (Miura and Reckendorf, 1967; 
Williamson, 1962). Variability in the efficacy of nitrofurazone has also been observed 
in humans, with cure elicited in approximately half of the treated patients (Williamson, 
1962). Likewise, nifurtimox was found to vary hugely (30 – 80%) in its efficacy in 
clinical trials with T. b. gambiense patients. Although these trials used different doses 
and regimens of the drug, the range of variation led to speculation that there may also be 
regional differences in the nifurtimox susceptibility of T. b. gambiense (patients in Zaire 
were more refractory than patients in Sudan; Pépin et al., 1992). This was supported by 
recent studies with clinical isolates of T. b. gambiense, which revealed that there is a 10-
fold variation in their in vitro susceptibility to nifurtimox (0.34 – 3.8 μM; Likeufack et 
al., 2006; Maina et al., 2007).  
Undoubtedly, nitro drug resistance is understudied in T. brucei. However, with 
the recent introduction of NECT as part of the chemotherapeutic arsenal against 
sleeping sickness and with ongoing clinical trials of fexinidazole for use against both 
stages of HAT, there is now a pressing need to understand the potential of these 
organisms to acquire nitro drug resistance in the field.  
 
1.4. Project aims  
The overall aim of this project is to gain a better understanding of the potential for nitro 
drug resistance in Africa trypanosomes. The specific aims are: 
- to examine the in vitro and in vivo resistance potentials of nifurtimox and 
fexinidazole in BSF T. brucei, and  
- to investigate the involvement of TbNTR in drug activation of nitroheterocycles.  
Chapter 2 -            
Materials and methods  
  
- 30 -
2.1. Materials  
Initial studies with fexinidazole were carried out with compound kindly provided by 
Professor Frank W. Jennings, University of Glasgow. Fexinidazole used in subsequent 
studies, together with fexinidazole sulfoxide, fexinidazole sulfone and PA-824 were 
synthesised in our laboratory by Dr Stephen Patterson as previously described 
(Sokolova et al., 2010). The following compounds were kindly donated to Professor 
Alan H. Fairlamb: 
- nifurtimox from Bayer, Argentina  
- benznidazole from Dr Ralph A. Neal, London School of Hygiene & Tropical Medicine  
- metronidazole from The Boots Company PLC, Nottingham  
- eflornithine from Marion Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio  
All other chemicals were of the highest grade and purity available commercially. Stocks 
of nitroaromatic compounds were prepared in DMSO (supplied by BDH). Buffers and 
other reagents were prepared with ultrapure (Type 1, 18.2 MΩ cm) Milli-Q® water, 
unless otherwise stated.  
 
2.1.1. Analysis of nitroaromatic compounds  
The identity of all compounds synthesised in-house was confirmed by 1H-NMR, 13C-
NMR, 19F-NMR (PA-824 only) and high resolution MS, performed by Dr Stephen 
Patterson. All compounds were determined to be >95% pure by liquid chromatography 
(LC)-MS and the optical purity of PA-824 was confirmed by optical rotation 
measurements (Sokolova et al., 2010). Solubility screenings by nephelometry, which 
measures the concentration of particulate matter as a function of the intensity of 
scattered light (Agarwal and Berglund, 2004), were carried out in collaboration with 
Suzanne Norval, Drug Metabolism and Pharmacokinetics (DMPK) group, University of 
Dundee. The solubility of PA-824, fexinidazole, fexinidazole sulfoxide and fexinidazole 
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sulfone in 0.5% (v/v) DMSO in HMI-9T culture media (section 2.5.1) was determined 
in a 96-well format, using a published high-throughput method (Bevan and Lloyd, 
2000). Measurements were performed using BMG Labtech NEPHELOstar Galaxy laser 
nephelometer, which measures the forward-scattered light when a laser beam is directed 
through a solution. Data were analysed using the MARS analysis software (version 
1.11, BMG Labtech).  
 
2.2. Molecular biology  
2.2.1. Isolation of genomic DNA from T. brucei  
Genomic DNA (gDNA) was isolated from 50 – 100 ml late-log phase BSF T. brucei 
S427 (1 x 106 – 3 x 106 cells ml-1). Cells were harvested by centrifugation (800 x g, 10 
min, room temperature (RT)) and lysed overnight at 56°C in 450 µl TENS buffer (10 
mM Tris-HCl, pH 8.0, 25 mM EDTA, 100 mM NaCl, 0.5% (w/v) SDS) containing 0.1 
mg ml-1 proteinase K. DNA was extracted with Tris-buffered (pH 8.0) 
phenol/chloroform/isoamyl alcohol (PCI, 25:24:1). The organic and aqueous phases 
were separated by centrifugation at 16,000 x g for 1 min, RT. The upper (aqueous) 
phase containing gDNA was subject to a second extraction with PCI and a final 
extraction with CI (24:1). To separate gDNA from inorganic contaminants, PCI-
extracted DNA was precipitated and washed twice in 70% (v/v) ethanol. Finally, DNA 
was allowed to air-dry to remove traces of ethanol. The purified gDNA was 
resuspended in 10 mM Tris-HCl, pH 8.5 and stored at 4°C.  
 
2.2.2. DNA amplification  
DNA was amplified by PCR using Pfu DNA polymerase and buffers (Promega) 
according to the manufacturer’s guidelines. A typical 50-µl reaction contained 120 – 
160 pmol of gene-specific forward and reverse primers (Table 2.1) and approximately 
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50 – 200 ng of template DNA. All PCRs were carried out in 0.2 ml thin-walled tubes 
(Thermo Scientific) in a Thermo-Hybaid MBS 0.2G thermal cycler with a heated lid. 
Usually, DNA was denatured at 94°C for 10 min before the addition of 3 – 6 U Pfu 
DNA polymerase. PCR was continued for 35 cycles of denaturation (30 s at 94°C), 
annealing (30 s at 55 – 68°C depending on Tm of the primers) and extension (2 min per 
kb at 72°C). A final extension for 10 min at 72°C was included after the last cycle. PCR 
products were stored at 4°C.  
 
2.2.3. Agarose gel electrophoresis and extraction of DNA  
DNA size and purity were analysed by agarose gel electrophoresis. Gels were prepared 
by dissolving 0.8% (w/v) agarose in TAE buffer (40 mM Tris-acetate, pH 8.0, 1 mM 
EDTA) containing 0.1 µg ml-1 ethidium bromide for DNA staining. Separation was 
performed in TAE buffer at 80 V. DNA was visualised using either UVP AutoChemi 
transilluminator or U:Genius Gel Documentation System (Syngene). One Kb Plus DNA 
Ladder (Invitrogen) was used to determine the apparent size of the resolved DNA. 
When extraction of DNA from the agarose gel was required, the DNA band of interest 
was excised from the gel and purified with the QIAquick® Gel Extraction Kit (Qiagen) 
as per manufacturer’s guidelines.  
 
2.2.4. Cloning of PCR products  
Following PCR (section 2.2.2) and, when necessary, gel extraction (section 2.2.3), 
blunt-end PCR products were usually sub-cloned into the Vaccinia virus DNA 
topoisomerase I (TOPO®)-activated pCR®-BluntII-TOPO® vector (Invitrogen). 
Alternatively, blunt-end PCR products were cloned in the directional expression vector 
pET151/D-TOPO® (Invitrogen), by means of a 3′-overhang present on the non-coding 
vector strand. Ligations were carried out for 30 min on ice, following the 
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manufacturer’s guidelines. Ligated TOPO® vectors were immediately transformed into 
50 µl TOP10 chemically competent cells (Table 2.2), as described in section 2.2.5.  
 
2.2.5. Transformation of competent E. coli cells  
Chemically competent E. coli cells (see Table 2.2 for an exhaustive list) were 
transformed by heat shock. Briefly, cells (10 – 50 µl aliquots) were allowed to thaw on 
ice for 10 min, before the addition of 50 ng plasmid DNA. Alternatively, 5 – 10 µl of a 
typical ligation reaction (sections 2.2.4 and 2.2.9) was added to the cells. Following 30 
min incubation on ice, cells were heat-shocked for 45 s at 42°C and immediately 
transferred on ice for 2 min. The only exception was ArcticExpress™(DE3)RP 
competent cells, which were incubated with DNA in the presence of 2-mercaptoethanol 
and were heat-shocked for 20 s. Transformed cells were incubated with 250 µl of the 
nutrient rich SOC media* for 20 – 75 min at 37°C. Finally, 50 – 200 µl aliquots of the 
transformed cells were plated on Luria-Bertani (LB) agar plates containing the 
appropriate selection antibiotics, and incubated at 37°C overnight.  
 
2.2.6. Purification of plasmid DNA  
Plasmid DNA was isolated from bacterial cells using the QIAprep® Spin Miniprep Kit 
(Qiagen) according to the manufacturer’s guidelines. Briefly, TOP10 or JM109 E. coli 
cells (Table 2.2) were transformed with the plasmid of interest as described in section 
2.2.5. Single colonies were incubated overnight at 37°C in 5 ml LB media with the 
appropriate selection antibiotics. Overnight cultures were harvest by centrifugation at 
3800 x g for 10 min at RT. The bacterial pellets were lysed under alkaline conditions 
(based on the modified method of Birnboim and Doly, 1979). Following neutralisation, 
                                                 
* All bacterial growth media and plates were prepared by Media Services at the University of Dundee, 
using standard protocols (Sambrook and Russell, 2001).  
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plasmid DNA was adsorbed on silica membranes in the presence of high salt 
(Vogelstein and Gillespie, 1979). Finally, the purified DNA was eluted in a low-salt 
buffer (10 mM Tris-HCl, pH 8.5) suitable for subsequent applications. Alternatively, for 
large scale preparations (up to 50 µg DNA), plasmid DNA was isolated in a similar way 
from 80 – 150 ml overnight culture using the HiSpeed® Plasmid Midi Kit (Qiagen).  
 
2.2.7. DNA sequencing 
DNA sequencing was performed by DNA Sequencing and Services™ at the University 
of Dundee (http://www.dnaseq.co.uk), using Applied Biosystems Big-Dye® Terminator 
chemistry version 3.1 on an Applied Biosystems 3730 automated capillary DNA 
sequencer. Plasmid DNA samples were submitted at concentrations of 16 – 20 ng µl-1, 
whereas gel-purified PCR products were submitted at 40 ng µl-1. All primers used in 
DNA sequencing are listed in Table 2.1.  
 
2.2.8. Digestion of plasmid DNA with restriction endonucleases  
Analysis of DNA with restriction enzymes was typically performed on 2 – 4 µl purified 
plasmid DNA (see above) in a 5 µl reaction. The total amount of restriction 
endonucleases (5 – 6 U, Promega or Fermentas FastDigest® enzymes) was maintained 
at 10% of the final volume for both single and double digests. Reactions were incubated 
at 37°C for 3 – 16 h and the resulting band pattern was visualised by gel electrophoresis 
(section 2.2.3). For preparative digests, up to 2 µg of plasmid DNA was digested with a 
total of 20 – 25 U of restriction enzymes in a final volume of 25 – 60 µl. Reactions were 
incubated for at least 5 h at 37°C. Preparative digests of cloning vectors were incubated 
for an additional 1 h in the presence of Shrimp alkaline phosphatase (SAP, 1 U, 
Promega). Immediately following the incubation, SAP was heat-inactivated for 15 min 
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at 65°C. Prior to ligation, either the vector or insert of interest was purified by gel-
extraction as previously described (section 2.2.3). 
 
2.2.9. Ligation  
Ligation reactions were carried out with gel-purified restriction fragments (section 2.2.3 
and 2.2.8). Purified target vector (~50 ng) and insert were typically combined in molar 
ratios of 1:1, 1:3 and 1:5 respectively, in a 10-µl reaction. To control for background 
vector self-ligation, 50 ng of vector was incubated in the absence of insert. Ligations 
were carried out in the presence of 1 U T4 DNA ligase (Promega or Roche) at RT for 5 
h or at 14°C overnight. Following incubation, 5 – 10 µl of ligation reaction was 
transformed in 30 – 50 µl XL10-Gold® Ultracompetent cells as in section 2.2.5. Single 
colonies of the transformed cells were used for plasmid purification (section 2.2.6), and 
the accuracy of the assembled constructs was verified by restriction digest and DNA 
sequencing as previously described. A list of the resulting ligation products used for 
bacterial expression studies is given in Table 2.3.  
 
2.2.10. Replacement of the thrombin recognition site in pET43.1c_TbNTRΔ83  
The sequence encoding the thrombin protease recognition motif was replaced with the 
Tobacco Etch Virus (TEV) protease recognition motif using oligonucleotides 
TEV_forward and TEV_reverse (Figure 2.1). The two oligonucleotides (4 nmoles each) 
were heated to 99°C and annealed by slow cooling to RT over 5 – 6 h. The annealed 
DNA was phosphorylated at the 5′-end using T4 polynucleotide kinase (Promega) as per 
manufacturer’s guidelines and ligated into the SacI/SacII-digested vector as described in 
section 2.2.9. Replacement of the recognition motif was confirmed by restriction digest 
and DNA sequencing. 
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2.2.11. Southern analysis of genomic DNA  
Genomic DNA isolated from wild-type and nitrodrug-resistant T. brucei was analysed 
by Southern blot (Southern, 1975). DNA (1 – 5 µg) was digested overnight at 37°C in 
the presence of various restriction enzymes (Promega). The digested DNA was resolved 
on a 0.8% (w/v) agarose gel (section 2.2.3) and depurinated in 0.25 M HCl for 10 min. 
Following equilibration in 0.4 M NaOH, DNA was transferred to a positively charged 
nylon membrane (GE Healthcare or Roche) by the downward capillary transfer method 
(Sambrook and Russell, 2001). When the transfer was complete, the membrane was 
rinsed in 5-fold SSC buffer (supplied as 20-fold buffer by Invitrogen) for 25 min and 
DNA was cross-linked to the membrane by UV irradiation at 1200 µJ cm-2. If required, 
the cross-linked DNA was visualised using Methylene Blue (Amresco®) DNA stain (1-
fold in Milli-Q® water, filter sterilised), followed by washing with 0.1% (w/v) SDS. The 
membrane was pre-hybridised at 42°C for 2 h in DIG Easy Hyb (Roche) prior to 
overnight hybridisation at 42°C with the denatured digoxigenin-dUTP-labelled DNA 
probe.  
Probes were prepared in advance from the open reading frame (ORF) of TbNTR, 
using either DIG-High Prime DNA Labelling and Detection Starter Kit II (Roche) or, in 
later experiments, PCR DIG Probe Synthesis Kit (Roche), following the manufacturer’s 
guidelines. The labelled ORFs of dihydrofolate reductase-thymidylate synthase 
(TbDHFR-TS) and trypanothione synthetase (TbTryS) from T. brucei S427 (section 
2.5.1) were courtesy of Dr Susan Wyllie, Dr Sandra L. Oza and Dr Natasha Sienkiewicz 
(Sienkiewicz et al., 2008; Wyllie et al., 2009).  
Washing of the membrane post hybridisation, as well as the immunological 
detection of the probe, were performed with the DIG Wash and Block Buffer Set and 
the CSPD ready-to-use reagent (Roche), according to the manufacturer’s guidelines. 
The processed membrane was exposed to Amersham Hyperfilm ECL™ (GE Healthcare) 
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for 2 min. To re-use the membrane for subsequent hybridisations, the membrane was 
rinsed in autoclaved ultrapure Milli-Q® water and stripped with 3 x 50 ml 0.4 M NaOH, 
1% (w/v) SDS at 45°C over a total of 50 min. The stripped membrane was neutralised 
in 2 x SSC buffer and either stored at 4°C or pre-hybridised and processed further, as 
described. 
 
2.3. Expression and purification of recombinant proteins  
2.3.1. Expression of recombinant TbNTR  
Expression constructs (Table 2.3), carrying full-length or truncated versions of TbNTR, 
were transformed into a number of expression strains of E. coli (Table 2.2) as described 
in section 2.2.5. Cells transformed with empty vectors were processed in parallel and 
used as expression controls. Single colonies were selected and incubated overnight at 
37°C in 10 – 100 ml LB media supplemented with the appropriate selection antibiotic. 
Overnight cultures were harvested by centrifugation (3800 x g, 10 – 15 min, RT), 
resuspended in one volume of fresh media with antibiotics, and diluted 20- to 100-fold 
in either autoinduction or LB media with selection antibiotics. Cells in autoinduction 
media were incubated with agitation at 200 rpm for 1 h at 37°C, followed by 24 – 48 h 
incubation at the selected expression temperature. Cells in LB media were incubated at 
37°C until the optical density at λ = 600 nm (OD600) reached 0.5 – 0.8. For expression at 
37°C, cells were induced by the addition of 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG, 0.2 µm filter sterilised) and incubated further, up to 20 h. Alternatively, cells 
were equilibrated for 30 – 60 min at the selected expression temperature (OD600 ≈ 1.2 – 
1.8) prior to addition of 1 mM IPTG. Following incubation, cells were harvested by 
centrifugation (4,000 x g, 30 – 45 min, 4°C). Cell pellets were washed once with PBS 
and either processed as described in section 2.3.2, or flash frozen in dry ice/ethanol and 
stored at -80°C.  
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2.3.2. Preparation of cell-free bacterial lysates  
All procedures were carried out on ice unless otherwise specified. Following expression 
of recombinant protein, cell pellets were resuspended in the appropriate lysis buffer 
(Table 2.4) supplemented with DNAse I (Sigma) and a complete EDTA-free protease 
inhibitor cocktail (Roche). Typically, cells were lysed using a One-Shot or a Continuous 
Cell Disruptor (Constant Systems) under pressure of 30 kpsi. Alternatively, samples of 
≤2 ml were lysed in the presence of lysozyme (from chicken egg white, Sigma) by 5 
cycles of flash-freezing and rapid thawing, followed by sonication (3 x 15 – 30 s, with 
intermittent cooling) using a Soniprep 150 sonicator (Sanyo) at 15 µm amplitude with 
an exponential probe. When required, bacterial cell lysates were clarified by 
centrifugation (10,000 – 50,000 x g, 10 – 45 min, 4°C).  
 
2.3.3. Immobilised metal affinity chromatography (IMAC)  
Nickel affinity chromatography was performed using a 5 ml HisTrap™ HP* pre-packed 
column, pre-equilibrated in 10 column volumes of binding buffer (lysis buffer 
supplemented with ≤40 mM imidazole, Table 2.4). Clarified bacterial cell lysates 
(section 2.3.2) were applied to equilibrated columns at a constant flow rate (2 – 2.5 ml 
min-1) using a peristaltic pump and the flow-throughs were collected. Columns were 
connected to an ÄKTApurifier™ 100 FPLC system (GE Healthcare), and washed in 10 – 
20 column volumes binding buffer. Bound proteins were eluted at a flow rate of 5 ml 
min-1 with a 0 – 100% (v/v) gradient of 1 M imidazole in binding buffer. Elution was 
monitored at λ = 280 nm and 2-ml fractions were collected using the in-built Frac-950 
automated fraction collector. Samples of loaded, flow-through and eluted proteins were 
analysed by SDS-PAGE (section 2.4.2), and when necessary, by Western blotting 
(section 2.4.3).  
                                                 
* All HisTrap™, HiTrap™ and HiLoad™ columns were purchased from Amersham/GE Healthcare.  
  
- 39 -
2.3.4. Ion exchange chromatography  
Protein separation by anion exchange chromatography was performed on a small scale 
using 5 ml HiTrap™ Q HP and 5 ml HiTrap™ Q FF columns. Large scale anion 
exchange was carried out in a similar manner using a HiLoad™ 16/10 Q Sepharose® HP 
column. Cation exchange chromatography was carried out only on a small scale, using a 
1 ml HiTrap™ SP FF column. Columns were pre-equilibrated in a low-salt binding 
buffer (ionic strength ≤100 mM), prior to sample loading. Small-scale samples were 
loaded manually with a syringe. Following column washing (~10 column volumes 
binding buffer), proteins were eluted with a three-step gradient of 0 – 1 M NaCl in 
binding buffer. Flow-through and elution steps were collected for analysis. 
Alternatively, large samples were loaded on the column by automated sample injection 
using an ÄKTApurifier™ 100 FPLC. Column washing, protein elution and fraction 
collection were performed as in section 2.3.3, with a 0 – 100% (v/v) continuous gradient 
of 1M NaCl in binding buffer at 2 ml min-1. All samples were analysed by SDS-
PAGE/Western blotting as described.  
 
2.3.5. Size exclusion chromatography  
Protein separation by gel filtration was performed using either HiLoad™ 26/60 
Superdex™ 75 or HiLoad™ 16/60 Superdex™ 200 prep grade columns. Column 
equilibration, automated sample loading and protein separation were carried out 
according to the manufacturer’s guidelines. Fractions (2 ml) were collected and 
analysed as previously described (section 2.3.3). Following each run, gel filtration 
standards (Bio-Rad) were applied to the column and resolved under the same conditions 
as the sample. To determine the molecular weight (MW) of the resolved samples, a 
calibration curve was prepared by plotting log MW for each gel filtration standard as a 
function of its elution volume divided by the void volume of the column (VR ÷ V0).  
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2.3.6. Other chromatographic methods  
In addition to the standard IMAC (section 2.3.3) and ion exchange chromatography 
(section 2.3.4), several other methods were tested in attempts to purify recombinant 
TbNTRΔ54-His6. Initially, a protein preparation in 20 mM sodium phosphate, pH 7.0, 
was applied to a 1 ml Co-MAC™ column (Novagen), which is an IMAC column pre-
charged with Co2+ ions in place of Ni2+. The column was washed manually in 6 column 
volumes of binding buffer and bound proteins were eluted in 250 mM imidazole in 
binding buffer.  
Alternatively, an identical preparation was applied to a 5 ml HiTrap™ Blue HP 
column, which not only binds proteins via hydrophobic and electrostatic interactions, 
but also mimics nucleotide co-factors (e.g. NAD+) and provides an alternative method 
for affinity chromatography. Following a washing step (10 column volumes binding 
buffer), proteins bound to HiTrap™ Blue HP were eluted manually in 2 M NaCl. 
Aliquots from all steps were taken and analysed as described (section 2.4.2 and 2.4.3).  
 
2.3.7. Batch affinity chromatography  
Clarified bacterial cell lysates (10,000 x g, 30 min, 4°C; section 2.3.2) of E. coli BL21-
CodonPlus®(DE3)-RP expressing TbNTRΔ54-His6 (section 2.3.1) were incubated with 
10% (v/v) Ni-NTA (nitrilotriacetic acid) agarose beads (Qiagen) for 2 h at 4°C with 
gentle agitation. Cells transformed with an empty pET15b_TEV vector were used to 
control for non-specific protein interactions with the beads. Binding was carried out in 
the presence of 50 mM sodium phosphate, pH 7.8 or in NaCl/sucrose/CHAPS-buffer 
(50 mM sodium phosphate, pH 7.8 supplemented with 0.5 M NaCl, 40% (w/v) sucrose 
and 1% (w/v) 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate 
(CHAPS)). Unbound proteins were removed by centrifugation (1,000 x g, 10 s, RT) in 
0.8 ml centrifuge columns (Thermo Scientific). Beads were washed with 20 column 
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volumes of 20 mM imidazole in phosphate buffer with 0.5 M NaCl, and proteins were 
eluted in 3 x 2 column volumes of 0.5 M imidazole in washing buffer with 0.5% (v/v) 
Triton® X-100. Samples were analysed by SDS-PAGE.  
 
2.3.8. Buffer exchange and sample concentration  
Buffer exchange was carried out by three different methods: dialysis, gel filtration and 
following sample concentration. The preferred method for dialysis was using Slide-A-
Lyzer dialysis cassettes (Thermo Scientific) with a molecular weight cut-off (MWCO) 
of 3.5 kDa or 10 kDa and a capacity of 0.5 – 12 ml. Dialysis buffer (150- to 500-fold 
sample volume) was exchanged three times over 1.5 – 16 h. Samples of <0.5 ml were 
dialysed using D-Tube™ Mini Dialyzer (6 – 8 kDa MWCO; Novagen), according to the 
manufacturer’s guidelines. Alternatively, desalting and/or buffer exchange of very small 
samples was performed by the principle of gel filtration using 0.5 ml Zebra™ Spin 
desalting columns (7 kDa MWCO; Thermo Scientific) according to the manufacturer’s 
guidelines. Large (>10 ml) or dilute samples were concentrated by centrifugation at 
3,800 x g, 4°C, using Vivaspin 20 concentrators (Sartorius Stedim Biotech) with 10 kDa 
MWCO and polyethersulfone membranes. For simultaneous buffer exchange, the 
concentrated sample was diluted in the required buffer and concentrated again. The 
procedure was repeated at least 3 times.  
 
2.3.9. Proteolytic cleavage of affinity tags  
Three types of proteases were used for the removal of fusion tags from recombinant 
proteins: thrombin, enterokinase and TEV protease. Thrombin (from bovine plasma; GE 
Healthcare) was incubated overnight at RT or 4°C with affinity purified (section 2.3.3) 
NusA-TbNTRΔ83 (1 – 10 U protease per 100 µg substrate (total protein)). Samples were 
removed at various times for analysis by SDS-PAGE. Alternatively, NusA-TbNTRΔ83 
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was digested at RT or 4°C with recombinant enterokinase (rEK, Novagen; 1 – 5 U per 
100 µg), following the manufacturer’s guidelines. Other fusion proteins (Table 2.3) 
were cleaved using His-tagged recombinant TEV protease produced in our laboratory, 
at a mass ratio between 1:5 and 1:25, protease to substrate respectively. Incubation at 
(23 – 37)°C was carried out for a maximum of 2 h, whereas incubation at (4 – 14)°C 
was carried out for 24 h.  
 
2.3.10. Protein purification under denaturing conditions  
Purification of recombinant His6-TbNTRΔ7 from inclusion bodies was performed under 
denaturing conditions, using Pierce B-PER™ (Bacterial protein extraction reagent) and 
Inclusion Body Solubilisation Reagent (IBSR; Thermo Scientific). Recombinant protein 
was purified from BL21-CodonPlus®(DE3)-RP cells, following IPTG-induced 
expression (16°C, 62 h; section 2.3.1). Cell pellets were lysed over 20 min at RT in 5 ml 
B-PER per 1 g pellet, supplemented with DNAse I (Sigma) and a complete EDTA-free 
protease inhibitor cocktail (Roche). Soluble E. coli proteins were removed by 
centrifugation (27,000 x g, 15 min, 4°C) and inclusion bodies-containing pellets were 
washed once in B-PER. To remove further E. coli contaminants, pellets were 
sequentially washed in 2, 4 and 6 M urea in 100 mM sodium phosphate, pH 8.0, 10 mM 
Tris-HCl (5 ml per g pellet; method based on Reischl et al., 1996). Washed pellets were 
solubilised in IBSR (8 ml per g pellet) at 4°C overnight. Recombinant protein was then 
purified under denaturing conditions (5 M guanidinium-HCl in 50 mM Tris-HCl, pH 
6.8, 0.3 M NaCl, 10% glycerol) by Ni2+-affinity chromatography as described (section 
2.3.3). Fractions were analysed by SDS-PAGE and fractions of the highest purity were 
pooled for use in subsequent experiments.  
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2.3.11. Expression and purification of recombinant EcNfsB  
The gene encoding E.coli NfsB was amplified by PCR from E. coli K12 gDNA, kindly 
provided by Professor William N. Hunter, University of Dundee. EcNfsB, cloned into 
the pET-3a expression vector (section 2.2.9), was expressed in BL21-Gold(DE3) cells 
(Table 2.2) overnight at 20°C in autoinduction media, as previously described (section 
2.3.1). Recombinant EcNfsB was purified according to a published method (adapted 
from Anlezark et al., 1992). Briefly, clarified bacterial cell lysates (50,000 x g, 40 min, 
4°C; section 2.3.2) were applied to a 5 ml HiTrap™ Phenyl HP column in the presence 
of 20 mM potassium phosphate, pH 7.0, 0.3 M (NH4)2SO4. Flow-through fractions were 
collected, concentrated and dialysed against 20 mM Tris-HCl, pH 7.6 (section 2.3.8). 
Dialysed fractions were applied to a 5 ml HiTrap™ Q FF column and eluted with a 0 – 
0.2 M KCl gradient over 10 column volumes, using ÄKTApurifier™ 100 FPLC as 
described (section 2.3.4). Fractions of the highest purity (section 2.4.2) and activity 
(section 2.4.5) were pooled and concentrated to 0.5 mg ml-1. Aliquots were flash-frozen 
in the presence of 10 µM FMN and 20 % (v/v) glycerol, and stored at -80°C.  
 
2.3.12. Cell-free expression of recombinant TbNTR  
Recombinant TbNTRΔ54-His6 was expressed using the TNT® (transcription and 
translation) T7 coupled wheat germ extract system (Promega). To prepare DNA for use 
with this expression system, purified pET20b_TEV_TbNTRΔ54 (section 2.2.6) was 
linearised by restriction digest with PvuI (Promega, section 2.2.7) and extracted with 
PCI (section 2.2.1). Following precipitation in 70% (v/v) ethanol, the linearised DNA 
was resuspended in nuclease-free water (Promega) to 0.5 µg µl-1. An empty 
pET15b_TEV vector was used as a negative control and pET3a_EcNfsB was used as a 
positive expression control. Expression was performed in the presence of RNasin® 
ribonuclease inhibitor (Promega), for 1.5 h at 30°C, according to the manufacturer’s 
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guidelines for non-radioactive reactions. Immediately following expression, the reaction 
mix was incubated for 2 h at 4°C with 5% (v/v) Ni-NTA agarose resin (Qiagen). 
Unbound proteins were separated by centrifugation at 1,000 x g, 10 s, RT. Bound 
proteins were eluted in 0.5 M imidazole in 50 mM sodium phosphate, pH 7.4, 0.5 M 
NaCl, 40% (w/v) sucrose. Protein expression and binding to the resin were analysed by 
Western blotting (section 2.4.3) and nitroreductase activity assays (section 2.4.5).  
 
2.4. Protein detection and characterisation 
2.4.1. Protein quantification  
Proteins were quantified using the Bio-Rad protein assay (Bio-Rad) based on the 
method of Bradford (Bradford, 1976). The assay was performed according to the 
manufacturer’s guidelines for the microassay procedure, using BSA as a standard. 
Absorbance at λ = 595 nm was measured in a UV-1601 Shimadzu spectrophotometer. 
Standard curves were prepared using UV Probe software (Shimadzu).  
 
2.4.2. SDS-PAGE  
SDS-PAGE (Laemmli, 1970) was used to determine the size and purity of recombinant 
proteins. Briefly, samples were boiled for 10 min in the presence of Laemmli sample 
buffer (Bio-Rad) containing either 5% (v/v) 2-mercaptoethanol or 10 mM dithiotreitol 
(DTT). Protein bands were resolved on a NuPAGE® Novex® 12% Bis-Tris gel (1.0 mm, 
Invitrogen), using the XCell SureLock™ Mini-cell electrophoresis apparatus 
(Invitrogen). Electrophoresis was carried out at 180 V in 1-fold NuPAGE® MES SDS 
running buffer (Invitrogen), until the desired separation was achieved. Gels were stained 
with Coomassie® Brilliant Blue [0.1% (w/v) G-250 or 0.01% (w/v) R-250, in 40% (v/v) 
methanol, 10% (v/v) acetic acid] and destained with 20% (v/v) methanol, 10% (v/v) 
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acetic acid. Mark12™ (Invitrogen), Broad Range (Bio-Rad) and Precision Plus™ (All 
Blue, Bio-Rad) protein standards were used to determine the MW of the resolved bands.  
 
2.4.3. Western blotting  
Prior to analysis by Western blotting, unstained SDS-PAGE gels (section 2.4.2) were 
equilibrated in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol; Towbin et al., 1979). Proteins were transferred onto Protran™ nitrocellulose 
membrane (Whatman) using Trans-Blot® SD semi-dry electrophoretic transfer cell 
(Bio-Rad) at 25 V for 20 min. To block non-specific binding sites, membranes were 
incubated for at least 1 h with 5% (w/v) dry milk in PBS containing 0.5% (v/v) Tween® 
20. Primary and secondary (horseradish peroxidise (HRP)-conjugated) antibodies 
(Table 2.5) were incubated with the blot for 1 h each in PBS containing 1% (w/v) dry 
milk and 0.5% (v/v) Tween® 20, with an intermediate washing step (3 x 10 min) in 
antibody dilution buffer. Finally, membranes were washed (3 x 10 min) in buffer 
without milk. Alternatively, immunological detection was performed using the 
His•Tag® Antibody HRP Conjugate Kit (Novagen) according to the manufacturer’s 
guidelines, with alkali-soluble casein as a blocking reagent and PBS with or without 
0.5% (v/v) Tween® 20 as a washing buffer. Washed blots were incubated with 
Amersham ECL™ or ECL Plus™ detection reagent (GE Healthcare) and exposed to 
Hyperfilm ECL™ (GE Healthcare), following the manufacturer’s protocol.  
 
2.4.4. Protein fingerprinting analysis  
Identification of proteins by mass fingerprinting analysis was performed by the 
FingerPrints Proteomics Facility at the University of Dundee. Samples were submitted 
to the facility resolved on a NuPAGE® Novex® 12% Bis-Tris gel (section 2.4.2) and 
stained with SimplyBlue™ Safe Stain (Invitrogen). Protein bands of interest were 
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excised from the gel and trypsin-digested, prior to analysis by nano-LC coupled to 
electrospray ionisation tandem MS (ESI-MS-MS), using the 4000 QTRAP (Applied 
Biosystems) tandem MS system.  
 
2.4.5. Nitroreductase activity in bacterial lysates  
The nitroreductase activity of bacterial cell lysates or protein preparations was measured 
according to a modified nitroreductase activity assay (based on Zenno et al., 1996). 
Briefly, assays were performed in 50 mM sodium phosphate, pH 7.0, 1% (v/v) DMSO, 
at 27°C in 1 ml acrylic cuvettes (1-cm path length, BrandTech Scientific). Protein 
preparations (up to 300 µl) were equilibrated to 27°C for 1 min in the presence of 100 
µM nitrofurazone (Sigma) and background reduction of nitrofurazone was recorded for 
further 2 min, using a Shimadzu UV-1601 spectrophotometer equipped with a 
temperature-regulating Peltier device. The reaction was initiated with 100 – 250 µM 
NADH or NADPH (Melford Laboratories) and the initial rate of nitrofurazone 
disappearance was monitored for up to 1 min at λ = 420 nm (ε420 nm = 5,590 M-1 cm-1; 
Race et al., 2005). One unit of nitroreductase activity was defined as the amount of 
protein required to reduce 1 µmol of nitrofurazone per minute. The change in moles of 
substrate (n) was derived from the initial change in absorbance over time (ΔA/Δt), based 
on Beer’s law (1): 
 lcA ⋅⋅= ε   (1) 
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Δ∴ ε   (2), 
where ε and c are the extinction coefficient and concentration of nitrofurazone, 
respectively, l is the path length and V is the assay volume.  
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2.4.6. Disc diffusion test  
Disc diffusion or Kirby-Bauer test (Bauer et al., 1966) was employed as an alternative 
method to detect nitroreductase activity in whole-cell E. coli. BL21-CodonPlus®(DE3)-
RP competent cells were transformed (section 2.2.5) with either pET20b_TEV_ 
TbNTRΔ54 or pET20b_TEV_TbNTRΔ54(Val106Ile). Cells transformed with an empty 
pET15b_TEV vector were used a negative control for background activity. Conversely, 
cells transformed with pET3a_EcNfsB were used as a positive control. Expression of 
recombinant protein was induced in 100 ml LB media supplemented with 1-fold 
carbenicillin (50 µg ml-1), as previously described (section 2.3.1). Following 60 h 
incubation at 16°C, 200 rpm, cells were harvested by centrifugation (3,800 x g, 10 min, 
4°C). Cell pellets were resuspended in ice-cold LB media with 1-fold carbenicillin to 
OD600 ≈ 5 (approximately 5 x 109 cells ml-1, Wiegand et al., 2008) and cell suspensions 
(200 µl per plate) were spread evenly on duplicate LB agar plates with 1-fold 
carbenicillin. Plates were allowed to dry at RT for 2 h, prior to the addition of discs. 
Each disc contained 5 µl of 0.1 – 10 mM nitrofurazone or 1 – 100 mM nifurtimox in 
100% (v/v) DMSO. Streptomycin sulphate (Merck) was used at 2 mg ml-1 in Milli-Q® 
H2O as a control drug with a known zone of inhibition (Bauer et al., 1966). 
Alternatively, discs containing 5 µl of DMSO or H2O were used to control for the zone 
of inhibition due to solvent/carrier. Following overnight incubation at 37°C, the 
diameter of the zone of inhibition was recorded for each disc to the nearest whole 
millimetre.  
 
2.5. Cell culture of T. brucei  
2.5.1. Cell lines and culture conditions  
All T. brucei cell lines were derived from BSF T. brucei ‘single-marker’ S427, 
constitutively co-expressing T7 RNA polymerase (T7RPOL) and Tet repressor (TETR) 
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in tandem with the drug-resistance marker gene neomycin phosphotransferase (NEO; 
Wirtz et al., 1999). For convenience, these cells are hereafter referred to as wild-type T. 
brucei. Wild-type and derivative T. brucei cell lines were routinely subcultured every 2 
– 3 days by dilution in fresh modified HMI-9T media (HMI-9 containing 56 µM 1-
thioglycerol in place of 200 µM 2-mercaptoethanol) supplemented with 2.5 µg ml-1 
G418 to maintain the expression of the T7RPOL TETR NEO expression cassette 
(Hirumi and Hirumi, 1989; Wyllie et al., 2009). Cells were incubated at 37°C in a 5% 
CO2 humidified atmosphere.  
 
2.5.2. Cell density measurements  
T. brucei cell numbers were determined using a CASY® cell counter Model TT (Shärfe) 
according to the manufacturer’s guidelines. Alternatively, cells were counted manually 
using a Neubauer haemocytometer chamber under a light microscope (Zeiss). 
 
2.5.3. Generation of TbNTR single knock-out (SKO) cell lines  
To generate a TbNTR gene replacement cassettes, a region spanning ~600 bp either side 
of the TbNTR ORF was amplified by PCR from T. brucei S427 gDNA (section 2.2.1), 
using primers 5′UTR_-595_F and 3′UTR_+600_R (Table 2.1). This sequence was then 
used to amplify the 5′- and 3′-untranslated regions (UTRs) immediately adjacent to the 
start and stop codons of TbNTR, using primers listed in Table 2.6. The 470 bp long 
UTRs were joined in a subsequent knitted PCR via a linker BamHI-PmeI-HindIII 
region, introduced by the PCR primers. The endogenous NotI site present within the 3′-
UTR was silenced using primers 3′UTR_mut_G89C_F and 3′UTR_mut_G89C_R, and 
the QuikChange Lightning site-directed mutagenesis kit (Stratagene) as per 
manufacturer’s guidelines. The mutant 5′- 3′-UTR construct was then cloned in the NotI 
site of the pGEM-5Zf(+) vector (Promega), followed by the insertion of either 
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puromycin acetyltransferase (PAC) or hygromycin phosphotransferase (HYG) resistance 
genes between the BamHI and HindIII restriction sites (sections 2.2.8 and 2.2.9). The 
accuracy of the final SKO constructs was verified by DNA sequencing, prior to use in 
transfection (section 2.5.4).  
 
2.5.4. Generation of transgenic T. brucei cell lines  
Wild-type BSF T. brucei were transfected using the patented Amaxa® Nucleofector® 
system (Lonza), according to the improved protocol of Burkard and colleagues (Burkard 
et al., 2007). Briefly, plasmid DNA was linearised by digestion with NotI (section 
2.2.8), purified by precipitation in 70% (v/v) ethanol containing 80 mM sodium acetate, 
and resuspended in ultrapure Milli-Q® water to 1 µg µl-1. For each electroporation, 10 
µg of the purified DNA were added to 4 x 107 wild-type cells, resuspended in 100 µl 
human T-cell Nucleofector® solution. Cells were transfected using programme X-001 of 
the Nucleofector® II electroporator and were allowed to recover overnight in 25 ml pre-
warmed HMI-9T media. Following overnight incubation, 25- and 625-fold dilutions of 
the transfected cultures were plated in 12-well plates in the presence of the appropriate 
selection antibiotic (5 µg ml-1 phleomycin, puromycin or hygromycin). After 3 – 4 days, 
wells containing dividing cells were subcultured in flasks as in section 2.5.1. 
Subsequent experiments were performed on clonal lines (see below) derived from the 
primary transgenic line in the presence of selection antibiotics. In cells transfected with 
expression constructs, the expression of the respective exogenous protein was induced 
by the addition of 2.5 µg ml-1 tetracycline every 2 days for a minimum of 1 week.  
 
2.5.5. Isolation of T. brucei clones  
Clones of all T. brucei cell lines were prepared by limiting dilution. After the initial cell 
density of the relevant line was determined (see section 2.5.2), the cell suspension was 
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diluted to 1.5 cells ml-1 and plated in 96-well plates. Each well contained 200 µl 
suspension (equivalent to ⅓ of a cell per well). After 1 week, dividing cells were present 
in 15% – 30% of the wells. Usually, 5 – 10 clones were selected for further analysis.  
 
2.5.6. Growth inhibition studies of T. brucei  
The effective compound concentration which inhibits cell growth by 50% (EC50) was 
used as an estimate for the in vitro sensitivity of T. brucei to various compounds. EC50 
values were determined in 96-well plates (Greiner) as previously described (Jones et al., 
2010a). Test compounds were prepared in DMSO and serially diluted in HMI-9T 
media, with the highest compound concentration in the range of 0.05 – 500 µM based 
on solubility (section 2.1.1) and predicted EC50 values. The final DMSO concentration 
in the assay was kept constant at 0.5 % (v/v). Wild-type or derivative BSF T. brucei 
were added, to a final concentration of 1 x 105 ml-1 for slow-growing cells or 2.5 x 103 
ml-1 for fast-growing cells, in a final assay volume of 200 µl. Following a 3-day 
incubation (section 2.5.1), 45 µM resazurin (Sigma) was added and the plates were 
incubated at 37°C for further 4 – 5 h. Fluorescence due to the formation of resorufin 
(O'Brien et al., 2000) was measured at λexcitation = 528 nm and λemission = 590 nm. Data 
were corrected for background fluorescence (wells with media only) and expressed as a 
percentage of non-treated cells. Corrected data were fitted to the following two-
parameter non-linear regression, using GraFit software: 
 m
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I
y
⎟⎟⎠
⎞
⎜⎜⎝
⎛+
=
50
][1
100  (3) 
In equation (3), y is the growth percentage at inhibitor concentration [I], and m is the 
slope factor. Measurements were repeated on at least three occasions and the data were 
presented as the weighted mean ± the weighted standard error of the mean (S.E.M.). 
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The weighted mean EC50 and m values were subsequently used to calculate the 
minimum inhibitory concentration (EC99) using equation (4): 
 mECEC 15099 99×=  (4) 
 
2.5.7. Generation of resistant T. brucei cell lines  
A nifurtimox-resistant line was generated by subculturing wild-type T. brucei in the 
continuous presence of nifurtimox. Starting at a sublethal concentration of 1.5 µM, the 
drug concentration in the culture media was increased in a step-wise manner, usually by 
2-fold. Cells, resistant to ≥6 µM drug, were cryopreserved before the drug concentration 
was increased. After a total of 140 days in culture, when trypanosomes were able to 
survive and grow in 50 µM nifurtimox, the resulting T. brucei line (designated NfxR) 
was cloned in the absence of nifurtimox (section 2.5.5). Two clones (NfxR1 and 
NfxR2) displaying the highest resistance to nifurtimox, were selected for further studies. 
Resistance to fexinidazole was generated in T. brucei is a similar manner, starting at 1.0 
µM fexinidazole. Fexinidazole-resistant clones were derived from the resulting FxR line 
after 137 days in culture, and clones FxR1 and FxR2 were selected for further analysis.  
 
2.5.8. Measurement of the doubling time of T. brucei   
To determine the doubling time (td) of T. brucei, the cell density was recorded (section 
2.5.2) over a period of 10 days. The logarithm of the resulting cumulative cell number 
(N) was plotted as a function of time (t) and the Hill slope of the linear regression,  
 tNNm )log(log 0−=     
was calculated using GraFit (N0 is the initial cell number). The doubling time was then 
calculated using equation (5): 
  ( ) mNN
ttd
2log2log
loglog 0
=×−=  (5) 
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2.5.9. Analysis of intracellular thiols  
The intracellular levels of glutathione (GSH) and trypanothione (T[SH]2) were 
determined in wild-type and nitrodrug resistant T. brucei. Late-log phase trypanosomes 
(1 x 108 cells) were harvested by centrifugation (950 x g, 10 min, 4°C) and washed once 
in ice-cold PSG buffer (PBS, pH 8.0, 1.5% (w/v) glucose and 0.5 mg ml-1 BSA). Thiols 
were derivatised with monobromobimane according to a published protocol (Shim and 
Fairlamb, 1988). Analysis of the acid-soluble thiols by reverse phase (RP) HPLC was 
performed by Dr Susan Wyllie as previously described (Wyllie et al., 2009).  
 
2.5.10. Pull-down of TbNTR-myc  
A tetracycline-inducible (Ti) ectopic copy of gene encoding for TbNTR fused to a C-
terminal c-myc tag (TiTbNTR-myc) was introduced into wild-type BSF T. brucei using 
the pLew82 vector (Wirtz et al., 1999), which targets the gene of interest to the 
ribosomal DNA locus. Clones of transgenic T. brucei were isolated under phleomycin 
selection and expression of TbNTR-myc was induced by the addition of tetracycline to 
the culture media (sections 2.5.4 and 2.5.5). Expression from the ectopic gene was 
confirmed by a shift in nifurtimox sensitivity (section 2.5.6), observed for the induced 
transgenic line compared to wild-type cells. Immunoprecipitation of TbNTR-myc was 
carried out based on a protocol by Dr Maria Lucia S. Güther (Güther et al., 2006). 
Wild-type and induced transgenic T. brucei were harvested by centrifugation (10 min, 
1000 x g, 4°C) and washed once in PSG buffer (section 2.5.9). Trypanosomes were 
lysed in 20 mM Tris-HCl, pH 7.2, 2% (w/v) SDS (1 ml per 109 cells). Samples were 
vortexed for 3 min to shear gDNA and reduce viscosity, and then boiled for 10 min. 
Following equilibration to RT, samples were diluted to 0.1% (w/v) SDS in 20 mM Tris, 
pH 7.2, 1% Triton® X-100 and immunoprecipitated with anti-Myc Tag mAb (clone 
4A6, Upstate/Millipore; 1 µg per 1 x 108 cells) overnight at 4°C with gentle agitation. 
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The TbNTR-myc-mAb complex was pulled-down using Pierce® Protein G Plus Agarose 
(Thermo Scientific) according to the manufacturer’s guidelines, at a ratio of 5 µl beads 
per 1 µg mAb. Washed beads were boiled for 10 min in 2 x Laemmli sample buffer 
with 10 mM DTT, resolved by SDS-PAGE (section 2.4.2), and analysed by Western 
blotting onto a Sequi-blot PVDF membrane (Bio-Rad) as previously described (section 
2.4.3).  
 
2.6. Animal studies  
The work under this section was carried out following review by the Ethical Review 
Committee of the University of Dundee and performed under the Animals (Scientific 
Procedures) Act 1986 in accordance with the European Committee Council Directive 
(86/609/EEC).  
All animal work during the generation of anti-TbNTR sera (section 2.6.1), as 
well as the study on virulence (section 2.6.2) and susceptibility to nifurtimox (section 
2.6.3), was carried out by Dr Susan Wyllie. The study on fexinidazole susceptibility 
(section 2.6.4) and all pharmacokinetic analysis of fexinidazole and its metabolites 
(section 2.6.5) were performed by Dr Kevin D. Read and the DMPK group, University 
of Dundee.  
 
2.6.1. Generation of anti-TbNTR sera  
Polyclonal anti-TbNTR antisera were raised in male Wistar rats using recombinant His6-
TbNTRΔ7, purified under denaturing conditions from inclusion bodies (section 2.3.10). 
To remove traces of guanidinium-HCl, purified protein was diluted and washed once in 
PBS. The resulting protein precipitate was resuspended in fresh PBS to 1 mg ml-1, 
emulsified in Freund’s (in)complete adjuvant (Sigma-Aldrich®) and used to raise 
antisera exactly as described (Greig et al., 2009). Blood was harvested from the animals 
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5 weeks after the initial inoculation and clotted at 37°C for 1 h. Cells were discarded 
following centrifugation (3,000 x g, 15 min, 4°C) and the resulting antisera were flash-
frozen and stored at -20°C in the presence of 0.05% (w/v) sodium azide.  
 
2.6.2. Virulence studies  
The ability of NfxR1 and NfxR2 BSF trypanosomes (section 2.5.7) to establish an in 
vivo infection was studied in an animal model. Sets of 5 NMRI mice were infected via a 
single intraperitoneal (i.p.) injection of 1 x 104 cells (wild-type, NxfR1 or NfxR2) in 0.2 
ml HMI-9T media. Animals were monitored daily for clinical signs of infection and wet 
tail-blood smears were taken for microscopic examination, in order to determine the 
levels of parasitaemia (Sienkiewicz et al., 2008). When parasitaemia levels reached or 
exceeded 1 x 108 ml-1, the animals were humanely killed, since it was previously 
established that these animals would succumb to an over-whelming infection within 24 
h. Results are reported as the mean survival time ± standard deviation (S.D.). 
 
2.6.3. In vivo susceptibility to nifurtimox  
To determine whether NfxR1 trypanosomes maintain their nifurtimox resistance in vivo, 
the following experiment was conducted. Infection with wild-type and NfxR1 parasites 
was established in groups of 5 NMRI mice as in section 2.6.2. Twenty-four hours 
following infection, wild-type- and NfxR1-infected mice were either dosed with 
nifurtimox (100 mg kg-1 body weight, based on Fairlamb et al., 1992) or left untreated. 
Nifurtimox was administered daily for a total of four days via i.p. injection, using 10% 
(v/v) DMSO in peanut oil as a carrier. Parasitaemia was monitored for a maximum of 
30 days, when the experiment was terminated. In addition to animals with high levels of 
parasitaemia, animals showing signs of acute drug toxicity were also euthanized. The 
data are presented as a Kaplan-Meier survival plot.  
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2.6.4. In vivo susceptibility to fexinidazole  
The susceptibility of NfxR1 and wild-type trypanosomes to fexinidazole was studied in 
a mouse model. Experiments were performed as described for nifurtimox (section 
2.6.3), with the following modifications. Fexinidazole was administered orally and at 
doses of 25 – 200 mg kg-1. Parasitaemia was monitored for up to 60 days post infection, 
and animals that survived for the entire duration of the experiment were defined as 
“cured”. The fraction of cured animals was plotted against the respective dose of 
fexinidazole using GraFit software. The effective dose, required to elicit 50% cure 
(ED50) was calculated using equation (6): 
 mc
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where fc is the fraction of cured animals, D is the administered dose, and m is the Hill 
slope. The ED99 was derived from the above equation as: 
 mEDED 15099 99×=   (7) 
 
2.6.5. Fexinidazole exposure in mice after a single oral dose  
NMRI mice (n = 3) were dosed with a single oral dose of 200 mg ml-1 fexinidazole in 
10% (v/v) DMSO in peanut oil. At defined time points after dosing, 10 µl blood 
samples were withdrawn from the tail vein of each animal, lysed in 20 µl deionised 
water (Milli-Q®) into Micronic tubes (Micronic BV) and stored at -80°C prior to 
analysis. Following extraction with acetonitrile in the presence of an undisclosed 
internal standard, the samples were analysed by ultraperformance liquid 
chromatography (UPLC)-MS-MS, using Waters Acquity UPLC® system and a Quattro 
Premier™ XE mass spectrometer (Waters, UK) as described (Sokolova et al., 2010). The 
levels of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in these samples 
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were determined from calibration curves, that were prepared by analysing blood 
samples with known amounts of fexinidazole (in the range of 1 – 1,000 ng ml-1) and its 
metabolites (200 – 15,000 ng ml-1).  
 
References included in the figures: 
(Human African trypanosomiasis (sleeping sickness): epidemiological update, 2006; 
Simarro et al., 2010; Vickerman, 1985; Fenn and Matthews, 2007; Brun et al., 2010; 
Fries and Fairlamb, 2003; Priotto et al., 2009; Muller et al., 2007; Wilkinson et al., 
2008; Hall et al., 2010)  
 
Chapter 3 -  Expression 
and activity studies of 
recombinant TbNTR  
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3.1. Isolation and characterisation of NTR from T. brucei S427  
3.1.1. DNA sequencing analysis  
Search of the trypanosomatid genome database (http://www.genedb.org) revealed two 
sequences of a putative nitroreductase: one in the genome reference strain T. brucei 
TREU927 GUTat 10.1 (Tb927.7.7230 or TbNTR-927) and another one in T. b. 
gambiense (Tbg972.7.8530 or TbgNTR). The two sequences were almost identical and 
had only two differences at the nucleotide level and one at the amino acid level (Ile57 
replaced by Thr in TbgNTR). To isolate the sequence of NTR from the laboratory strain 
T. brucei S427 (designated TbNTR-427), amplification and sequencing primers were 
designed based on the TbNTR-927 sequence. The ORF of TbNTR and the adjacent 5′- 
and 3′-UTRs (~600 bp each) were amplified by PCR from T. brucei S427 gDNA and 
the resulting 2.16 kb fragment (Figure 3.1 A) was cloned into the pCR®-Blunt II-
TOPO® vector. Initial sequencing analysis of clones derived from 3 independent PCRs 
revealed the presence of single nucleotide polymorphisms (SNPs) in the ORF. To 
confirm that these were not caused by PCR or sequencing error, TbNTR-427 ORF was 
amplified in a second set of three PCRs, cloned and re-sequenced. A total of four SNP 
positions were identified (Figure 3.1 B), two of which were either T or C (Y) and the 
other two were either G or A (R). Although the polymorphism in codon 31 (aaY = Asn) 
was silent, it is worth noting that the same codon is aat in TbNTR-927 and aac in 
TbgNTR. The remaining three SNPs, which resulted in amino acid changes, were in 
codons 57 (atc = Ile or acc = Thr), 69 and 261 (both gat = Asp or aat = Asn). Each 
couple of polymorphic nucleotides was not equally represented in the sequenced clones. 
For example, aat31 was present in 2 out of 6 clones, whereas aac31 was present in the 
remaining 4 clones. As a result, the sequence variant of TbNTR-427 that was observed 
most frequently (Thr57/Asp69/Asn261) was selected and used in all subsequent cloning 
and expression studies, and is hereafter referred to as TbNTR for simplicity.  
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3.1.2. Determination of the NTR gene copy number in T. brucei S427  
To investigate whether the observed sequence variations in TbNTR-427 were caused by 
the presence of multiple gene copies, a Southern hybridisation analysis was performed. 
Restriction enzymes, which cut outside (KpnI and HindIII) or within (BamHI, PstI and 
SalI) the TbNTR ORF (Figure 3.2 A) were identified in the genome database and used 
to digest T. brucei S427 gDNA. Following hybridisation with a digoxigenin-dUTP-
labelled TbNTR probe, single restriction fragments were detected in the KpnI and 
HindIII digests (Figure 3.2 B), whereas two fragments were visualised in DNA 
digested with the endonucleases which cut within the TbNTR ORF. Although PstI is 
predicted to cut TbNTR twice and produce three fragments, the shortest of those would 
be only 146 bp and would not be visible on the blot. Collectively, these results conform 
to the predicted patterns for a single gene copy (per haploid genome) of TbNTR. 
Therefore, multiple copy number cannot account for the observed sequence variations 
TbNTR-427, which leaves two alternative explanations. Either there is an allelic 
variation at the TbNTR gene locus, or the T. brucei culture, from which the gDNA was 
extracted, is no longer clonal.  
 
3.2. Expression, purification and activity studies of EcNfsB  
The host E. coli nitroreductase with highest similarity to TbNTR (EcNfsB, 27% 
similarity) was used as a positive control for expression trials and activity studies. 
EcNfsB was purified by sequential hydrophobic interactions and anion exchange 
chromatography to >95% purity (Figure 3.3 A), with a total protein yield of 12 – 13 mg 
per 1 L culture. The specific activity of purified EcNfsB with nitrofurazone was found 
to increase from 4 U mg-1 to 16 ± 1 U mg-1 upon addition of 10 µM FMN either to the 
assay mix (Figure 3.3 B) or to the purified enzyme stock (EcNfsB ≈ 20 μM). The 
specific activity obtained in the presence of FMN is in close agreement with the 
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reported literature value of 13 U mg-1 for FMN-bound EcNfsB (Zenno et al., 1996). The 
purified enzyme retains >80% of its activity after storage for 1 year at -80°C in the 
presence of 20% (v/v) glycerol and 10 µM FMN.  
 
3.3. Expression and partial purification of full-length TbNTR  
3.3.1. Optimisation of conditions for the expression of V5-TbNTR  
Initial attempts to express and purify recombinant TbNTR were based on protocols 
available at the time for purification of the protozoal nitroreductase from Giardia 
lamblia GlNR1 (Muller et al., 2007). To facilitate purification, full-length TbNTR was 
cloned into the pET151/D-TOPO® vector for expression of the V5-TbNTR fusion 
protein, which features an N-terminal hexahistidine (His6) tag, followed by the V5 
epitope and a TEV recognition site (Table 2.3). Pilot expression was carried out in 
BL21 Star™(DE3), which expressed recombinant NTR at very low levels, detectable 
only by Western blot analysis with monoclonal anti-His antibodies (Figure 3.4 A). 
Furthermore, the presence V5-TbNTR in the supernatant was found to be caused by 
contamination with insoluble material from the very soft pellet obtained following 
centrifugation. Since V5-TbNTR could be expressed neither at high levels nor as a 
soluble protein, several alternative strategies (Table 2.4) were attempted in order to 
improve expression and solubility of the recombinant protein.  
Optimisation of the expression strain was suggested by sequence analysis of 
TbNTR-427 (Figure 3.1 B), which revealed the presence of at least 21 codons not 
commonly found in the E. coli host (Zhang et al., 1991). Although E. coli 
CodonPlus®(DE3)-RP and -RIL strains, engineered to produce tRNAs for such rare 
codons, resulted in much higher levels of recombinant protein expression (Figure 3.4 
B), V5-TbNTR expressed by these strains remained completely insoluble.  
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The best results were achieved using ArcticExpress™(DE3)RP cells (Figure 3.4 
C), which not only combine increased protein levels (via additional Arg and Pro 
tRNAs) with reduced expression rates (at 12°C), but also have an improved ability to 
process heterologous proteins at low temperature, conferred by co-expression of 
chaperonins Cpn60 and Cpn10 from Oleispira antarctica (Ferrer et al., 2004; Ferrer et 
al., 2003). To date, these were the only cells among those tested that expressed 
apparently soluble V5-TbNTR, albeit only a small proportion of the total recombinant 
protein.  
 
3.3.2. Partial purification of V5-TbNTR  
Following expression of partly soluble recombinant TbNTR in ArcticExpress™(DE3) 
RP, attempts were undertaken to purify V5-TbNTR. However, the method of choice – 
Ni2+ affinity chromatography, proved unsuccessful for V5-TbNTR purification under 
the test conditions (Figure 3.5). Part of the protein did not bind to the column (lane 2), 
and the remainder was found associated with numerous contaminating bands in both 
peak 1 (lane 3) and peak 2 (lane 4) following elution with an imidazole gradient. In 
addition, contaminants, including chaperonin OaCpn60, were much more abundant than 
the protein of interest after chromatography.  
Bearing in mind the poor yield and recovery, further experiments were aimed at 
improving the ratio of recombinant TbNTR found in the supernatant and pellet 
fractions. To explore the effects of buffer composition, pH and ionic strength, several 
lysis buffers were tested (Table 2.4, condition 4). Best results were achieved in 50 mM 
HEPES, pH 7.5, in the absence of 0.25 M NaBr (Figure 3.6 A), suggesting that high 
ionic strength may decrease solubility of V5-TbNTR. Similar results were obtained with 
50 mM Tris-HCl, pH 8.5, without NaBr (not shown). More recombinant protein was 
found to sediment with greater centrifugal force (Figure 3.6 B), which prompted the 
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addition of 10% (v/v) glycerol to the final optimised lysis buffer. Other factors, such as 
change of expression media, freezing of the cell pellet prior to lysis, and the addition of 
FMN or Triton® X-100 to the lysis buffer, did not affect solubility of V5-TbNTR (data 
not shown).  
Under the optimised cell lysis conditions (50 mM HEPES, pH 7.5, 10% (v/v) 
glycerol), V5-TbNTR did not bind to the affinity column (Figure 3.7 lane 3). 
Nonetheless, this step was used to remove contaminating histidine-rich host proteins. 
Surprisingly, recombinant TbNTR was also found not to bind to a cation exchange 
column (HiTrap™ SP FF, not shown) at pH 7.5, despite a predicted pI of 9.84 for 
TbNTR and 9.67 for the tagged V5-TbNTR (ProtParam tool on the ExPASy Proteomics 
Server, http://www.expasy.org/). Further purification was achieved by two sequential 
anion exchange steps under the same conditions, which removed a considerable amount 
of the major contaminant OaCpn60 (Figure 3.7 lanes 4 and 5). The remaining 
contaminants (visible in lane 6) could not be resolved by gel filtration on a HiLoad™ 
16/60 Superdex™ 200, and co-eluted with V5-TbNTR as a single peak at the void 
volume (V0 = 600 kDa) of the column (lane 7). Mass-fingerprinting analysis of SDS-
PAGE samples positively identified the two major bands as recombinant TbNTR (at 
~39 kDa) and OaCpn60 (at ~60 kDa), and confirmed that lower MW bands were mostly 
contaminants, rather than NTR degradation products. Although host E. coli 
nitroreductases (NfsA, 26.8 kDa and NfsB, 23.9 kDa) were not found in this proteomics 
analysis, which is important for future activity studies, the vast majority of the 
remaining contaminants were chaperonins, membrane transporters, electron transport 
components and ribosomal proteins. Together these results indicated that V5-TbNTR 
was either associated with or entrapped in membrane vesicles. Consequently, 
purification of recombinant full-length TbNTR was not pursued any further.  
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3.4. Truncated forms of TbNTR  
3.4.1. Truncations based on bioinformatics predictions: TbNTRΔ57 and TbNTRΔ 85  
ClustalW (Larkin et al., 2007) multiple sequence alignment of TbNTR and other 
protozoal and bacterial nitroreductases (Figure 3.8) revealed a distinct stretch of 70 – 
80 amino acids with little sequence conservation at the N-terminus of the kinetoplastid 
sequences, which is absent from the bacterial enzymes. By contrast, in the remaining C-
terminal sequence, kinetoplastid NTRs share >55% identity and >70% similarity. This 
C-terminal domain is referred to as the nitroreductase domain, since it contains all key 
conserved residues (highlighted in bold), shown to hydrogen bond with the FMN co-
factor in bacteria (Parkinson et al., 2000). In the genome database, part of the variable 
N-terminal region is annotated as a mitochondrial targeting sequence for three of the 
four putative Leishmania NTRs (from L. major, L. infantum and L. braziliensis). To 
confirm whether this is the case in T. brucei, the protein sequences of TbNTR-927 and -
427 were analysed using MitoProt II (version v1.101, Claros and Vincens, 1996). Both 
proteins were predicted as targeted to the mitochondria with a probability of p ~ 0.88, 
and a putative cleavage site was assigned after amino acid 57, regardless of the 
sequence variant (Thr57 or Ile57). Based on these results, two truncated forms of 
TbNTR were engineered. TbNTRΔ57 lacks the sequence predicted to be cleaved after 
import into the mitochondrion, whereas TbNTRΔ85 lacks the entire variable N-terminal 
region and has a start site aligned with the first amino acid after the initiator methionine 
of EcNfsB.  
The expression profiles of both V5-TbNTRΔ57 and V5-TbNTRΔ85 were very 
similar to that of the full-length recombinant protein. Under the initial lysis conditions, 
V5-TbNTRΔ57 appeared completely insoluble (Figure 3.9 A), and under the optimised 
lysis conditions, partly soluble V5-TbNTRΔ85 could not be purified by affinity 
chromatography (Figure 3.9 B), as was previously observed for the full-length 
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construct. These results indicated that removing potential mitochondrial targeting 
sequences from TbNTR alone may not be sufficient to improve solubility or amenability 
to purification of the recombinant protein.  
To address the poor retention of recombinant TbNTR by the affinity resin, full 
length and truncated forms of the protein were expressed with a C-terminal, TEV-
cleavable His6 tag, using the modified pET20b_TEV expression vector (Table 2.3). 
However, results for all three forms of TbNTR-His6 were almost identical to those for 
the N-terminally tagged constructs. Recombinant TbNTR-His6 (full-length and 
truncations) was predominantly insoluble (>95% by Western), and TbNTRΔ85-His6 
failed to bind to a HisTrap™ HP affinity column (data not shown). Therefore, 
positioning of the His6 tag at the C-terminus did not improve interaction with the 
affinity resin.  
During the course of the above experiments, purification and partial 
characterisation of NTR from T. cruzi (Wilkinson et al., 2008) and T. brucei (Hall et al., 
2010) was reported. To match the form of TcNTR described in the former study, a 
slightly different truncated form of TbNTR (lacking the first 83, not 85 amino acids) 
was cloned into the pTrcHis C vector with an N-terminal, enterokinase-cleavable, His6 
tag (Table 2.3). Several unsuccessful attempts (Figure 3.9 C and D) were made to 
purify His6-EK-TbNTRΔ83, hampered by lack of detail in the authors’ experimental 
protocol. Subsequent conversations with Wilkinson and colleagues established that 
CHAPS, sucrose and high salt were all used in the lysis buffer, in order to retain the 
recombinant protein in solution and facilitate interaction with affinity columns. 
However, these specific conditions were not tested with the current construct (His6-EK-
TbNTRΔ83) due to new information that arose throughout the course of the investigation 
(see section 3.4.3).  
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3.4.2. Expression of TbNTRΔ83 with large soluble tags  
In order to improve the solubility, and potentially amenability to purification, of 
recombinant TbNTR, the new truncated form (Δ83) was fused to various E. coli 
proteins, which could serve as molecular anchors and help retain the passenger protein 
in solution (Terpe, 2003). Initial tests were carried out using elongation factor Ts (Tsf, 
30.5 kDa) as a fusion partner, which had been shown to enhance the solubility of the 
putatively mitochondrial DHFR-TS from T. brucei (Marc W. Gibson, PhD thesis, 
University of Dundee, 2009). Although the recombinant Tsf-TEV-TbNTRΔ83 protein 
fusion was highly soluble (at 50,000 x g, 1 h), it was only partially retained on a 
HisTrap™ affinity column (data not shown). Furthermore, the Tsf-TEV tag was not 
susceptible to TEV protease cleavage at near optimal conditions (25 – 37°C) and high 
protease to substrate ratios (up to 1:5 w/w). Similar difficulties in purification by Ni2+ 
affinity chromatography and removal of the tag had also been observed by Dr Gibson 
for the analogous Tsf-TEV-TbDHFR-TS construct, suggesting that steric occlusion by 
the large tag was the most likely cause. However, in contrast to Tsf-TEV-TbDHFR-TS, 
which was enzymatically active (Gibson, PhD thesis, 2009), no nitroreductase activity 
could be detected for recombinant Tsf-TEV-TbNTRΔ83.  
In a second approach, the transcription termination anti-termination factor N-
utilising substance A (NusA, 55 kDa) was used as a soluble anchor, followed by affinity 
His6 and S tags, and thrombin and enterokinase recognition motifs upstream of 
TbNTRΔ83 (Figure 3.10). As expected, the resulting recombinant NusA-TbNTRΔ83 
protein fusion was expressed at high levels in a soluble form. However, the partially 
purified recombinant protein (lane 3) was not enzymatically active. To test whether 
removal of the tag would lead to gain of nitroreductase activity, NusA-TbNTRΔ83 was 
digested using thrombin protease. Proteolytic cleavage at 37°C resulted in the formation 
of lower MW products (lane 4), possibly due to recognition of the secondary thrombin 
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sites present in the TbNTR sequence (Figure 3.10 B). Although at lower temperatures 
(4°C) the formation of secondary cleavage products was reduced, the enzymatic digest 
was incomplete (lanes 5 and 6). Furthermore, TbNTRΔ83 cleaved at 4°C was found to 
co-elute with undigested NusA-TbNTRΔ83 (lane 7), possibly through heterodimer 
formation. Therefore, complete cleavage of the tag appeared to be a prerequisite for 
obtaining pure cleaved TbNTRΔ83. However, attempts to cleave NusA-TbNTRΔ83 with 
other proteases were unsuccessful. Digestion with enterokinase was highly inefficient 
even at the highest recommended ratio of 5 U per 100 µg substrate (data not shown). In 
a similar way, digestion with TEV protease of partly purified NusA-TEV-TbNTRΔ83 
(thrombin site replace with a TEV site) resulted in only partial cleavage of the tag (not 
shown). Given that both tagged and cleaved unpurified TbNTRΔ83 were not 
enzymatically active (preliminary data, not shown), and that pure cleaved TbNTRΔ83 
could not be obtained, this truncated form of TbNTR was not investigated further.  
 
3.4.3. Design of alternative TbNTR truncations  
During the course of the above investigations, an analysis of the mitochondrial 
proteome of procyclic T. brucei was published (Panigrahi et al., 2009) confirming the 
mitochondrial localisation of TbNTR. The above study identified six peptides derived 
from TbNTR (highlighted in red in Figure 3.11), the first of which started at Ser55. 
From these data, it was evident that the truncated versions of TbNTR, which have been 
studied so far (Δ57 and Δ83/85), were apparently missing parts of the mature protein, 
after import into the mitochondrion. Consequently, seven new truncated forms of 
TbNTR were designed so that their starting sites were upstream of Ser55 (Figure 3.11). 
The first residue for each truncation was selected taking into account secondary 
structures, such as α-helices and β-strands predicted by Jpred 3 (Cole et al., 2008), and 
the tertiary structure assigned by GlobPlot™, which predicted a globular NTR domain 
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for residues 47 to 296 (Linding et al., 2003). An additional consideration was given to 
the N-end rule, where the residue immediately following the initiator methionine can 
confer either stability or instability to the protein by affecting its half-life (Tobias et al., 
1991).  
 
3.4.4. Activity studies in truncated forms of TbNTR  
To find out which of the newly designed TbNTR truncations can be expressed in an 
enzymatically active form in E. coli, the nitroreductase activity of clarified bacterial 
lysates expressing each truncated form was compared to the background activity in cells 
transformed with the blank vector (Figure 3.12). To avoid any interference on 
recombinant protein activity, all TbNTR forms were expressed without 
affinity/solubilisation tags. A control lysate of cells expressing EcNfsB had almost 70 
times higher specific activity compared to the empty vector control lysate (800 ± 120 
mU mg-1 and 12 ± 3 mU mg-1, respectively, p = 0.001 by Student’s t-test). The only 
other lysate, which was found to have a significantly high activity above background 
(2.3-fold, p = 0.01), was of cells expressing TbNTRΔ54 (27 ± 5 mU mg-1). Although the 
specific activities of different lysates cannot be compared directly to each other because 
of huge variations in the expression levels of recombinant protein (Figure 3.12), the 
presence of activity above background indicates that at least some of the respective 
recombinant protein is expressed in an active form. On the other hand, lack of activity 
above background does not necessarily mean that a given truncated form of the protein 
is intrinsically inactive, as this protein may not be expressed in a soluble form at a 
sufficiently high amount for detection.  
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3.4.5. Positional effect of the affinity tag on TbNTRΔ54  
The only truncation of TbNTR that was expressed in an enzymatically active form in   
E. coli, TbNTRΔ54, was present only at low levels, which were deemed insufficient for 
protein purification by classical chromatography. Hence, the use of an affinity tag was 
necessary to facilitate purification. To test the effect of a His6 affinity tag on TbNTRΔ54, 
the recombinant protein was expressed with either an N-terminal or a C-terminal TEV-
cleavable His6 tag (Table 2.3), and compared to the non-tagged form (Figure 3.13). 
Significant nitroreductase activity above background was observed only in lysates 
expressing non-tagged (5.7-fold, p < 0.001) or C-terminally tagged (8-fold, p < 0.001) 
TbNTR Δ54. This data suggested that a tag at the N-terminus may lead to loss of activity 
in TbNTRΔ54, whereas a C-terminal tag is better tolerated.  
Estimated data for the activity of TbNTRΔ54 and TbNTRΔ54-His6 were obtained 
by subtraction of the endogenous nitroreductase activity (8.8 ± 0.1 mU mg-1 in vector-
only cells). The resulting background corrected specific activity value was 37 ± 2.5 mU 
per mg lysate for non-tagged TbNTRΔ54, and 57 ± 2 mU per mg lysate for TbNTRΔ54-
His6. After overnight storage at 4°C, those values decreased to 28 ± 4 mU mg-1 lysate 
(~76%) and 46 ± 3 mU mg-1 lysate (~80%) for non-tagged and tagged TbNTRΔ54, 
respectively, possibly due to proteolytic degradation. Almost identical values were 
obtained using nifurtimox as a substrate after overnight storage (23 ± 1 mU mg-1 lysate 
for TbNTRΔ54 and 44 ± 3 mU mg-1 lysate for TbNTRΔ54-His6), suggesting that the 
enzymes uses both nitrodrugs as substrates with equal efficiency.  
 
3.4.6. Activity studies, partial purification and solubilisation of TbNTRΔ54-His6  
Once it was established that C-terminally tagged TbNTRΔ54 could be expressed in an 
enzymatically active form in E. coli, purification by affinity chromatography of 
recombinant TbNTRΔ54-His6 was attempted. However, the majority of TbNTRΔ54-His6 
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was found in the flow-though fraction (Figure 3.14, lane 4), together with 87% of both 
the protein mass and the nitroreductase activity that were applied to the HisTrap™ 
column. Better results were obtained using anion exchange chromatography (at pH 7.0), 
which was previously shown to remove the minor host nitroreductase EcNfsB (pI = 5.8, 
ProtParam; section 3.2). As expected, TbNTRΔ54-His6 did not bind to the anion 
exchange column (lane 5; predicted pI = 9.2, ProtParam), but only ~50% of the protein 
mass and as much as 75% of the activity were recovered in the flow though. 
Consequently, a 1.5-fold increase in the specific activity of the TbNTRΔ54-His6-
containing fraction was observed (from 50 ± 4 mU mg-1 to 78 ± 8 mU mg-1). Other 
chromatographic methods, including cation exchange chromatography (HiTrap™ SP FF, 
lane 6), Co2+ affinity chromatography (lane 7) and nucleotide-mimicking Blue 
Sepharose™ chromatography (lane 8), failed to bind recombinant TbNTRΔ54-His6. 
Similar to N-terminally tagged full-length TbNTR (V5-TbNTR, Figure 3.7), TbNTRΔ54-
His6 was apparently not amenable to purification. Furthermore, TbNTRΔ54-His6 was 
found in the void volume of a Superdex™ 75 gel filtration column (lane 10, V0 = 75 
kDa), co-eluting with many of the chaperonins, membrane transporters and electron 
transport components that were previously identified after gel filtration of V5-TbNTR. 
Collectively, these results indicate that recombinant TbNTRΔ54-His6 may also be 
associated with/entrapped in membrane vesicles, as suggested for V5-TbNTR.  
To establish whether TbNTRΔ54-His6 is truly soluble or membrane-associated, 
clarified lysates of cells expressing TbNTRΔ54-His6 (Figure 3.15, lane 2) were subjected 
to centrifugation at 100,000 x g for 1 h. At this high centrifugal force, TbNTRΔ54-His6 
was found almost exclusively in the pellet fraction (lane 5), which was associated with 
~50% of the nitroreductase activity recorded before centrifugation. By contrast, only 
~20% of the initial nitroreductase activity was recovered in the supernatant, and half of 
this activity was shown to be caused by endogenous E. coli enzymes. In sharp contrast, 
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in control cell lysates (vector-only), >99% of the nitroreductase activity was recovered 
in the high-force supernatant. Treatment of the 100,000 x g pellet with 0.1% (w/v) n-
dodecyl-β-D-maltoside (DDM; cmc = 9.2 % w/v, Privé, 2007) marginally increased the 
specific activity of the sample (by 10%), but failed to solubilise recombinant TbNTRΔ54-
His6. An alternative treatment suggested by Dr S.R. Wilkinson (section 3.4.1) involved 
cell lysis in the presence of 0.5 M NaCl, 40% (w/v) sucrose and 1% (w/v) CHAPS. 
However, this buffer also failed to prevent TbNTRΔ54-His6 from sedimentation at 
100,000 x g for 1 h (note that the centrifugation speed used by Wilkinson and 
colleagues was 16,000 x g). Unsurprisingly, affinity purification in the presence of 
either DDM (see Figure 3.18 C) or NaCl/sucrose/CHAPS-buffer was unsuccessful. 
Collectively, these findings indicate that TbNTRΔ54-His6 is not soluble even under the 
conditions reported to work by Wilkinson and colleagues.  
To determine whether TbNTRΔ54-His6 is an integral membrane protein or is 
associated at the periphery, clarified cell lysates were centrifuged at 100,000 x g for 1 h 
in the presence of detergents (CHAPS, 5-cyclohexylpentyl β-D-maltoside, n-decyl-β-D-
maltoside, DDM, n-octyl-β-D-glucoside, n-dodecylphosphocholine and SDS, 1% (w/v) 
each), high salt (1 M NaCl), urea (4 M) or alkali (0.2 M Na2CO3). From the tested 
detergents, only n-dodecylphosphocholine and the control SDS were able to solubilise 
TbNTRΔ54-His6 (Figure 3.16). However, nitroreductase activity was completely lost 
upon SDS treatment and substantially reduced (to ~7%) in the presence of n-
dodecylphosphocholine (from 42 ± 4 mU mg-1 to 3 ± 0.3 mU mg-1, corrected for 
endogenous activity). By contrast, in vector-only cell lysates the nitroreductase activity 
was reduced to ~34% (from 8 ± 1.3 mU mg-1 to 2.7 ± 0.1 mU mg-1). Although recovery 
of enzyme activity in the high-force supernatant treated with n-dodecylphosphocholine 
was >99%, compared to 9% recovered in non-treated control samples (in buffer with 
150 mM NaCl), the specific activity of the two supernatants was almost identical (5.5 ± 
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0.4 mU mg-1 for treated and 4.3 ± 1.1 mU mg-1 for non-treated samples, background 
corrected). Other detergents, including CHAPS, and high salt (both used by Wilkinson) 
were ineffective for solubilisation of TbNTRΔ54-His6. Urea and alkali, which are known 
to solubilise only peripheral but not integral membrane proteins (De Leeuw et al., 
2001), resulted in partial retention of the recombinant protein in the 100,000 x g 
supernatant. However, samples treated with either of these reagents lost their 
nitroreductase activity completely. Collectively, these results suggesting that TbNTRΔ54-
His6 may be membrane associated (rather than integral to the membrane) and that 
solubilisation of TbNTRΔ54-His6 with the tested reagents results in loss of enzymatic 
activity.  
 
3.5. Cell-free expression of TbNTRΔ54-His6  
To test if it is possible to obtain active TbNTRΔ54 in the absence of biological 
membranes, recombinant TbNTRΔ54-His6 was expressed in a wheat germ cell-free 
extract, using linearised pET20b_TEV_TbNTRΔ54 vector (Figure 3.17 A). 
Recombinant EcNfsB was expressed in parallel as a positive control. Although the 
nitroreductase activity in EcNfsB-expressing extract was at the limit of detection, 
addition of 5 – 20 µM FMN was found to increase the specific activity of those extracts 
almost 10-fold (from ~2.5 µU µl-1 extract to 23 µU µl-1; Figure 3.17 B). Extrapolating 
from the specific activity of recombinant EcNfsB (section 3.2), it was calculated that 
~1.4 ng EcNfsB per µl extract was expressed as an enzymatically active protein. By 
contrast, no nitroreductase activity above background could be detected in TbNTRΔ54-
His6-expressing extracts, despite the presence of FMN. Expression of trace amounts of 
TbNTRΔ54-His6 was verified by Western blot analysis (Figure 3.17 C) and the 
concentration of the recombinant protein was estimated at ~6.5 ng µl-1, based on the 
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band intensity of a similar His-tagged construct of a known amount (His6-TbNTRΔ7; see 
section 3.6.1 and Figure 3.18 B).  
The estimated concentration of TbNTRΔ54-His6 is within the expected range for 
this particular system (1 – 10 ng µl-1) and studies with the positive control (EcNfsB) 
have shown that it is possible to detect nitroreductase activity at such low enzyme 
concentrations, with no apparent inhibition from the cell-free system. It may be 
tempting to speculate that association of TbNTRΔ54-His6 with biological membranes 
may be required for its enzyme activity, as previous studies demonstrated that 
solubilisation of the recombinant protein with detergents resulted in loss of activity. 
However, absence of detectable activity may be due to incorrect folding of the 
recombinant protein in the cell-free system. This notion is partially supported by the 
fact that TbNTRΔ54-His6 could not be purified from cell-free extracts by affinity 
chromatography (Figure 3.17 C, lane 4), although it is not known whether this cell-free 
system is permissive for Ni2+-affinity binding. Furthermore, the expression temperature 
(30°C) optimised for this system may be too high, since expression of TbNTRΔ54-His6 
in bacteria at 37°C resulted in an inactive recombinant protein, whereas TbNTRΔ54-His6 
expressed at 16°C was enzymatically active (not shown).  
 
3.6. In pursuit of the true start site of mature TbNTR  
In order to detect the first residue of mature TbNTR, two strategies were undertaken for 
the isolation of the processed protein from T. brucei by immunoprecipitation. The first 
strategy was dependent on the use of anti-TbNTR antibodies raised in house, whereas 
the second one involved expression of TbNTR with an epitope against which antibodies 
are commercially available.  
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3.6.1. Production of anti-TbNTR serum in rats  
It was necessary to obtain purified recombinant TbNTR to raise polyclonal antisera in 
rats. Given that purification of the enzymatically active form of the protein (TbNTRΔ54-
His6) proved difficult under native conditions, efforts were directed to other forms of 
TbNTR. Inactive recombinant His6-TbNTRΔ7 was purified to >90% under denaturing 
condition (Figure 3.18 A) and the identity of the purified protein was confirmed by 
mass fingerprinting. Contaminants migrating at both higher and lower MW than the 
recombinant protein were also identified as TbNTR, suggesting the formation of dimers 
and degradation products during the purification process. Antisera raised against 
purified His6-TbNTRΔ7 in collaboration with Dr Susan Wyllie, University of Dundee, 
were able to recognise both recombinant His6-TbNTRΔ7 and TbNTRΔ54-His6 (with and 
without the His6 tag, Figure 3.18 B and C). However, in T. brucei lysates, the antisera 
cross-reacted with a non-specific band (~100 kDa) just above the highly abundant VSG 
(visible by SDS-PAGE, lane 7) and no band was detectable in the expected range for 
TbNTR of 25 – 37 kDa. Hence, immunoprecipitation of endogenous TbNTR with the 
available antiserum was not possible.  
 
3.6.2. Pull-down of TbNTR-myc from T. brucei lysates  
An alternative approach for isolation of TbNTR involved expression of the protein with 
a C-terminal tag in T. brucei, so that the tag would not interfere with mitochondrial 
processing at the N-terminus. It was expected that a subsequent pull-down with an 
appropriate antibody should allow identification of the mature protein start site. Based 
on a similar experiment, aimed at isolation of TbGPI12myc (Güther et al., 2006), a c-
myc-tagged tetracycline-inducible copy of TbNTR (TiTbNTR-myc) was introduced into 
wild-type BSF T. brucei under phleomycin selection. The resulting transgenic cell line 
was cloned and protein expression was induced with tetracycline in randomly selected 
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clones. In order to verify whether TiTbNTR-myc was expressed in an enzymatically 
active form, the EC50 value for nifurtimox was determined against the tetracycline-
induced clones and compared to the EC50 against wild-type T. brucei. This step was 
necessary because the endogenous nitroreductase activity in T. brucei was below the 
limit of detection of the available spectrophotometric assay (unpublished observations). 
The TiTbNTR-myc-expressing clone which displayed the highest shift in EC50 (clone c2, 
Figure 3.19 A) was found to be 3-fold more sensitive to nifurtimox, compared to wild-
type T. brucei. This shift in sensitivity was less that the approximately 10-fold shift in 
EC50 determined against BSF T. brucei expressing either a similarly tagged TbNTR 
(Wilkinson et al., 2008) or a non-tagged TiTbNTR from an ectopic gene copy (see 
Chapter 4). Nonetheless, the result was sufficient to conclude that at least part of the 
tagged TiTbNTR-myc was processed in a manner similar to native TbNTR and was able 
to cause a detectable change in nitroreductase activity.  
To test the ability of the commercial anti-myc antibody to recognise TiTbNTR-
myc in T. brucei lysates, a Western blot analysis was conducted (Figure 3.19 B). As 
expected, a distinct protein band migrating below the 37 kDa marker* was detected in 
the induced TiTbNTR-myc-expressing clone c2, but not in wild-type T. brucei. Although 
an additional, non-specific 50-kDa band was recognised in both transgenic and wild-
type cells, the difference in size was deemed sufficient to discriminate between the two 
bands, should the 50-kDa protein co-precipitate with the anti-myc mAb. However, due 
to a number of technical difficulties, subsequent immunoprecipitation experiments 
carried out with the same anti-myc mAb failed to pull-down recombinant TiTbNTR-myc.  
In summary, this chapter describes some of the numerous attempts that were 
made in an effort to obtain pure enzymatically active recombinant TbNTR. These 
attempts included expression of full-length and various N-terminally truncated forms of 
                                                 
* The molecular weight of full-length, unprocessed TiTbNTR-myc is 37.0 kDa. 
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TbNTR, with or without affinity and solubilisation tags at either the N- or the C-
terminus, in several E. coli expression strains under a range of expression and lysis 
conditions, and even in cell-free lysates. Despite these endeavours, no pure, soluble, 
enzymatically active TbNTR could be obtained, most probably due to the membrane 
association of the recombinant protein. Although further work, such as identification of 
the start site of mature TbNTR, might reveal a solution to this problem, subsequent 
efforts were concentrated on studies of nitroaromatic drug resistance in T. brucei.  
 
Chapter 4 - Studies in 
bloodstream form T. brucei  
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4.1. Functional studies of TbNTR in bloodstream form T. brucei  
4.1.1. Overexpression of TbNTR in T. brucei  
In the previous chapter, the nitroreductase activity of recombinant TbNTR was 
demonstrated in clarified bacterial lysates. However, partly due to its membrane 
association, pure enzymatically active recombinant TbNTR could not be obtained, 
although an inactive form of the recombinant protein was eventually purified. 
Furthermore, purification of recombinant His-tagged TbNTRΔ83, reported by Wilkinson 
and colleagues (Hall et al., 2010; Wilkinson et al., 2008), could not be reproduced for 
various reasons (see Chapter 5), potentially including differences in the amino acid 
sequence. Therefore, to further validate that the sequence variant of TbNTR used in our 
studies (Thr57/Asp69/Asn261) can function as a nitroreductase, this variant was 
overexpressed in BSF T. brucei and the drug sensitivity of the resulting transgenic line 
was compared to that of wild-type and of TbNTR single knock-out T. brucei.  
To create an NTR-overexpressing cell line of T. brucei, a tetracycline-inducible 
ectopic copy of the gene (TiTbNTR) was introduced into wild-type BSF cells under 
phleomycin selection (Figure 4.1 A). The transgenic line was cloned, and expression of 
TiTbNTR was induced in three of the clones by addition of tetracycline to the culture 
media for at least one week. Induced clones were found to be approximately 10-times 
more sensitive to nifurtimox than wild-type cells, with EC50 values in the range of 0.17 
– 0.21 µM (Figure 4.1 B), compared to 1.8 µM against wild-type T. brucei. Due to lack 
of TbNTR-specific antibodies (section 3.6.1) or other methods for detection of NTR in 
T. brucei lysates, such as a sufficiently sensitive enzyme assay, the increased sensitivity 
to nifurtimox could not be correlated directly to increased NTR levels. Nonetheless, the 
substantial shift in the EC50 value for nifurtimox against induced TiTbNTR-expressing 
cells indicated that this particular sequence variant (Thr57/Asp69/Asn261) is 
functionally active in T. brucei in terms of nifurtimox activation.  
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4.1.2. TbNTR single knock-out cell lines  
Prior to generation of TbNTR SKO lines, it was demonstrated that the gene is present as 
a single copy per haploid genome in T. brucei S427 (section 3.1.2), as annotated for the 
genome reference strain of T. brucei TREU927. Following from these results, one of the 
two alleles of the TbNTR gene was replaced by homologous recombination with a 
selectable marker gene (either HYG or PAC; Figure 4.2 A), resulting in the transgenic 
T. brucei lines SKOHYG and SKOPAC. To verify that the marker genes were integrated at 
the NTR locus, gDNA extracted from wild-type cells and from SKOHYG and SKOPAC 
clones was analysed by PCR. A single product at the expected size of 1.2 kb was 
amplified from wild-type gDNA using primers 5′UTR_-107_F and 3′UTR_+152_R 
(Table 2.1), which align to sequences within the 5′- and 3′-UTRs of the replacement 
cassette (Figure 4.2 B). An additional product at either 1.3 kb or 0.87 kb was amplified 
with the same primer pair from the gDNA of SKOHYG clone 2 and SKOPAC clone 1 
respectively, which confirmed the presence of the selectable marker genes in the SKO 
clones. Similar results were observed with primers 5′UTR_-595_F and 3′UTR_+600_R, 
aligned to sequences outside the recombination region. PCR with this primer pair 
resulted in a single 2.16 kb band when wild-type gDNA was used as a template, 
whereas using gDNA template from SKOHYG clone 2 and SKOPAC clone 1 resulted in an 
additional band at 2.2 kb and at 1.8 kb, respectively. Collectively, these findings 
confirmed that one allele of TbNTR had been knocked-out and replaced by the 
selectable marker gene in both SKO clones.  
To investigate how reduction of the NTR gene copy number affects the ability of 
BSF T. brucei to process nifurtimox and other nitroaromatic compounds, the drug 
sensitivity of the cloned SKO lines was examined. In two independent experiments, 
SKOHYG clone 2 was found to be 1.7- and 1.6-fold less sensitive to the drug than wild-
type T. brucei, whereas in the same experiments SKOPAC clone 1 was less sensitive than 
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the wild-type cells by 1.9- and 2.3-fold, respectively (Figure 4.2 C). These results are 
comparable with published data for other NTR SKO lines of T. brucei (Wilkinson et al., 
2008), where up to 3-fold reduction in sensitivity was reported. Having established that 
the sensitivity to nifurtimox is dependent on the level of NTR copy number in T. brucei, 
future work will focus on examining how the sensitivity to other nitroaromatic drugs, 
such as the clinical candidate fexinidazole, is affected under similar circumstances.  
 
4.2. Resistance to nitroaromatic drugs in T. brucei *  
4.2.1. Generation of nifurtimox-resistant T. brucei cell lines  
In order to investigate the potential of BSF T. brucei to acquire resistance to nifurtimox, 
cells were cultured under the continuous selective pressure of increasing drug 
concentrations (Figure 4.3 A). Initially, trypanosomes were exposed to a sublethal 
concentration of 1.5 µM nifurtimox, which reduces cell growth in wild-type T. brucei 
by less than 25%. Once the cells were able to grow at normal rates in the presence of a 
low concentration of nifurtimox, they were introduced to a higher, usually double drug 
concentration. After a total of 140 days in the presence of drug, the cells were able to 
grow routinely in 50 µM nifurtimox, which is more than 3-times the EC99 value against 
wild-type T. brucei. At this stage, the resulting nifurtimox-resistant line, designated 
NfxR, had a doubling time in the absence of drug of 8 h, which was similar to the 7.3-h 
doubling time of wild-type T. brucei (Figure 4.3 B). By contrast, in the presence of 50 
µM, NfxR had an increased doubling time of 12.8 h, whereas the parental wild-type 
cells died within 3 – 4 days of exposure to the same drug concentration. These results 
confirmed that NfxR were indeed resistant to nifurtimox and that generating such 
resistance did not affect the cells ability to grow in culture.  
                                                 
* Part of this section has been published in Sokolova et al., 2010 (Appendix).  
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To determine the exact extent of nifurtimox resistance of NfxR, several clones 
were derived from this cell line in the absence of drug immediately following the 140-
day selection process. The two most resistant clones, NfxR1 and NfxR2, had EC50 
values for nifurtimox of 20.1 ± 0.9 µM and 20.3 ± 1.3 µM, respectively, which is 8-fold 
higher than the EC50 against wild-type T. brucei (2.4 ± 0.1 µM; Figure 4.4). Although 
NfxR1 and NfxR2 were cloned and routinely cultured in the absence of the selective 
drug, they retained their resistant phenotype for over 60 days (30 passages) in culture.  
The resistance of these clones appeared to be specific for nifurtimox, as their 
sensitivity to the non-nitroaromatic drugs pentamidine and eflornithine was comparable 
(within 3-fold) with that of the wild-type parental strain (Figure 4.4 and Table 4.1). 
Initially, NfxR1 and NfxR2 appeared to be more sensitive than wild-type cells to 
eflornithine, with EC50 values of 11.9 ± 0.7 µM and 11.5 ± 0.6 µM versus 16.4 ± 0.6 
µM, respectively. The difference in these EC50 values between the nifurtimox-resistant 
and -sensitive cells was found to be statistically significant (p < 0.01, Student’s t-test) 
only when the weighted mean EC50 values were compared. However, when the range of 
individual EC50 determinations was taken into account (10.2 – 16.8 µM against resistant 
and 11.0 – 19.8 µM against sensitive cells), no such significance was found (p > 0.17). 
In the case of pentamidine, the weighted mean EC50 values were found to be statistically 
significantly different (p < 0.001) not only between nifurtimox-resistant and -sensitive 
cells, but also between NfxR1 and NfxR2. However, similar to eflornithine, the 
individual EC50 values for pentamidine, which were in the range of 1.3 – 5.0 nM against 
NfxR clones and 0.7 – 6.1 nM against wild-type cells, showed no statistically 
significant difference (p > 0.7).  
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4.2.2. Cross-resistance to nitroaromatic compounds in vitro  
To determine whether generation of nifurtimox resistance in T. brucei can confer cross-
resistance to other nitroaromatic drugs, the sensitivity of Nfx1 and NfxR2 to a number 
of compounds was examined (Table 4.1). Both clones were found to be cross-resistant 
to nitrofurazone, with a resistance factor of 12, similar to that for the related drug 
nifurtimox. Nitrofurazone is overall more potent than nifurtimox against T. brucei, but it 
is also highly toxic in humans, which has led to the discontinuation of its use as a 
treatment for second-stage sleeping sickness soon after it was introduced (Williamson, 
1970). More importantly, however, cross-resistance was observed to the current clinical 
candidate fexinidazole, which measured the highest resistance factor of the tested 
compounds (27- and 29-fold for NfxR1 and NfxR2, respectively). Furthermore, the 
NfxR clones were highly resistant (up to 15-fold) to the two proposed metabolites of 
fexinidazole, the sulfoxide and sulfone (Winkelmann and Raether, 1977; Winkelmann 
and Raether, 1978). In addition, NfxR1 and NfxR2 were cross-resistant (by a factor of 
5) to benznidazole, which has a relatively low potency against wild-type T. brucei (EC50 
= 30.0 ± 0.2 µM) and is currently only used against acute or early-chronic infections 
with T. cruzi. By contrast, NfxR1 and NfxR2 were not resistant to the anti-tubercular 
nitrodrug PA-824 (Singh et al., 2008), with EC50 values in the range of 30 – 40 µM 
against both NfxR and wild-type T. brucei. Another antibacterial and antiprotozoal 
drug, metronidazole, which is primarily used against microaerophilic organisms 
(Löfmark et al., 2010), was ineffective against both wild-type and NfxR cells even at 
highest test concentration of 500 µM. The final test compound was the anticancer pro-
drug CB1954, which was first identified as an antitrypanosomal agent during a 
phenotypic screen in our laboratory (Jones et al., 2010b). Furthermore, CB1954 is a 
substrate for the bacterial nitroreductases which are known to activate nitrofurazone 
(Anlezark et al., 1992). Both NfxR1 and NfxR2 were found to be resistant to CB1954 
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by factors of 15- and 19-fold respectively, similar to the resistance factors obtained with 
nitrofurazone and the fexinidazole metabolites against these clones. In summary, these 
results demonstrate that generation of nifurtimox resistance in BSF T. brucei has led to 
high levels of cross-resistance to several nitroaromatic compounds, which belong to 
three related chemical classes and are thought to share a similar mode of action and 
mode of activation with nifurtimox.  
 
4.2.3. Cross-resistance to nitroaromatic compounds in vivo  
The biological relevance of nifurtimox resistance generated in vitro in NfxR cells was 
tested in several mouse-model studies. In a pilot experiment, performed by Dr Susan 
Wyllie, University of Dundee, NMRI mice were infected with wild-type, NfxR1 or 
NfxR2 T. brucei (104 cells per mouse, 5 mice per group) and monitored daily for signs 
of infection. Mice infected with wild-type cells succumbed to infection within 5 to 6 
days, with a mean survival time of 5.2 ± 0.4 days. Mice infected with NfxR1 and NfxR2 
had almost identical survival times (5.2 ± 0.4 and 5.4 ± 0.9 days, respectively), which 
indicated that NfxR cells were able to establish fatal levels of parasitaemia at the same 
rate as wild-type cells. Therefore, the virulence of these nifurtimox-resistant cells was 
not compromised in the process of generating such resistance.  
A second study, also carried out by Dr Susan Wyllie, aimed to determine 
whether NfxR cells were resistant to nifurtimox in vivo. Mice (n = 5 per group), infected 
with NfxR1 or wild-type T. brucei (104 cells per mouse), were either left untreated as 
controls or given a 4-day course of 100 mg kg-1 day-1 (i.p.) nifurtimox, starting 24 h post 
infection (Figure 4.5 A). This regimen was based on the 99% effective dose of 
nifurtimox (ED99 ≈ 128 mg kg-1 day-1), calculated using equation (7) and published data 
on ED50 (36.7 mg kg-1 day-1) and Hill slope (m = 3.7) values for nifurtimox (Fairlamb et 
al., 1992). As expected from the pilot study, the control groups, which did not receive 
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treatment, succumbed to infection by either wild-type or NfxR1 cells within 5 to 7 days. 
Furthermore, one mouse from each group that received nifurtimox had to be sacrificed 
as it experienced severe adverse side effects caused by the drug, which suggested that 
100 mg kg-1 day-1 was at the limit of or exceeding the maximum tolerated dose for 
nifurtimox in these animals. From the mice which survived treatment with nifurtimox, 
those infected with wild-type T. brucei were cured by this treatment and shown to be 
free from parasitaemia for the duration of the experiment (a total of 30 days). However, 
mice infected with NfxR1 and treated with nifurtimox succumbed to infection within 
the same time period as mice that did not receive the drug. Collectively, these results 
indicate that, even at the highest tolerated dose, nifurtimox has no effect on the growth 
of NfxR1 cells, which remained resistant to this drug both in vitro and in vivo.  
To determine whether NfxR1 were also cross-resistant to fexinidazole in vivo, a 
similar study was performed by Dr Kevin Read and the DMPK group at the University 
of Dundee. In this case, mice infected with either NfxR1 or wild-type T. brucei received 
4 doses of oral fexinidazole ranging from 25 to 200 mg kg-1 day-1 and starting on day 1 
post infection (Figure 4.5 B). Data for the control groups, which did not receive 
treatment, is presented as a 0 mg-1 kg-1 dose. Unlike nifurtimox, fexinidazole had no 
adverse effects in these mice even at the highest administered dose, which suggested 
that fexinidazole is better tolerated than nifurtimox. Fexinidazole also appeared to be 
more effective, because it had a lower ED50 value (21 mg-1 kg-1 day-1; m = 7.9) against 
wild-type cells and an ED99 of 37.6 mg-1 kg-1 day-1, which would only result in a ~50% 
cure rate if applied for nifurtimox. Nonetheless, similar to nifurtimox, fexinidazole was 
not effective against NfxR1 infection at its ED99 dose. The ED50 of fexinidazole against 
NfxR1 cells in mice was estimated to be 171 mg-1 kg-1 day-1, 8.5-fold lower than that 
against the parental wild-type cells. This estimate was based on the survival of 3 out of 
5 mice infected with NfxR and dosed with 200 mg kg-1 day-1 fexinidazole. However, 
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only two of those mice were cleared of parasitaemia as a result of the treatment, 
whereas the third mouse experienced several relapses between end of treatment (day 4) 
and day 18. Eventually, this mouse appeared to be able to overcome the infection by 
itself and survived until the termination of the experiment on day 60.  
In conclusion, the above results confirm that generation of resistance to 
nifurtimox in BSF T. brucei can confer in vivo cross-resistance to the clinical candidate 
fexinidazole.  
 
4.2.4. Generation of a fexinidazole-resistant T. brucei line  
To investigate whether the relationship between nifurtimox and fexinidazole resistance 
is reciprocal, a fexinidazole-resistant T. brucei line was generated essentially as 
described for NfxR (section 4.2.1). Wild-type trypanosomes were initially exposed to a 
sublethal concentration of fexinidazole (1 µM), which was subsequently increased in a 
step-wise manner as the cells adapted their growth (Figure 4.6 A). Similar to NfxR, the 
resulting fexinidazole-resistant line (FxR) was adapted to growth in 50 µM drug after a 
total of 137 days in culture, with the notable exception that FxR was able to survive an 
increase in drug concentration from 25 µM to 50 µM, whereas NfxR required an 
intermediate concentration step (Figure 4.3 A and 4.6 A). Clones FxR1 and FxR2, 
derived from this line at the end of the selection period, were almost 10-fold less 
sensitive to fexinidazole compared to the parental wild-type cells (Figure 4.6 B). The 
respective weighted mean EC50 (and Hill slope) values against these clones were 16.9 ± 
0.8 µM (m = 1.5) and 16.0 ± 1.2 µM (m = 1.2), whereas in the same experiment (four 
independent determinations), the weighted mean EC50 against wild-type T. brucei was 
1.7 ± 0.1 µM (m = 1.6; Table 4.2). Similar data were obtained for nifurtimox in three 
independent determinations, where the weighted mean EC50 values against FxR1 and 
FxR2 (19.0 ± 0.8 µM, m = 2.8 and 18.6 ± 0.7 µM, m = 2.3, respectively) were 9- to 10-
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fold higher than the corresponding EC50 value against the parental cells (2.0 ± 0.1 µM, 
m = 2.8).  
These results emphasise the fact that in both wild-type and nitrodrug-resistant 
cells the Hill slope for nifurtimox is consistently steeper than that for fexinidazole. 
Consequently, the relationship between the EC50 values for these two compounds 
against a given cell line will not be the same as their corresponding EC99 values. For 
example, against wild-type T. brucei fexinidazole has a 2.4-fold lower EC50 than 
nifurtimox, which would suggest that fexinidazole is the more potent compound in 
vitro. However, the actual concentration required for 99% growth inhibition of wild-
type cells is very similar for both nifurtimox and fexinidazole (15.2 μM versus 17.8 μM, 
respectively). By contrast, in all nitrodrug-resistant clones, nifurtimox and fexinidazole 
have similar EC50 values, but in each case, the EC99 for fexinidazole is higher than that 
for nifurtimox. Therefore, despite almost identical EC50 data for the two compounds, 
nitrodrug-resistant cells can survive much higher levels of fexinidazole than of 
nifurtimox.  
The second implication of the above study comes from the different resistance 
factors determined for NfxR and FxR clones. It appears that when resistance was 
generated to nifurtimox, the resulting NfxR cells were more resistant to fexinidazole 
than they were to nifurtimox, when judged by either their RF50 or their RF99 resistance 
factors. By contrast, when the selection drug was fexinidazole, the resulting FxR cells 
developed almost equal levels of cross-resistance to both drugs. This observation 
indicates that FxR cells may have a different mode of resistance to nitroaromatic drugs, 
compared to NfxR cells.  
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4.2.5. Pharmacokinetic studies of fexinidazole  
When fexinidazole was initially considered as a therapeutic option for African sleeping 
sickness, it was suggested (Winkelmann and Raether, 1978) that in mammals this 
compound is most probably metabolised to sulfoxide and sulfone derivatives via 
oxidation of the sulphur atom (Figure 4.7 A). To test this hypothesis, Dr Kevin Read 
and the DMPK team at the University of Dundee analysed blood samples from mice 
dosed with a single oral dose of 200 mg kg-1 fexinidazole. Data revealed that 
fexinidazole reached a total concentration peak at 960 ng ml-1 (~3.4 µM) in the first half 
an hour after dosing (Figure 4.7 B). Soon after fexinidazole levels started to decline    
(1 – 2 h after dosing), fexinidazole sulfoxide was found to peak at the much higher total 
concentration of 40,000 ng ml-1 (135 µM). The subsequent steady decline of the levels 
of fexinidazole and its sulfoxide derivative was coincident with a prolonged and 
sustained increase in the level of the second metabolite, fexinidazole sulfone, which 
reached 55,000 ng ml-1 (176 µM) when last measured 8 h after dosing. Based on these 
results, it was evident that the maximum peak concentration of fexinidazole, following a 
single oral dose, is far below its EC99 value against wild-type T. brucei (4,900 ng ml-1 or 
17.8 µM) determined from previous in vitro studies (Table 4.2). By contrast, both 
fexinidazole sulfone and sulfoxide were present at concentrations much higher than 
their corresponding EC99 values (7,300 ng ml-1 and 3,400 ng ml-1, or 25 µM and 11 µM, 
respectively) for a period of over 6 h. These observations hold true even if only the free, 
unbound fraction (fu) of the drug and its metabolites in plasma is taken in account. A 
separate study by Dr Kevin Read and the DMPK group established that fu of 
fexinidazole is 0.147, whereas fexinidazole sulfoxide and sulfone have much higher 
values for fu (0.858 and 0.728, respectively; Sokolova et al., 2010). Collectively, these 
findings confirm that fexinidazole is unlikely to act as the bioactive agent against T. 
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brucei. Instead, most of the trypanocidal activity in vivo is probably exerted by its 
sulfoxide and sulfone metabolites.  
 
4.3. Role of TbNTR in resistance to nitroaromatic drugs in T. brucei  
4.3.1. Southern analysis of gDNA from nitrodrug-resistant and -sensitive lines  
A recent study on laboratory-generated nifurtimox-resistant T. cruzi has implicated loss 
of the nitroreductase gene, TcNTR (Tc00.1047053510611.60), as a potential mechanism 
of resistance to nitroaromatic drugs (Wilkinson et al., 2008). To investigate whether the 
T. brucei homologue of TcNTR has been affected in our NfxR and FxR cell lines in the 
process of generating such resistance, gDNA extracted from these cells, as well as from 
wild-type T. brucei, was analysed by Southern hybridisation using two reference genes 
(Figure 4.8 A). These genes were selected so that one of them (TbDHFR-TS) was 
positioned on the same chromosome as TbNTR and the other (TbTRYS) was on a 
different chromosome. Furthermore, both TbDHFR-TS and TbTryS are single copy 
genes per haploid genome (Gamarro et al., 1995a; Gamarro et al., 1995b; Oza et al., 
2003), and most importantly, they are thought to be unrelated to the mode of action and 
mode of activation of nitroaromatic pro-drugs.  
Prior to the hybridisation analysis, agarose gel electrophoresis of the EcoRV-
digested samples revealed that the gDNA of NfxR1 had a different restriction pattern of 
fragments below 2 kb (Figure 4.8 B), compared to wild-type gDNA. This indicated that 
NfxR1 cells had undergone some form of genetic modification, although at this stage no 
distinction could be made between insertions/deletions of DNA fragments and 
mutations at certain EcoRV recognition sites.  
Following hybridisation with the labelled ORF of TbNTR, a band at the expected 
size of 6.8 kb was observed in all samples (Figure 4.8 C), which confirmed that at least 
one allele of NTR was present in both NfxR and FxR cell lines. To determine whether 
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changes in the number of TbNTR alleles have occurred in these cell lines, the intensity 
ratio of the band corresponding to TbNTR and the bands corresponding to the two 
reference genes was determined in each gDNA sample (Figure 4.8 C). Based on 
comparison of these ratios between the resistant lines and wild-type T. brucei (Figure 
4.8 C), it was evident that only FxR2 cells had the same proportion of all three gene 
sequences as in wild-type cells, which would suggest that no change in the NTR copy 
number had occurred in these cells. The other FxR clone (FxR1) was found to have 
altered band intensity ratios of DHFR-TS to both NTR and TryS, whilst the ratio 
NTR:TryS was similar to that in wild-type cells. In theory, this would suggest that FxR1 
cells had lost an allele of DHFR-TS, or lost part of chromosome 7 containing DHFR-TS 
but not NTR. An alternative, but highly unlikely explanation would be that both NTR 
and TryS copy numbers had been increased by an equal amount and no change had 
occurred at the DHFR-TS locus. In each case, this result is unexpected and highlights 
potential technical issues with the experiment, most probably at the stage of determining 
the individual band intensities. Much more logical data were obtained with the two 
NfxR clones, where the band intensity ratio of NTR to each of the two reference genes 
was reduced by approximately 1.5-fold, relative to the corresponding ratios in wild-type 
T. brucei. Similar to the above results, this was an indication that one allele of NTR was 
lost in both NfxR1 and NfxR2 cells. However, in this case the data was consistent with 
the expected role of NTR in activation of nitroaromatic pro-drugs. Although these 
results require confirmation, they indicate that the four nitrodrug-resistant clones are 
genetically different from one another. Interestingly, the main difference between the 
NfxR and FxR clones appears to be in the partial loss of TbNTR in the former.  
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4.3.2. Sequence analysis of gDNA from nitrodrug-resistant and -sensitive lines  
To determine whether any alterations had occurred in the TbNTR sequence of nitrodrug-
resistant cells, the ORF of TbNTR, flanked by 100 bp at the 5′ terminus and 150 bp at 
the 3′ terminus, was amplified by PCR from gDNA and analysed by sequencing. As 
previously reported (section 3.1.1), TbNTR from wild-type T. brucei was found to be 
polymorphic at four nucleotide positions, which presented as double peaks of equal 
signal intensity on the sequencing electropherogram (Figure 4.9). By contrast, in 
NfxR1 and NfxR2 cells, which had lost one allele of TbNTR (section 4.3.1), only one 
sequence variant of the gene was present (Thr57/Asp69/Asn261), and consequently 
only a single nucleotide peak was observed at each SNP position. Furthermore, in both 
NfxR clones the remaining allele of TbNTR was found to contain a unique point 
mutation (G316A; black asterisks on Figure 4.9), which was not present in any of the 
FxR clones, and which results in the amino acid substitution Val106 to Ile. This was the 
only mutation found in TbNTR from nitrodrug-resistant cells, because the sequence of 
NTR from the FxR clones was identical to that from the wild-type parental cells. Since 
the FxR clones had more than one allele of TbNTR, they also displayed polymorphism 
at all four SNP sites identified in wild-type cells. From these data, it could be concluded 
that TbNTR was not affected in the process of generating in vitro resistance to 
fexinidazole in BSF T. brucei, whereas using a similar process to generate nifurtimox 
resistance in these cells resulted in loss of one TbNTR allele and a substitution mutation 
in the remaining allele.  
 
4.3.3. Analysis of TbNTRVal106Ile  
The gene encoding TbNTR in all NfxR clones was found to contain a point mutation 
which affects its amino acid sequence. Ideally, to determine whether this particular 
amino acid change (Val106Ile) affects the nitroreductase activity of the resulting mutant 
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form (TbNTRVal106Ile), purified recombinant protein would be required. However, 
numerous attempts to obtain recombinant TbNTR have failed to produce pure and at the 
same time enzymatically active protein (see Chapter 3). Therefore, to circumvent the 
need for protein purification, the ability of recombinant TbNTRVal106Ile to reduce 
nitroaromatic compounds was examined in whole cell E. coli using a specifically 
adapted disc diffusion test. For this purpose, TbNTRVal106Ile was expressed as a 
hexahistidne-tagged, truncated form (TbNTRVal106Ile_Δ54-His6), corresponding to the 
truncated form of non-mutant TbNTR that was previously shown to have a detectable 
nitroreductase activity in E. coli lysates (TbNTRΔ54-His6; see sections 3.4.4 and 3.4.5). 
The sensitivity of the resulting E. coli strains, expressing either TbNTRΔ54-His6 or 
TbNTRVal106Ile_Δ54-His6, was determined for nitrofurazone, at concentrations of 0.1, 1 
and 10 mM (5 µl per disc, Figure 4.10 A). The disc diffusion test was also performed 
with nifurtimox, although this compound had to be applied at 10-fold higher 
concentrations to produce similar-sized zones of inhibition (Table 4.3). In each case, 
there was a clear zone with no visible growth around the disc with the highest test 
concentrations, whereas the intermediate concentrations only reduced the colony size 
and number around the disc (data in brackets in Table 4.3), and the lowest test 
concentrations failed to produce any visible zone of inhibition. By contrast, fexinidazole 
failed to produce clear zones of inhibition in any of the E. coli strains even at 100 mM 
(not shown), and is not discussed further. The drug carrier DMSO did not produce any 
visible reduction in growth, which suggested that the observed zones of reduced or 
absent growth were the result of inhibition by the drug itself. As predicted, in positive 
control cells expressing EcNfsB, the zones of inhibition for nitrofurazone were broader, 
indicating higher drug sensitivity, compared to cells with background nitroreductase 
activity alone (transformed with an empty vector). A comparable increase in the zone of 
inhibition was also observed in cells expressing either wild-type or mutant TbNTRΔ54-
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His6, thereby confirming that both of these proteins were capable of reducing and 
activating nitrofurazone. Interestingly, only cells expressing TbNTRΔ54-His6 or 
TbNTRVal106Ile_Δ54-His6, but not EcNfsB, displayed a marginal increase in their zone of 
inhibition for nifurtimox, visible at the highest test concentration (100 mM). A possible 
explanation is that nifurtimox is a good substrate for TbNTR and a poor one for 
EcNfsB, although this would require further investigation to confirm. In any case, the 
above experiments demonstrate that mutant TbNTRVal106Ile is enzymatically active and 
can reduce nitroaromatic drugs, at least when expressed in E. coli.  
To verify that TbNTRVal106Ile is also enzymatically active in T. brucei, a 
tetracycline-inducible ectopic copy of the mutant gene was introduced into wild-type 
cells under phleomycin selection as previously described (section 4.1.1). All 
tetracycline-induced clones, derived from the resulting TbNTRVal106Ile-overexpressing T. 
brucei cell line, were found to be 3- to 5-fold more sensitive to nifurtimox than the 
parental wild-type cells (see example in Figure 4.10 B). The mean EC50 (and Hill 
slope) values determined for all clones on two separate occasions were 0.36 ± 0.06 µM 
(m = 2.6) and 0.46 ± 0.08 µM (m = 2.1), with corresponding EC50 values of 1.3 ± 0.1 
µM (m = 1.8) and 1.9 ± 0.1 µM (m = 2.2) against wild-type cells. The consistent shift in 
nifurtimox sensitivity confirmed that mutant TbNTRVal106Ile was capable of activating 
nifurtimox in BSF T. brucei. Therefore, the synonymous mutation (Val106Ile) present 
in NfxR1 and NfxR2 clones cannot account for nitrodrug resistance in these cells.  
In summary, this chapter demonstrated that resistance to either nifurtimox or 
fexinidazole could be generated easily in BSF T. brucei, and that the resulting resistant 
cell lines were cross-resistant to a range of nitroaromatic pro-drugs. Such reciprocal 
cross-resistance indicated the presence of common resistance mechanisms shared by 
both cell lines. However, there were also clear differences between NfxR and FxR T. 
brucei, as demonstrated by variation in the resistance factors determined for each cell 
  
 
- 92 -
line and by the genetic differences found at the NTR locus. Unravelling further 
mechanisms of resistance would be a priority for future investigations, which may not 
only contribute to better understanding of the biology of trypanosomes, but may also 
help to prevent such resistance from occurring in the field.  
 
Chapter 5 -          
Discussion  
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5.1. Key findings  
The lack of better and safer chemotherapeutic options for African sleeping sickness has 
led to the re-introduction of nitroaromatic compounds, such as nifurtimox (in 
combination with eflornithine, NECT) and fexinidazole (undergoing clinical trials), for 
use against the second stage of the disease (Torreele et al., 2010). However, relatively 
little is known about the implications of widespread use of these drugs against HAT, 
especially about the resistance potential of this class of compounds in the African 
trypanosome. Furthermore, the mode of action of nitroaromatic pro-drugs against 
trypanosomes remains poorly understood, with studies almost exclusively carried out in 
the South American T. cruzi. To address some of these unknowns, I have undertaken the 
current study, in which I have demonstrated that:  
- It is relatively easy to generate in vitro resistance nifurtimox in BSF T. brucei, 
without loss of virulence  
- The resulting NfxR cells are cross-resistant (to a variable degree) to a number of 
nitroaromatic compounds in vitro, as well as to nifurtimox and fexinidazole in vivo  
- Conversely, it is relatively easy to generate resistance to fexinidazole, and the 
resulting FxR cells are cross-resistant to both fexinidazole and nifurtimox in vitro  
- Cross-resistance to nifurtimox and fexinidazole indicates that the two pro-drugs 
share some common mechanisms of action, activation and resistance  
- Nonetheless, there appear to be a subtle difference in these mechanisms, 
depending on which drug was used to generate resistance, nifurtimox or fexinidazole  
- Loss of a TbNTR gene copy is only partially responsible for resistance to 
nifurtimox (but not to fexinidazole), and point mutations in this gene seem unlikely to 
play any role in nitrodrug resistance  
- Purification of enzymatically-active TbNTR could not be achieved, as 
recombinant TbNTR was found to be insoluble and membrane-associated.  
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5.2. Mode of action of nitroaromatic pro-drugs in T. brucei  
5.2.1. Mechanisms of action of nitroaromatic pro-drugs in trypanosomes  
Nitroheterocyclic drugs have been used against South American trypanosomiasis since 
the 1970s (Fries and Fairlamb, 2003). Many attempts have also been made since the 
1950s to introduce these drugs for the treatment of HAT (Pépin and Milord, 1994; 
Williamson, 1962), culminating in the replacement of eflornithine with NECT for use 
against the second disease stage (Yun et al., 2010). Nonetheless, the precise mode of 
action of nitroaromatic drugs in trypanosomes is still unclear. Pioneering work by 
Docampo and co-workers (Docampo et al., 1981; Docampo and Stoppani, 1979) has 
suggested that nitrofurans, in particular nifurtimox, act via the formation of nitro anion 
radicals, which undergo futile redox cycling to generate reactive oxygen species in T. 
cruzi. However, this hypothesis has been challenged in a recent study (Boiani et al., 
2010), which argued that growth-inhibitory concentrations of nifurtimox did not induce 
the formation of reactive oxygen species. The mode of action of nitroimidazoles, such 
as benznidazole and megazol, in trypanosomes is also uncertain, but appears to be 
different from that of nitrofurans and to involve damage to macromolecules and 
depletion of intracellular thiols (Diaz-de-Toranzo et al., 1988; Enanga et al., 2003; 
Maya et al., 2003).  
Despite the vast uncertainties regarding the mode of action of nitroaromatic pro-
drugs in trypanosomes, it is universally accepted that the first step in the process is drug 
activation by enzyme-mediated reduction of the nitro group. Several different enzymes, 
which catalyse electron transfer reactions, have been proposed to perform this initial 
step. Both recombinant TryR (from T. cruzi and the insect-infective Crithidia fasciculata) 
and recombinant lipoamide dehydrogenase (from T. cruzi) have been shown to conduct 
one-electron reduction of nifurtimox and other nitroaromatic derivatives (Blumenstiel et 
al., 1999; Henderson et al., 1988). However, activation of nitroaromatic pro-drugs by 
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lipoamide dehydrogenase has not been demonstrated in intact cells, whereas 
overexpression of TryR was found to have no effect on nifurtimox sensitivity in T. 
cruzi, suggesting that TryR did not play a significant role in the bioactivation of 
nitrodrugs (Hall et al., 2011; Kelly et al., 1993). Another flavoprotein, TcOYE, was 
found to catalyse two-electron reduction of nifurtimox only under anaerobic conditions, 
both as a purified enzyme and in T. cruzi cell lysates (Kubata et al., 2002). Interestingly, 
TcOYE was not able to catalyse reduction of benznidazole, yet the gene and protein 
levels of OYE were reduced in two benznidazole-resistant strains of T. cruzi (Andrade 
et al., 2008; Murta et al., 2006). Even though this enzyme may be required for 
bioactivation of nitrofurans in T. cruzi (under anaerobic conditions), there are no 
homologues of TcOYE in the genome of T. brucei (http://www.genedb.org). Finally, the 
NADPH-cytochrome P450 reductase TcCPR-B was found to act not as a bioactivator 
but as a detoxifying enzyme, conferring protection from benznidazole, and to a lesser 
extent from nifurtimox (Portal et al., 2008). By contrast, neither prostaglandin F2α 
synthase (TbPGS; non-homologous to OYE) nor two homologues of TcCPR-B 
(TbCPR2 and TbCPR3) were found to have any effect on the sensitivity of T. brucei to 
nifurtimox (Hall et al., 2011). Thus, the only remaining candidate that can realistically 
act as a bioactivator of nitroaromatic pro-drugs in T. brucei is the newly uncovered 
bacterial-like nitroreductase TbNTR (Tb927.7.7230).  
In this study, I have demonstrated the role of TbNTR as a bioactivator by 
overexpression of the protein in BSF T. brucei, resulting in a ~10-fold increase in 
sensitivity to nifurtimox. I have also shown that deletion of a TbNTR copy by gene 
knock-out results in parasites that are 1.6- to 2.3-fold less sensitive, as would be 
expected for loss of a major activating enzyme. These results are in good agreement 
with studies by Wilkinson and colleagues, which have shown up to 3-fold loss of 
sensitivity in TbNTR SKO cell lines, and a 10-fold increase in sensitivity to nifurtimox 
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and other nitroaromatics in cells overexpressing C-terminally tagged TbNTR 
(Wilkinson et al., 2008). Furthermore, generation of in-vitro resistance to nifurtimox 
has resulted in loss of an NTR gene copy in T. brucei (this study) and loss of a 
chromosome containing NTR in T. cruzi (Wilkinson et al., 2008). Moreover, depletion 
of TbNTR by RNA interference has resulted in resistance to nifurtimox (Baker et al., 
2010). In studies with recombinant protein, TcNTR has been shown to reduce 
nifurtimox, nitrofurazone, nitrofurantoin, benznidazole and megazol, whereas TbNTR 
has been shown to activate nifurtimox and CB1954 (Bot et al., 2010; Wilkinson et al., 
2008). The final reduction products, generated through reduction by TbNTR, were 
identified as the 2- and 4-hydroxylamino derivatives of CB1954 (Bot et al., 2010) and 
speculatively as the open nitrile chain of nifurtimox (Hall et al., 2011), although the 
formation of these products in T. brucei needs to be confirmed. These recent studies, 
combined with my current work, have greatly enhanced our understanding of the 
mechanism of nifurtimox activation in trypanosomes, and the role of TbNTR therein. In 
the near future, it will be imperative to carry out similar investigations into the 
mechanisms of action and resistance of fexinidazole.  
 
5.2.2. Studies with recombinant TbNTR  
Nitroaromatic pro-drugs have recently experienced a revival, not only for used against 
African sleeping sickness, but also as effective antimicrobial, antiviral and anticancer 
agents. This diversity in the clinical applications of nitro drugs stems from the fact that 
their only requirement for biological activity is a nitro group attached to an aromatic 
moiety, thus leaving plenty of scope for modification of the aromatic structure (benzene, 
furan, imidazole, etc.) and its substituents to alter drug specificity and toxicity 
(Grunberg and Titsworth, 1973). This chemical flexibility can hopefully be exploited 
for the development of second-generation nitro pro-drugs, with increased potency and 
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lower toxicity, for use against HAT. However, for this to be achieved, detailed 
knowledge of the mechanisms of activation and action of these compounds will be 
required. This was partly resolved with the help of the genome-sequencing project 
(Berriman et al., 2005), which led to the identification of the key activator of these nitro 
pro-drugs in trypanosomes – the bacterial-like enzyme NTR. What is lacking to date is a 
crystal structure of this enzyme to guide structure-based drug design. The limiting factor 
has proven to be the lack of high quantities of purified recombinant enzyme. In the 
course of the current study, Wilkinson and colleagues reported on the expression and 
purification of both TbNTR and TcNTR, with protein yields that might have been 
enough for preliminary kinetic analysis, but were insufficient for crystallographic 
studies (Hall et al., 2010; Wilkinson et al., 2008). In fact, using what little information 
was provided in the published protocol (Wilkinson et al., 2008), I was not able to 
reproduce the expression and purification (no protein was recovered) of the truncated 
form of TbNTR* studied by these authors. By contrast, I have successfully obtained 
pure and enzymatically active recombinant EcNfsB by following previously published 
methodology (Anlezark et al., 1992; Zenno et al., 1996). The reasons for the 
discrepancies between my work and that of Wilkinson and co-authors became clear 
during subsequent personal communications with Dr Wilkinson. It was revealed that 
high salt and sucrose, as well a specific detergent, had been used in the purification of 
recombinant TbNTR. More crucially, the use of only a single type of culture media 
from a specific supplier was found to support protein expression. Unfortunately, due to 
time constraints, I was not able to test expression and purification under these exact 
conditions.  
                                                 
* Full-length TbNTR was expressed mostly as an insoluble protein (this study and Hall et al., 2010), 
which prompted the use of truncated forms of the recombinant protein.  
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In the mean time, new information regarding TbNTR became available through 
studies on the mitochondrial proteome of procyclic T. brucei (Panigrahi et al., 2009). 
TbNTR had been previously shown to localise to the mitochondrion of BSF 
trypanosomes (Wilkinson et al., 2008), and the new data confirmed this localisation. 
Furthermore, the new study indicated that truncated forms of TbNTR, which had been 
studied both by the Wilkinson group and myself, were missing part of the mature 
protein. Based on this information, I designed several alternative truncations of TbNTR, 
one of which (TbNTRΔ54) was found to be enzymatically active both in bacterial lysates 
and in intact E. coli cells (using the disc diffusion method). The presence of measurable 
nitroreductase activity with recombinant TbNTRΔ54 enabled me to determine that 
TbNTRΔ54 nitroreductase activity was abolished by the presence of an affinity His6 tag 
at the N-terminus, whereas a similar tag at the C-terminus was better tolerated. In 
addition, the recombinant protein was not amenable to purification and was found to be 
insoluble by gel filtration and high-force (100,000 x g, 1 h) centrifugation. A number of 
detergents were not able to solubilise TbNTRΔ54, with the exception of SDS and n-
dodecylphosphocholine, incubation with both of which resulted in loss of nitroreductase 
activity. Finally, partial retention of TbNTRΔ54 in solution by urea and alkaline Na2CO3 
suggested that TbNTRΔ54 was membrane associated. Based on these findings, the work 
of Wilkinson and colleagues can be questioned in terms of their recombinant TbNTR, 
which was shorter than the mature native protein, was tagged at the N-terminus and 
most importantly, was not proven to be entirely soluble by any qualitative technique.  
As is usually the case in research, the current study of recombinant TbNTR has 
posed more questions than answers. For example, it remains to be established if Ser55 is 
the first amino acid of the processed mature TbNTR in T. brucei. If not, what is the true 
start site of the native protein? Thus far, attempts to isolate TbNTR from BSF T. brucei 
by two different methods have come to a halt due to technical challenges. Are the first 
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few amino acids of the mature protein important for enzyme activity, or are there 
shorter forms of TbNTR that are equally active? How do changes in the length of 
TbNTR, especially at the N-terminus, affect the protein solubility? Is it possible to 
obtain soluble, and at the same time enzymatically active, recombinant TbNTR or is 
membrane association required for nitroreductase activity? My expression studies with 
TbNTRΔ54 using cell- and membrane-free systems were inconclusive in answering this 
question. Moreover, the only mild detergent (n-dodecylphosphocholine) that was found 
to affect the solubility of TbNTR was at the expense of the enzyme activity. Could the 
interaction of TbNTR with this detergent, which differs from phospholipids only by the 
presence of one and not two hydrophobic chains, provide any clues to the nature of the 
membrane-TbNTR interaction? Finally, the most enigmatic question of all – what is the 
real biological function of TbNTR in trypanosomes?  
It is not easy to speculate on the answer to this final question, especially given 
that the physiological function or substrate(s) has not been identified for the closest 
TbNTR homologue – the bacterial type I nitroreductases of group B. Although EcNfsB 
(McCalla et al., 1978) and similar nitroreductases have been investigated for their 
ability to reduce a broad range of nitroaromatic compounds, these chemicals are 
predominantly xenobiotics, such as synthetic antibiotics (nitrofurazone), toxic (dinoseb) 
or explosive (trinitrotoluene) environmental pollutants. However, a few more relevant, 
physiological substrates, including quinones and flavin co-factors, can also be reduced 
by EcNfsB-like nitroreductases (Terpe, 2003). Recombinant trypanosomal NTRs have 
been shown to share some nitroaromatic substrates with EcNfsB, most notably 
nitrofurazone and CB1954 (this work; Bot et al., 2010; Wilkinson et al., 2008), and it is 
tempting to speculate that they may also be able to reduce quinones. Combined with the 
mitochondrial localisation of TbNTR, reduction of quinones would suggest a role in 
maintenance of the mitochondrial redox balance or even in respiration/oxidative 
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phosphorylation. Here, I propose that TbNTR may be identical to a rotenone-insensitive 
NADH-dehydrogenase, which was recently isolated from procyclic T. brucei and about 
which no sequence information is available (Fang and Beattie, 2002). The reasons for 
this proposal are the following. First, this alternative NADH-dehydrogenase is a 33-kDa 
protein, which forms 65-kDa functional dimers and binds non-covalently to FMN (Fang 
and Beattie, 2002). The protein size is consistent with that of TbNTR, which in its 
mature form is less than 35.5 kDa (full-length protein; ProtParam) and more than 29.5 
kDa (the shortest possible polypeptide, as identified by proteomics MS analysis; 
Panigrahi et al., 2009). As a homologue of EcNfsB, TbNTR would also be expected to 
form dimers, and sequence alignment has shown that the trypanosomal protein has 
conserved the key residues required for FMN-binding. Second, the alternative NADH-
dehydrogenase is “loosely bound to the inner mitochondrial membrane” (Fang and 
Beattie, 2002), which is consistent with the findings that TbNTR is most probably 
membrane-associated (this study) and localised to the mitochondrion in T. brucei 
(Panigrahi et al., 2009; Wilkinson et al., 2008). Finally, the rotenone-insensitive 
NADH-dehydrogenase was shown to reduce ubiquinone via one-electron transfer, 
preferentially using NADH as the electron donor (Fang and Beattie, 2002). Although 
the role of this alternative cytochrome-lacking reductase may be minor in procyclic T. 
brucei that have a fully functional cytochrome-dependent respiratory chain, the 
presence of such an NADH-dehydrogenase may be crucial for maintaining the 
NADH/NAD+ balance in BSF mitochondria (for more details, please refer to reviews by 
Besteiro et al., 2005 and Ginger, 2006). This crucial role of the 33-kDa rotenone-
insensitive NADH-dehydrogenase is again consistent with TbNTR, which was proposed 
to be essential in BSF T. brucei (Wilkinson et al., 2008). Therefore, it will be a priority 
for future investigations to establish whether TbNTR and this alternative T. brucei 
NADH-dehydrogenase are in fact the same protein.  
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5.2.3. Future work with TbNTR  
In order to determine whether the novel 33-kDa NADH-dehydrogenase corresponds to 
TbNTR, future efforts should be targeted at the isolation of this NADH-dehydrogenase 
from procyclic T. brucei according to the published procedure (Fang and Beattie, 2002). 
The isolated protein should be fully characterised in terms of its protein sequence and 
enzyme activity, including its ability to reduce nifurtimox and other nitroaromatic 
compounds. If this protein is indeed TbNTR, knowledge of its sequence will help to 
determine the elusive true start site of mature TbNTR. If the two proteins happen to be 
unrelated, isolation of mature TbNTR ought nevertheless be pursued, using an 
immunoprecipitation protocol that takes into account the technical issues with the 
current pull-down method. It is anticipated that knowledge of the correct length of 
mature TbNTR will address some of the issues regarding the solubility and enzymatic 
activity of the recombinantly expressed protein. An alternative method for improving 
the solubility of recombinant TbNTR has been suggested by a theoretical model of the 
tertiary TbNTR structure (Figure 5.1, done with the kind assistance of Dr Scott 
Cameron), which was based on the closest homologue of TbNTR with a published 
crystal structure – the NADH oxidase TtNOX (Hecht et al., 1995). According to this 
model, a particular stretch of amino acids in TbNTR (circled on the figure, not present 
in TtNOX) may be responsible for membrane association. Therefore, if TbNTR is 
engineered without this segment, the recombinant protein may have an improved 
solubility and will hopefully retain its enzyme activity. Alternatively, substitutions of 
some hydrophobic residues within this segment with suitable hydrophilic counterparts 
may aid solubility. Should all future efforts to express recombinant TbNTR result in 
insoluble protein, it will still be possible to assess the activity of the membrane-
associated recombinant protein in intact E. coli cells, using an optimised and adapted 
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disc diffusion technique. Finally, the activity of the native (through knock-out and 
overexpression) and recombinant TbNTR with fexinidazole should be investigated.  
 
5.3. Mechanisms of (cross-)resistance to nitro pro-drugs in T. brucei  
Resistance to nitroaromatic drugs occurs naturally in the South American trypanosome 
(Filardi and Brener, 1987), and there is some evidence to suggest that this may also be 
the case in African trypanosomes (Likeufack et al., 2006; Maina et al., 2007; Pépin and 
Milord, 1994). To determine what mechanisms may lead to such resistance in T. brucei, 
I have generated an in vitro nifurtimox-resistant T. brucei line, designated NfxR. Clones 
derived from this line (NfxR1 and NfxR2) were resistant not only to nifurtimox but also 
to several other nitroaromatic derivatives, including fexinidazole and its metabolites, the 
sulfone and sulfoxide. Conversely, when resistance was generated to fexinidazole, the 
resulting FxR cells were cross-resistant to nifurtimox, although the resistance factors to 
nifurtimox and fexinidazole were not reciprocal to those determined for NfxR.  Overall, 
these findings are in agreement with other studies, which have demonstrated that both 
naturally-derived and laboratory-generated lines of T. cruzi and of T. brucei can be 
cross-resistant to various nitroaromatic drugs (Enanga et al., 2003; Filardi and Brener, 
1987; Murta and Romanha, 1998; Wilkinson et al., 2008). The presence of such cross-
resistance strongly indicates that nitroaromatic compounds share common mechanisms 
of action and of resistance. However, there may also be some resistance mechanisms 
that affect only a certain type of nitrodrug, as demonstrated here by the non-reciprocal 
resistance to the nitrofuran nifurtimox and the nitroimidazole fexinidazole.  
 
5.3.1. Potential mechanisms of nitrodrug resistance in T. brucei  
The mechanisms that may lead to drug resistance in trypanosomatids can be classified 
into three categories – mechanisms that lower the drug levels within the cell, 
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mechanisms that affect the main enzymes interacting with the drug (in the case of pro-
drugs – the main activating proteins), and general defence and repair mechanisms (Croft 
et al., 2006).  
 
Alterations in pro-drug activating enzymes in nitrodrug-resistant T. brucei  
Bearing in mind that nitroaromatic pro-drugs are thought to require enzymatic 
activation as a prerequisite for biological activity, it would be obvious to consider loss 
of function (through either gene deletion or mutations) of the activating enzyme as the 
first possible mechanism of resistance. A precedent of gene loss of NTR – now thought 
to be the main activator of nitroaromatic drugs in trypanosomes, has already been 
described in laboratory-generated nifurtimox-resistant T. cruzi (Wilkinson et al., 2008). 
In this study, both deletion of one TbNTR copy and a substitution mutation in the 
remaining gene copy were found to arise in the process of generating resistance to 
nifurtimox, but surprisingly not to fexinidazole. These results, which were initially 
questioned due to the quality of the Southern hybridisation analysis, have now been 
confirmed by genome sequencing* of the parental wild-type cells and of NfxR- and 
FxR-derived clones (unpublished data). However, loss of a single TbNTR copy can 
account only for 1.6- to 3-fold resistance to nifurtimox (as shown in SKO T. brucei 
lines; Wilkinson et al., 2008 and this study), whereas the detected mutation can be 
disregarded as a resistance factor, because the resulting mutant protein (TbNTRVal106Ile) 
retained its nitroreductase activity when expressed in both T. brucei and E. coli. These 
findings clearly indicate that other mechanisms, in addition to loss or modification of 
TbNTR, must contribute to the 8-fold resistance to nifurtimox in the NfxR cell line. 
Furthermore, the above results suggest that resistance to fexinidazole can also be 
generated through mechanisms that do not affect the activation of this pro-drug by 
                                                 
* In collaboration with Matthew Berriman and the Wellcome Trust Sanger Institute  
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NTR. (It should be noted that activation of fexinidazole by NTR has not been 
investigated in the current study on T. brucei due to time constraints. However, studies 
in the related kinetoplastid Leishmania have confirmed the role of this enzyme in 
fexinidazole activation; Wyllie and Fairlamb, unpublished results).  
 
Mechanisms leading to reduced intracellular levels of nitrodrugs  
Other mechanisms that may lead to drug resistance in trypanosomes cause reduced 
exposure to the drug by decreasing the intracellular drug concentration. This can be 
achieved either via reducing the rate of drug uptake (for example by down-regulation of 
a transporter) or via increasing the rate of drug efflux. Alternatively, sequestration of the 
drug may also provide a protective effect and thus contribute to drug resistance (Croft et 
al., 2006). To my knowledge, there are no studies on the uptake of nifurtimox in T. 
brucei. However, in T. cruzi, this lipophilic drug has been suggested to enter the cells 
via passive diffusion (Tsuhako et al., 1991). In T. brucei, the related nitrodrug megazol 
is also taken up primarily via passive diffusion, even though megazol has a recognition 
motif for the P2 amino-purine transporter (Barrett et al., 2000). The uptake of both 
nifurtimox and megazol has been suggested to occur in two phases – a rapid first phase 
of equilibration between the drug concentration in the cell and the extracellular media, 
followed by a much slower phase that is driven by “removal” of the intracellular drug, 
either through drug metabolism or sequestration (Barrett et al., 2000). Our preliminary 
studies on uptake of radiolabelled nifurtimox in T. brucei seem to support this biphasic 
model, but shortage of the radiolabelled drug has prevented more thorough 
investigations. Should my findings be confirmed by future studies, active pro-drug 
uptake could be excluded as a mechanism of nitrodrug resistance due to the lack of a 
dedicated transporter, although the second phase of the passive diffusion mechanism 
may still be influenced by reduced metabolism or reduced drug sequestration.  
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In trypanosomes, both drug sequestration (to an intracellular compartment) and 
efflux (to the extracellular media) are thought to be facilitated by members of the ABC 
transporter family, known as P-glycoproteins or multidrug resistance associated proteins 
(Klokouzas et al., 2003). Overexpression of different ABC transporters in T. brucei has 
been shown to cause resistance to melarsoprol and suramin (Shahi et al., 2002). A 
similar mechanism of resistance to nifurtimox also appears to operate in a strain of T. 
cruzi, because the resistance phenotype of these cells could be reversed by the calcium-
channel inhibitor verapamil (Neal et al., 1989). However, other studies have shown that 
non-toxic concentrations of verapamil did not affect the sensitivity of T. brucei to two 
drugs active against animal trypanosomiasis (Kaminsky and Zweygarth, 1991), and 
more importantly to the nitrodrug megazol (Enanga et al., 2003). Based on these last 
reports, it would seem less likely than that efflux and/or sequestration are involved in 
nitrodrug resistance in the African trypanosome.  
 
Antioxidant and damage-repair mechanisms in nitrodrug resistance  
Cell defence mechanisms may help to protect the cell or reverse the damage caused by 
nitrodrugs, and therefore up-regulation of these mechanisms has the potential to 
enhance drug resistance. A link between nitrodrug resistance and oxidant defence has 
been implied in several benznidazole-resistant strains of T. cruzi, which were found to 
have increased levels of the antioxidant enzymes tryparedoxin peroxidase (TryP) and 
iron superoxide dismutase (Andrade et al., 2008). Both nitrofurans and nitroimidazoles 
have been shown to deplete reduced trypanothione in T. cruzi (Maya et al., 2003). 
Conversely, depletion of trypanothione by RNA interference of its synthetase, TryS, 
was found to increase the sensitivity of T. brucei to nifurtimox (Ariyanayagam et al., 
2005). Just as decreased levels of trypanothione are associated with increased nitrodrug 
sensitivity, it would be expected that increase of the intracellular trypanothione content 
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would provide a potential mechanism of nitrodrug resistance. However, unpublished 
studies performed by Dr Susan Wyllie in our laboratory, have found no significant 
difference in the levels of trypanothione and total thiols between our nitrodrug-resistant 
(NfxR and FxR) and -sensitive T. brucei cell lines. Similar results have also been 
obtained in laboratory-generated T. brucei resistant to megazol (Enanga et al., 2003).  
Trypanothione is a molecule central to the antioxidant defence mechanisms in 
trypanosomes (Ariyanayagam and Fairlamb, 2001). Combined with the above studies 
on TryP and superoxide dismutase, this would seem to imply that nitroaromatic pro-
drugs can act via inducing oxidative stress (for example, through redox cycling) and 
that counteracting such stress would provide a mechanism of resistance. However, 
trypanothione can also provide protection from chemical stress, induced by drugs 
(Mukhopadhyay et al., 1996), metabolites (Vickers et al., 2004) and xenobiotics 
(Fairlamb and Cerami, 1992; Vickers and Fairlamb, 2004). Moreover, nitrofurans are no 
longer thought to act via production of reactive oxygen species in trypanosomes (Boiani 
et al., 2010; Hall et al., 2011), and it is believed that nitroimidazole metabolites act via 
damage to DNA and other macromolecules (Diaz-de-Toranzo et al., 1988; Enanga et 
al., 2003). In fact, depletion of the reduced trypanothione pool in T. cruzi was thought 
to occur not via oxidation, but by formation of trypanothione-drug conjugates (Maya et 
al., 2003). Therefore, up-regulation of oxidative defences may not necessarily present a 
plausible mechanism of resistance in trypanosomes. Elevated levels of low molecular 
weight thiols can also be excluded as a mechanism for nitrodrug resistance in NfxR and 
FxR cells, although it is possible that other defence systems, such as DNA repair 
mechanisms, are involved.  
In conclusion, conventional methods have not been able to identify all of the 
resistance mechanisms operational in our NfxR and FxR cell lines. It is hoped that more 
detailed examinations of their respective genome sequences will reveal additional 
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insights into to nature of this resistance, and potentially into the mechanisms of action 
of nifurtimox and especially of fexinidazole.  
 
5.3.2. Future studies with nitrodrug-resistant T. brucei  
The genome sequence of our nifurtimox- and fexinidazole-resistant cells is currently 
under analysis and is expected to facilitate the identification of the potential 
mechanisms involved in nitrodrug resistance. The only mechanism identified so far is 
partial loss of TbNTR in NfxR-derived clonal lines. This finding is consistent with the 
resistance profile of NfxR1 and NfxR2, which were cross-resistant to nitrofurazone and 
CB1954 – two known substrates of TbNTR (Bot et al., 2010) and EcNfsB (Anlezark et 
al., 1992), but were not resistant to PA-824 – a nitrodrug that is activated by 
Mycobacterium tuberculosis deazaflavin reductase not found in T. brucei (Singh et al., 
2008 ). It should be determined whether FxR cells, which have retained their TbNTR 
genes and which have been tested only with nifurtimox, have a similar cross-resistance 
profile to other nitroaromatic pro-drugs. It would also be very important to establish 
whether TbNTR is expressed to the same levels in FxR as in the parental wild-type 
cells. Currently there is neither a suitable antibody that can detect TbNTR in T. brucei 
lysates, nor a sufficiently sensitive enzyme assay to measure the levels of nitroreductase 
activity in these lysates. However, changes in NTR expression levels might be detected 
by comparing mRNA levels between the nitrodrug-resistant and -sensitive cells, for 
example by Northern blot analysis (Sienkiewicz et al., 2008) or by real-time PCR 
(Mejia-Jaramillo et al., 2011). It might be of interest to determine at what stage in the 
selection process the loss of TbNTR occurred in the NfxR cell line. It has been proposed 
that this may have happened during selection with 38 µM nifurtimox, since this step 
was not required to select for fexinidazole resistance (the cells survived an increase 
from 25 µM to 50 µM fexinidazole). Another area of research that cannot necessarily be 
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addressed by reference to the genome sequence is the rate of nifurtimox uptake by NfxR 
and FxR compared to that in the parental wild-type T. brucei. However, such studies 
will require synthesis of isotopically labelled drug. Finally, the intracellular levels of 
trypanothione under normal culture conditions appear to be identical between the 
nitrodrug-resistant and -sensitive T. brucei, but there is a possibility that the thiol levels 
of these cell lines might be affected in a different way under nitrodrug exposure. 
Therefore, determination of thiol levels in NfxR and FxR cells under stress conditions 
would form an additional subject for future investigation.  
 
5.4. Clinical implications of nitrodrug resistance in T. brucei  
5.4.1. Resistance to nifurtimox  
In a clinical setting, drug resistance can occur either naturally, such as the inherent lack 
of susceptibility of T. b. rhodesiense to eflornithine (Fries and Fairlamb, 2003), or under 
selective drug pressure, such as resistance to antimonials in Leishmania, which is 
proposed to have arisen due to drug misuse (Croft et al., 2006). Regarding nitroaromatic 
drugs, naturally-occurring resistance to nifurtimox is now a well-established fact in T. 
cruzi (Filardi and Brener, 1987). The high failure-to-cure rates (up to 70%), established 
when nifurtimox was initially tested against T. brucei, have led to concerns that natural 
resistance may also be a factor in the African trypanosome (Pépin and Milord, 1994). 
However, when nifurtimox was first developed for use against Chagas’ disease, it was 
suggested that in a given strain of T. cruzi, it was not possible to select for “complete 
resistance” to nifurtimox in vivo over the course of two years (Haberkorn and Gonnert, 
1972). A more recent study has shown that resistance in T. cruzi can be selected under 
nifurtimox pressure in vitro within 8 months (Wilkinson et al., 2008), and a similar 
study in T. brucei demonstrated generation of in vitro resistance to megazol within 6 
months (Enanga et al., 2003). However, these two studies have not determined the 
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clinical relevance of their resistant lines. In the current work, I have reported on the in 
vitro generation of nifurtimox resistance in T. brucei, without loss of virulence in the 
resulting NfxR1 cells, and at clinically relevant levels as demonstrated by the failure of 
nifurtimox to cure NfxR1-infected mice even at near-lethal doses. Moreover, NfxR1 T. 
brucei were found to be cross-resistant to fexinidazole in vivo. At least 2 out of 5 
NfxR1-infected mice relapsed after a 4-day fexinidazole treatment at 200 mg kg-1 day-1 
(the highest dose that does not cause adverse effects; Torreele et al., 2010), whereas the 
number of relapses was double (4 out of 5) at 100 mg kg-1 day-1 (the curative dose in the 
acute model of infection; Torreele et al., 2010). These findings suggest that clinically-
relevant resistance to nifurtimox can be generated relatively easy in BSF trypanosomes. 
Should such resistance occur in the field (if it is has not already), it will not only 
compromise the widespread implementation of NECT, but may also preclude any plans 
to introduce fexinidazole (and potentially other nitroaromatics) as a treatment against 
HAT. As previously discussed (Sokolova et al., 2010), combination therapy provides an 
effective strategy to reduce the likelihood of emerging drug resistance. Bearing this in 
mind, the findings of this current study strongly support the notion that nifurtimox 
should continue to be used against sleeping sickness only in drug combination therapy, 
such as NECT.  
The rationale behind introducing combination therapy for a given indication is 
rarely prevention of emerging resistance, as exemplified by the first clinical trial to 
suggest the usefulness of NECT against HAT (Priotto et al., 2006). The anticipation at 
the onset of this clinical trial was that combination therapy would allow drugs to be 
used at decreased doses without loss of efficacy, but potentially with minimised 
toxicity. In the case of NECT, the use of lower eflornithine doses has also resulted in 
great reduction of the treatment cost (Yun et al., 2010). Maintaining the efficacy at 
lower drug doses would normally be expected if the two drugs, used in the combination, 
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have a synergistic or at least an additive effect. However, a recent study on drug 
interaction in vitro has reported that nifurtimox and eflornithine may be antagonistic 
(Vincent et al., 2010). This result is highly surprising, given that the efficacy of the 
nifurtimox-eflornithine combination (96.5%) was similar to, if not higher than that of 
eflornithine monotherapy (91.6%; Priotto et al., 2009), and much greater than 
previously reported for nifurtimox monotherapy (30 – 87%; Bouteille et al., 2003). In 
fact, initial findings in our laboratory (Fu, Wyllie and Fairlamb, unpublished) suggest 
that the interaction between nifurtimox and eflornithine is somewhat complex, and, 
although it appears to be antagonistic at low eflornithine concentrations, it may become 
synergistic at higher levels of eflornithine. One factor that is not taken into account in 
both of these studies is the effect of time. During in vitro determinations of drug 
interactions (such as by Vincent et al., 2010), the two compounds are usually tested 
simultaneously. It is possible that for a synergistic effect to occur eflornithine needs to 
be given first (or at much higher doses), so that sufficient reduction of trypanothione 
levels can occur (Fairlamb et al., 1987), before the cells become more susceptible to 
nifurtimox (Ariyanayagam et al., 2005). Finally, host-related factors, which cannot be 
accounted for during in vitro studies, such as drug metabolism or the host immune 
system, may also influence the outcome of the combination therapy. For example, the 
curative effect of eflornithine against HAT has been shown to depend on an effective 
immune response (Bitonti et al., 1986), whereas nifurtimox is known to be metabolised 
very rapidly (half-life in humans of only 3 h; Paulos et al., 1989) and extensively (<1% 
excreted unchanged in urine; Medenwald et al., 1972). Because the nature of these 
metabolites remains unknown, their effect on trypanosomes as well as their interaction 
with eflornithine cannot be determined. Therefore, more thorough investigations will be 
required to determine the type of drug interactions (synergism or antagonism) between 
nifurtimox and eflornithine, which should form the basis of our future studies. Initial 
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efforts should elaborate on the findings of dose-dependent synergism between the two 
drugs in vitro. An additional area to be explored may include the identification of 
nifurtimox metabolites (potentially in collaboration with the DMPK group) and their 
efficacy against trypanosomes. The starting point for such studies could be the related 
drug nitrofurazone, some metabolites of which have been identified as the 
hydroxylamino and amino derivatives, 4-cyano-2-oxobutyraldehyde semicarbazone and 
two other coloured compounds of unknown structure (Miura and Reckendorf, 1967). 
Interestingly, the 4-cyano metabolite of nitrofurazone corresponds to the “saturated 
open nitrile chain” of nifurtimox, derived after reduction by TbNTR (Hall et al., 2011). 
If similar metabolites are detected for nifurtimox in vivo, this should not only help to 
uncover the effect of these compounds on trypanosomes, but may also explain the 
relatively high toxicity of nifurtimox and other nitrofurans in mammals.  
 
5.4.2. Resistance to fexinidazole  
At the pinnacle of nitroaromatic drug discovery in the 1960s and ‘70s, it was noted that 
the in vitro potency of nitrodrugs does not necessarily correlate with their in vivo 
efficacy, due to host-related factors, such as drug absorption, metabolism and excretion 
(Grunberg and Titsworth, 1973). This holds true also for nifurtimox and fexinidazole, 
which are active against T. brucei over a similar concentration range in vitro (this study 
and Torreele et al., 2010). However, the efficacy of fexinidazole in vivo is higher than 
that of nifurtimox, as illustrated by the 99% effective dose of fexinidazole against T. 
brucei S427 in mice (~38 mg kg-1 day-1 over 4 days; this study), which would only 
result in ~50% cure if applied for nifurtimox under the same experimental conditions 
(Fairlamb et al., 1992). In part, this difference in activity between fexinidazole and 
nifurtimox in vivo could be explained by drug metabolism. Although both compounds 
are metabolised very rapidly in mammals (Duhm et al., 1972; Paulos et al., 1989; 
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Torreele et al., 2010), there is no information on the metabolites of nifurtimox, whereas 
at least two fexinidazole metabolites (the sulfone and sulfoxide; Winkelmann and 
Raether, 1978) have been identified. Both of these metabolites have similar potency to 
fexinidazole in vitro against all three subspecies of T. brucei (this study and Torreele et 
al., 2010). Moreover, the metabolites of fexinidazole reach blood concentrations higher 
than their respective EC99 values against T. brucei, and maintain these high 
concentrations over several hours both after a single (this study) or a 5-day (Torreele et 
al., 2010) oral exposure to fexinidazole in mice. Therefore, the combined activity of 
fexinidazole and its metabolites is likely to account for the high in vivo efficacy of this 
drug. Fexinidazole is not only more effective than nifurtimox against trypanosomes, but 
it is also much better tolerated in mammals as demonstrated in the current and other 
studies (no effect dose was 25 – 30 mg kg-1 for nifurtimox, Hoffmann, 1972; and 200 
mg kg-1 for fexinidazole, Torreele et al., 2010).  
Collectively, all of the above studies indicate that, unlike nifurtimox, 
fexinidazole can be safely administered at doses much higher than needed for an 
effective cure of African trypanosomiasis. The broad therapeutic window of 
fexinidazole may lead to the impression that relative to nifurtimox, it would be much 
more difficult to select for fexinidazole resistance in vivo or in a field setting. However, 
there are several arguments to the contrary. In the current work, I have demonstrated 
that it is just as easy to select for fexinidazole resistance in vitro as it is for nifurtimox. 
The resulting resistant cell line FxR was 10-fold less susceptible to fexinidazole than the 
parental wild-type cells. However, FxR have the potential to become even more 
resistant, if the cells were to lose a copy of the nitrodrug activating enzyme TbNTR. 
Furthermore, although the sensitivity of FxR to fexinidazole has not yet been 
determined in vivo, comparison of the fexinidazole sensitivity of FxR and NfxR cells 
from in vitro studies indicates that FxR cells may be refractory to fexinidazole 
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treatment. The EC99 for this drug against FxR2 (670 µM) was less than 2-fold lower 
than that against NfxR1 (1080 µM), which were resistant to the highest test 
concentration of fexinidazole in vivo. Theoretically, since two out of five NfxR1-
infected mice relapsed after treatment with 200 mg kg-1 fexinidazole in our acute model 
of infection, at least one out five FxR2-infected mice would be expected to relapse in a 
potential equivalent experiment. Additionally, our pharmacological studies in a mouse 
model indicate that the maximum achievable total concentration of fexinidazole and its 
metabolites in plasma is ~240 µM (8 h after a single oral dose of 200 mg kg-1), whereas 
the free maximum concentration of drug, not bound to plasma proteins and therefore 
available to interact with the parasites, was ~180 µM. The maximum achievable total 
and free concentrations of this drug in the brain, which is affected during the second 
disease stage, are expected to be even lower, as studies in the rat demonstrated a total 
“brain-to-blood concentration ratio of fexinidazole and its metabolites of 0.4 – 0.6” 
(Torreele et al., 2010). Even though no direct comparison can be made between these in 
vivo studies and the sensitivity of T. brucei to fexinidazole in vitro, our data seems to 
suggest that FxR cells might be able to survive at drug concentrations much higher that 
those achievable in the plasma and in the brain. If these expectations are confirmed 
through subsequent studies, they will prove that it is possible to generate clinically 
relevant resistance in T. brucei not only to nifurtimox but also to fexinidazole. In 
addition, early studies with fexinidazole in a chronic mouse model of sleeping sickness 
have already demonstrated that this drug is not always effective, even at high doses 
(Jennings and Urquhart, 1983). Therefore, the current plans to introduce fexinidazole as 
a short-course monotherapy for sleeping sickness in an oral formulation (Torreele et al., 
2010) may need to be revisited to include proper investigations on the potential of 
African trypanosomes to develop in vivo resistance to this drug. Finally, it should be 
noted that although orally administered drugs may be much less distressing for the 
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patient and less costly because no or minimal hospitalisation is required, they are more 
susceptible to patient non-compliance (Croft et al., 2006). Based on these arguments, it 
would be highly advisable to consider the use of fexinidazole not as a monotherapy, but 
as a combination therapy, similar to that of nifurtimox. Historical experiments with 
fexinidazole have suggested that combinations of this drug and other antitrypanosomal 
agents have a very high in vivo efficacy against T. brucei (Jennings, 1993). The same 
study had already demonstrated the high efficacy of fexinidazole in combination and 
eflornithine for the treatment of second-stage trypanosomiasis. Future efforts should be 
targeted at identifying other suitable partner drugs for fexinidazole. These partner drugs 
may include another new class currently under investigation for its antitrypanosomal 
activity – the oxaboroles (Barrett, 2010).  
 
5.5. Conclusions  
Some of the key findings of this current work have indicated that resistance to 
nifurtimox may be relatively easy to arise in the field in the African trypanosome. Due 
the small therapeutic index of nifurtimox, even a small decrease in the trypanosome 
sensitivity to nifurtimox would be expected to change the clinical outcome from cure to 
relapse. The therapeutic index of fexinidazole is much broader than that of nifurtimox 
and doses higher than those required for cure can be safely administered. Nonetheless, I 
speculate that resistance to this drug may be just as easy to arise in T. brucei as is for 
nifurtimox. One of the key mechanisms that can lead to such nitrodrug resistance in 
trypanosomes is partial loss of TbNTR, which I have confirmed to be a main activating 
enzyme of nitro pro-drugs in T. brucei. My attempts to purify recombinant TbNTR for 
further detailed analysis and eventually for crystallographic studies have been hampered 
by the insoluble nature of this protein, which was found to be membrane associated. 
Although TbNTR could be purified in a denatured form, which has been used to raise 
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anti-TbNTR polyclonal antibodies, it is arguable whether recombinant TbNTR can be 
obtained in a soluble and at the same time enzymatically active form. Undoubtedly, 
down-regulation of TbNTR presents an important mechanism of resistance to 
nitroaromatic drugs and presents a common mechanism, which can lead to cross-
resistance to all nitroaromatic pro-drugs that act as TbNTR substrates. However, partial 
loss of this protein causes only a low-level nitrodrug resistance in T. brucei. Therefore, 
multiple mechanisms of resistance, waiting to be discovered, must be operational in 
these parasites. Because of the shared mechanisms of action, activation and resistance 
between nitro pro-drugs, emerging resistance to one drug can affect multiple 
compounds of the same chemical class. If such cross-resistance arises in the field in the 
African trypanosome, this would have devastating consequences not only on the 
existing chemotherapeutic options, such as NECT, but on all future efforts to introduce 
other nitroaromatics, including fexinidazole, for the treatment of HAT. Therefore, the 
use of combination chemotherapy may be essential to protect both nifurtimox and 
fexinidazole against the emergence of resistance. From the findings in this study, it 
could be concluded that effective policies should be introduced to ensure compliance 
with the use of nifurtimox as a combination therapy and that partner drugs (for example 
eflornithine) should be sought for fexinidazole, before this drug is introduced against 
sleeping sickness.  
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